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Background: A continuous development of pharmacists’ skills and expertise in 
evidence based practice and patient care is enabling pharmacists to assume further 
patient centred responsibilities such as prescribing. Expanded pharmacist prescribing is 
emerging internationally, as a new professional practice area.  Pharmacists in Australia 
are currently restricted to prescribing from an over-the-counter list of medications. The 
number of medicines in this list is gradually expanding. In the UK pharmacists can act 
as supplementary or independent prescribers dependent on their training whereas in 
Canada pharmacists have also recently assumed additional prescribing roles. 
 
Aims: This research project aimed to evaluate Australian pharmacists’ and pharmacy 
clients’ views on expanded pharmacist prescribing with an emphasis on preferred 
prescribing models and therapeutic areas appropriate for an expanded prescribing role. 
This research project also aimed to explore improved medication supply models, 
including expanded pharmacist prescribing, which could be developed to address 
deficiencies in the current systems in residential aged care facilities (RACFs). 
 
Methods: To assess pharmacists’ views on expanded prescribing a self-administered 
postal questionnaire was distributed nationally to a random sample of pharmacists. 
Pharmacists were selected from State registration lists using an electronic randomizer, 
except in one State where a random selection of community pharmacies was used. A 
total of 2592 questionnaires were distributed nationally. Computer Assisted Telephone 
Interviewing (CATI) was used to obtain pharmacy clients’ views. Structured interviews 
were administered to 400 consenting pharmacy clients by a telemarketing company. In 
order to analyse the data SPSS® vs16 was used. Focus groups were conducted 
separately with doctors (two groups), pharmacists (two groups) and nurses/carers (two 
groups) to obtain qualitative data for exploration of potential ways to improve 
medication supply in RACFs and the potential role of expanded pharmacist prescribing. 
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Data analysis for this part of the project used NVivo® vs8. Agency theory was used 
post-hoc on the results to explore the relationship between the three main stakeholders 
affected by expanded pharmacist prescribing. 
 
Results: Of the 2592 distributed questionnaires 1049 were returned yielding a response 
rate of 40.4%. The 400 pharmacy clients were recruited from a pool of 1153 eligible 
respondents hence a response rate of 34.7%. Most pharmacist respondents (83.9%) 
strongly supported an expanded prescribing role for pharmacists despite perceived 
barriers. Most pharmacy clients (71%) trusted pharmacists to provide an expanded 
prescribing role. Both pharmacists and pharmacy clients acknowledged that further 
training was needed for pharmacists to assume additional prescribing roles. Pharmacist 
respondents indicated strongest support for a supplementary model of prescribing and 
this was also reflected by pharmacy clients’ views that showed support for an expanded 
role for pharmacists where doctors retained their role in disease diagnosis. Views of both 
pharmacists and pharmacy clients indicated that supplementary and independent 
prescribing models were positive predictors of expanding pharmacists’ prescribing role 
with the former being a stronger predictor in both groups (pharmacists: β=0.52, 
p<0.0001 vs. β=0.18, p<0.0001; pharmacy clients:β=0.160, p=0.003 vs. β=0.099, 
p=0.027). Improved medication access was the strongest predictor of pharmacy clients’ 
perception of trust in expanding pharmacist prescribing (β=0.368,p=0.0001).  
 
Application of the Agency Theory highlighted a greater complexity in introducing an 
expanded role for pharmacists as a supplementary model where it indicated a potential 
disruption of an existing agency relationship between doctors and patients through an 
introduction of a decision making authority of a second agent (i.e. pharmacist).  
 
Doctors, pharmacists and nurses/carers indicated strongest support for using a 
centralized medication chart in order to improve medication supply in RACFs. There 
was limited support for expanded pharmacist prescribing in RACFs with its application 
having a potential role in supplementing the medication chart model in the area of short-




Conclusions: Pharmacists and pharmacy clients showed support for expanding 
pharmacists’ prescribing role. This role appeared to have only a limited potential and 
support for improving current medication supply arrangements in RACFs. The Agency 
Theory conceptualizes the introduction of pharmacist prescribers, as potentially 
disrupting the patient-doctor relationship and its introduction is best managed by 
facilitating this already established relationship. This study provides important data for 
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The traditional role of the pharmacist is evolving. Prescribing is emerging as a new 
practice area for pharmacists and it has been an issue of interest in many countries. A 
strong argument favouring an expanded pharmacist prescribing role is that pharmacists 
are developing skills and expertise in evidence based practice and patient care therefore 
enabling them to assume further responsibilities such as prescribing.1,2 The fact that over 
the time pharmacists have been able to expand the list of medications they can prescribe 
over the counter (OTC) does also reflect this. In some countries, including Australia, 
medications previously only prescribed by medical practitioners can legally be 
prescribed by pharmacists as well.1,3,4 
 
 
The main objectives of this study were:  
 
1 To evaluate the attitudes and perceptions of Australian pharmacists expanding 
their  current prescribing role with emphasis on preferred prescribing models 
and therapeutic areas; 
 
2 To evaluate community pharmacy clients’ perceptions of expanded pharmacist 
prescribing including issues of improved access to medicines and preferred 
therapeutic areas of expanded prescribing; 
 
3 To explore improved medication supply models, including expanded pharmacist 
prescribing, which could be developed to address deficiencies in the current 




Agency theory was used post-hoc to explain the relationship between the three main 
stakeholders affected by expanded pharmacist prescribing.5,6,7 The agency relationship 
18 
 
was initially described from an economics perspective by Jensen and Meckling.7 Mott et 
al. provided a conceptual framework for using Agency theory in pharmaceutical care 
suggesting that selecting medicines to treat medical conditions was in fact a principal-
agent relationship.5 According to this theory one party (i.e. principal) depends on 
another one (i.e. agency) and also delegates decision-making authority to this agency for 
duties performed on its behalf.5,6,7 Taking into account the Agency theory, a triangular 
agency relationship exists between pharmacists, doctors and patients where pharmacists 





1.2  Background  
 
The American College of Clinical Pharmacy defined prescribing as a group of activities 
that included selecting, initiating, monitoring, continuing, modifying and administering 
drug therapy.8,9 There are two basic forms of prescribing termed independent and 
dependent.  
 
• Independent prescribing is defined as a process by which the prescriber is solely 
responsible for prescribing and assumes full responsibility for patient 
assessment, diagnosis and clinical management.1,8,9 
 
• Dependent prescribing is a form of prescribing in which there are agreed 
limitations on prescribing activities. This form of prescribing can be carried out 
in various models which include:  prescribing by protocol,1,11-13 patient group 
directions,1,11 formulary prescribing,1,12 patient referral,1,10,11 repeat 






1.2.1 Brief international perspective 
 
In the United Kingdom (UK) an existing supplementary pharmacist prescribing model 
has recently been expanded and now pharmacists, within specific criteria, may prescribe 
independently. A model course developed by the Royal Pharmaceutical Society of Great 
Britain (RPSGB) is available through several educational bodies for pharmacists to 
become accredited as independent prescribers. 1,8,14 Independent prescribing recently 
established in the UK allows pharmacists to prescribe any medication, within the area of 
competency, except for controlled drugs.11,15,16,17  In the United States (US) pharmacists 
are involved with doctors in collaborative drug therapy management.1,8  
 
Van Foppe et al. suggested that the pharmacy profession in the remainder of Europe was 
not at a stage where pharmacist prescribing could be implemented.18 It was suggested 
that pharmacists in Europe lacked authority in the decision-making processes for drug 
prescribing and that their active participation in healthcare teams was affected by lack of 
support from physicians.14,18 
 
Major developments in pharmacist prescribing have occurred recently in Canada, where 
many states are initiating expanded pharmacist prescribing. Recently the state of Alberta 
implemented a three category prescribing model: ‘adapting a prescription’, emergency 













1.2.2 Brief Australian perspective 
 
Prescribing is not an unfamiliar process for Australian pharmacists. Pharmacists in 
Australia are able to prescribe medications listed under Schedules 2 (S2) and 3 (S3) of 
the Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP). These 
medicines are available OTC only from pharmacies except in exceptional circumstances 
such as isolated communities. Australian pharmacists are also able to continue the 
supply of prescription only medications based on ‘emergency supply’ and ‘repeat 
prescription’ systems. The repeat system of prescribing allows Australian pharmacists to 
continue to re-fill doctors’ initial prescriptions for up to twelve months dependent on the 
medication. 
 
There are signals suggesting that the health system in Australia is not well prepared to 
face new challenges such as an ageing population with increased co-morbidity, 
increased prevalence of chronic disease and insufficient health professionals to keep 
pace with population growth. 21 Insufficient numbers of health professionals is driving 
task transfer.22 There are also signs that fewer medical graduates are choosing general 
practice as a career hence indicating a further exacerbation of the general practitioner 
shortage.23 Furthermore, a continued shortage of general practitioners in the near future 
for Australia has also been suggested, hence indicating that innovative primary care 
policies are necessary.24 
 
Utilization of pharmacists’ professional skills was one of the main aims of expanded 
pharmacists prescribing in the UK.11,16,18 Pharmacists have professional skills that other 
health professionals do not and many of these skills are not utilized.25 In this regard 
King26 argues that clinical pharmacists in Australia have an active role to play in drug 
and dose selection. Nissen27 has also emphasised the fact that Australian pharmacists 
already diagnose and prescribe Pharmacy Medicines and Pharmacist Only Medicines. 
Patient monitoring (mainly in a hospital setting) and medication reviews (hospital and 
community) are also performed by Australian pharmacists. These skills are essential if 




The Australian Government Productivity Commission has recommended that Australia 
should expand the roles of other health professionals to include aspects of current 
doctor’s tasks.28 The Royal Australasian College of Physicians (RACP) supported task 
transfer.22 The Australian Medical Association (AMA) embraced the idea of allocating 
clinical responsibilities to other medically trained health professionals “wherever it can 
be done safely and effectively”.29 However, when it comes to expanding pharmacist 





























This study will analyse data obtained from pharmacists working in all areas of the 
pharmacy profession in Australia and provide a representative perspective on the issue 
of pharmacist prescribing. Therefore, results of this project will be valuable in providing 
detailed knowledge of the grass-roots of professional attitudes when constructing 
policies and recommendations on the issue of pharmacist prescribing in Australia.  
 
Given the global interest in pharmacist prescribing, the findings will provide valuable 
information to stakeholders internationally especially for countries which have thus far 
not introduced an expanded prescribing role for pharmacists.  
 
By exploring the views of patients on pharmacist prescribing and appreciation of the 
possible support for expanded pharmacist prescribing will be achieved. 
 
Findings of this study will be important in designing new recommendations and policies 
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2.1 The impact of enhanced pharmaceutical care  
 
 
There is a trend of positive outcomes when pharmacists expand their scope of 
pharmaceutical care practice and are involved more actively within collaborative health 
care teams, therefore utilizing more of their skills. Evidence suggests that enhanced 
pharmaceutical care results in positive effects for a wide range of outcomes in patients 
with chronic conditions, elderly patients and patients at higher risk of drug related 
problems.1 Examples include clinical and financial outcome as well as  disease severity 
improvements for patients with heart failure, dyslipidaemia, hypertension, diabetes, 
asthma, atrial fibrillation,  patients’ medicine knowledge and adherence. 1-10 In studies 
reporting improvement of the above health outcomes, pharmaceutical care provided by 
pharmacists has included the following services: medicine and lifestyle counseling, 
general practitioner (GP) referral, provision of educational material, medicine 
management, clinical measurements, drug compliance discussion, pharmacists visiting 
patients after hospital discharge, home medicine reviews, formulation of drug 




2.1.1 Studies describing pharmacists’ impact on doctors’ prescribing 
 
Positive outcomes have been reported in the literature when pharmaceutical care is 
enhanced through pharmacists’ interventions on doctors’ drug prescribing.  
 
Carter et al. explored how a clinical pharmacist can influence doctors’ prescribing.10 
This study aimed at determining whether there were more favourable prescribing 
patterns in family practice offices which had a clinical pharmacist compared to those 
which had not. A blinded review panel evaluated the appropriateness of drug and dose 
selection. Prescriptions generated in offices with clinical pharmacists were rated more 




Favourable effects on doctors’ prescribing were also reported when patients’ medicine 
profiles were subjected to pharmacists’ feedback to doctors. For this group of patients 
the end effect was the reduction of polypharmacy by 4% compared to the groups of 
patients not undergoing the same pharmacist monitoring.12 Another Dutch study 
investigating the impact of medicine reviews conducted by pharmacists on quality of 
prescribing by a healthcare professional team also concluded that pharmacists’ medicine 
reviews results in improved quality of prescribing.13 
 
Eide and Schjott reported positive effects achieved on prescribing and administration of 
hypnotic medicines in residential aged care facilities (RACF) upon pharmacists’ 
intervention.14 This was achieved after pharmacists provided drug information on use of 
medicines to staff. The outcome was that benzodiazepine use was reduced and medicine 
administration timing was also improved. The use of long acting hypnotics (not 
recommended for use in elderly) was significantly reduced while the use of short-acting 
hypnotics was increased.14 
 
A study described the outcomes of pharmacists providing educational presentations and 
materials and problem-solving meetings in an acute care state psychiatric facility. 15 The 
aim was to review prescribing and administration of antibiotics. As a result, better 
utilization of culture and sensitivity tests, appropriate antibiotic dosage regimens and 
selection of cost-effective therapy as well as correct administration of antibiotics, were 
achieved as a result of pharmacists’ interventions.15 
 
Fletcher et al. indicated improved prescribing of vancomycin and tobramycin as a result 
of pharmacists’ interventions. Pharmacists’ role was to promote prescribing of nafcillin 
instead of vancomycin and of gentamicin instead of tobramycin, when and where 
appropriate.16 Similar results were seen in a study which investigated pharmacists’ 
impact on parenteral cefalosporin prescribing. 17  
 
A positive impact on drug prescribing and patients’ utilization of antibiotics as a result 
of hospital pharmacists providing recommendations to doctors on patients’ drug 
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management has also been reported by Thornton et al. in a multi-centered trial.18 
Literature data also suggested that therapeutic advice provided by pharmacists to general 
practitioners resulted in improved quality of antibiotic prescribing and a decreased 
number of prescriptions by general practitioners leading to cost savings. 19 
 
Reports of improvement in geriatric prescribing in patients receiving pharmacists’ 
interventions have been published.  The quality of prescribing in one study was 
measured by the Medicine Appropriateness Index (MAI). 20 Successful expansion of 
pharmacists’ scope of practice affecting doctors’ prescribing was also described in other 




2.1.2 Collaboration between pharmacists and doctors 
 
The key to the success of expanding pharmacists’ roles through prescribing is a 
collaboration of doctors and pharmacists.22 This should be viewed on the basis of better 
utilization of pharmacists’ skills and easing the burden from overloaded doctors. In this 
regard, as also  suggested by Royal Pharmaceutical Society of Great Britain (RPSGB), 
one should have in mind that traditional roles of pharmacists in medicine preparation 
and dispensing are to a large extent being replaced by the use of manufactured 
medicines in ready to use packs complete with manufacturers’ patient information.23,24 
Nevertheless, pharmacists are routinely involved in screening prescriptions for errors 
such as: dose, strength, quantity, missing or incorrect information, drug-interactions, 
allergies and even fraud and drug abuse.23  
 
Considering the diminishing of traditional roles of pharmacists in preparing and 
dispensing medicines, it has been suggested that pharmacists are enthusiastic in 
utilization of their knowledge of medicines. 23,24 The success of pharmacists in hospital 
settings where they are involved in collaborating with doctors to make prescribing 




McKinnon and Jorgenson have recently conducted a study with the aim of assessing the 
effects of collaborative prescribing by pharmacists and doctors.26 Pharmacists examined 
drug safety and effectiveness issues related to prescribing and then made collaborative 
decisions with doctors. This was compared to a control group in which doctors 
performed the above activities independently. The intervention group had more 
medication problems identified, medication changes made and new General Practitioner 
(GP) appointments scheduled. These authors have concluded that there is an 
improvement in medication management as well as process of care when pharmacists 
collaborate with doctors on prescribing decisions.26  
 
In evaluating prescribing problems and community pharmacists’ interventions to 
identify and resolve prescribing errors, Rupp et al. emphasized the significance of 
communication and collaboration between doctors and pharmacists in order to ensure a 
safe and effective provision of pharmaceutical care.27 These authors also have 
recommended that the inter-professional system of “checks and balances” be maintained 
and even expanded. 27 
 
In the United Kingdom (UK), the ‘white paper’ reports on primary care have also 
recommended inter-professional cooperation between pharmacists and doctors in 
providing health services.  An increased mixing of skills was encouraged.28,29 
 
Aiming to promote collaboration between pharmacists and doctors, specific projects 
were developed in the UK.30 One example was the pairing of community pharmacists 
with general practitioners in order to review patients’ notes and hence identify 
prescribing errors. Problems were identified in 48% of 6131 medicines reviewed. 31 
Other similar programs in the UK between doctors and pharmacists included drug 
prescribing audits by clinical pharmacists in cooperation with doctors and provision of 
prescribing recommendations by pharmacists to general practitioners. In all these 




Closer collaboration of pharmacists and doctors which resulted in a reduction of costs 
has also been reported in the literature.25 Bradley suggested that whilst community 
pharmacists were in a good position to ensure more rational and cost effective 
prescribing, this was best achieved in a situation where pharmacists and doctors worked 
closely together. 25 Disadvantages of this close relationship have also been suggested. In 
this regard, Bradley has put forward the view that in trying to control the cost of 
prescribing, doctors and pharmacists could end up competing and colliding with each 





2.2 An international perspective on pharmacist prescribing 
 
 
2.2.1 Pharmacist prescribing in the UK 
 
Literature from the UK has suggested that pharmacists have reduced their activities in 
the sale, supply and manufacturing of medicines and instead are continuously re-
defining their professional role in the healthcare system by engaging more in activities 
such as medicine management, health promotion and diagnostic testing. 36 Expanded 
prescribing by pharmacists is an example of this re-defined role.  
 
Pharmacists in the UK are able to prescribe using supplementary or independent 
protocols, dependent on their qualifications. 37 These two models are currently the main 
models of pharmacist prescribing in the UK. However, pharmacists there can also be 
involved in other forms of expanded prescribing such as: Patient Group Directives 






2.2.1.1 Supplementary prescribing 
 
The supplementary prescribing model involves a partnership between an independent 
prescriber (i.e. doctor) and pharmacist to implement an agreed patient specific 
management plan. In this model doctors make the diagnosis while pharmacists prescribe 
according to the agreed clinical management plan.36,38,39,40  
 
In the UK, in 1999, a Health Department report titled ‘The Review of Prescribing, 
Supply and Administration of Medicines’ recommended that prescribing be expanded to 
other healthcare professionals.41 This extension of prescribing which resulted in 
pharmacists being involved in supplementary prescribing occurred in the UK in 2003. 
36,41,42 Better utilization of pharmacists’ skills, improvement of patients’ access to 
medicines as well as easing the burden of GPs were the main objectives for introducing 
supplementary prescribing for pharmacists. 36,40 In addition to pharmacists, prescribing 
roles have been expanded to other healthcare professionals such as: nurses, 
physiotherapists, radiographers and optometrists.43 
 
Supplementary prescribers have to undertake additional training in order to become 
accredited to prescribe and also demonstrate competencies in specific therapeutic areas 
of prescribing.42,43 Pharmacist supplementary prescribers (PSP) working in a community 
pharmacy setting prescribe for chronic conditions. PSPs based in the hospital prescribe 
in wards and outpatient situations.44  
 
The core guidance for supplementary prescribing is the Clinical Management Plan 
(CMP). The CMP is the framework agreement between an independent prescriber, 
supplementary prescriber and patient. This framework is designed for every individual 
patient. 45 Community pharmacists felt that this model offered their patients improved 
access to medicines and therefore was an advantage for those patients who do not 
regularly visit their doctors’ surgery.44,46 During the initial stages of its introduction, it 
was suggested that this model basically legitimised pharmacists’ current practices as 
they already performed duties such as recommendations of specific therapy and dosage 
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adjustments of prescribed medicines.44,47 It was also argued that pharmacist 
supplementary prescribing initiated innovative services such as community pharmacists 
being involved in the management of cardiovascular disease. 44,48  
 
Prescription Analysis and Cost Data (PACT) indicates that there has been a significant 
increase in the number of prescriptions written by PSPs (i.e. 2706 in 2004 and 31052 in 
2006).36 In 2006, in the UK, 0.004% of all prescribing in community and primary care 
setting was done by PSPs.36 This indicates that supplementary prescribing, although 
increasing, represented a small proportion of prescribing in the UK.  PACT data also 
indicated that cardiovascular medicines represented the main therapeutic area for which 
PSPs prescribed.36 Furthermore it should be noted that George et al. reported that most 
pharmacists who answered a survey on supplementary prescribing focused more on 
cardiovascular conditions during their practical learning period. 49 PACT data shows that 
the cardiovascular therapeutic prescribing area was followed by the central nervous 
system, respiratory, endocrine and gastrointestinal therapeutic areas for which PSP’s 
prescribed.36  
 
The supplementary prescribing model does not specify clinical situations in its definition 
so that it does not exclude others.38,41,50 However, this model is not suitable for 
emergency medical conditions. This prescribing model is essentially a team-focused 
approach therefore is not limited to a one to one partnership.38,41,50 
 
The introduction of an independent prescribing model for pharmacists in the UK 
occurred alongside the supplementary model. It was considered an important model for 
new pharmacist prescribers and also suitable for specific situations such as pharmacists 
working within a healthcare team, where controlled drugs (which cannot be prescribed 
by pharmacist independent prescribers) are needed and also for chronic stable conditions 
such as cardiovascular disease and diabetes. 36,43,51 Therefore, the supplementary 




A survey conducted in the UK by Hobson and Sewell, indicated that despite concerns 
with training model for supplementary prescribing, pharmacists had a positive attitude 




2.2.1.2  Independent prescribing 
 
Independent prescribing is a process by which the prescriber is solely responsible and 
assumes full responsibility for patient assessment, diagnosis and clinical management. 
38,51 
 
Independent prescribing was introduced in the UK and as of May 2006, pharmacists 
were able to prescribe any medicine within their competency with the exception of 
controlled drugs.42,43,45 This restriction on controlled drugs is likely to change once the 
relevant legislation is amended.53 Pharmacist Independent Prescribers (PIP) cannot 
prescribe for themselves.51 The English Health Department emphasises that PIPs must 
only prescribe within their level of competency in accordance with guidelines published 
by the RPSGB.51 The RPSGB standards on prescribing also state that pharmacists 
should separate dispensing from prescribing. In exceptional circumstances where a 
pharmacist is involved both in dispensing and prescribing there should be a checking 
process of dispensing by a second person with final accuracy check also performed by 
this second person (i.e. pharmacist).51 
 
Lloyd and Hughes have reported that while some pharmacists questioned their training 
level for such a role they viewed independent prescribing as a natural progression of the 
supplementary model.53 In addition, they also reported that doctors generally had 
negative views about the independent prescribing model.43,53 A similar finding was 
reported by Warchal et al. who found that pharmacists considered the independent 
model to be a “logical step” from the supplementary prescribing model. A majority of 
respondents planned to become independent prescribers despite the fact that they had 
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reservations in terms of acceptability of doctors towards pharmacists assuming this 
role.54 An important link between supplementary and independent prescribing was 
identified by George et al. who found that due to increased confidence, pharmacists who 
commenced with supplementary prescribing were more likely to assume an independent 
prescribing role.55 
 
It should be noted that nurses in the UK are also able to prescribe independently. As of 
May 2006 an expanded formulary nurse prescriber became an independent prescriber. 
Nurse independent prescribers are able to prescribe any licensed medicine including 




2.2.1.3 Formulary prescribing 
 
UK non-medical healthcare professionals can also prescribe through a formulary model. 
This is based upon an agreed list of medicines developed between general practitioners 
and pharmacists. This delegates prescribing authority to pharmacists for formulary 
drugs.38,57,58 The drug formulary includes the list of medicines, symptoms, length of 
treatment, referral criteria and limitations.38  
 
There are cases where local formularies are established between doctors’ surgeries and 
community pharmacies. In some places where a formulary model is applied, some of the 
medicines in the formulary are already available over the counter.38,57,58 
 
It is worth emphasizing that a Scottish study reported positive acceptance of this model 






2.2.1.4 Patient group directions (PGD) 
 
This form of prescribing was introduced during the year 2000. This model is a well-
defined protocol, developed locally and involves a written direction signed by a doctor 
or dentist and by a pharmacist. It only relates to supply and administration of 
prescription medicines.38 The main objectives in introducing this model were to improve 
medicine access, reduce GP workload, increase inter-professional collaboration and also 
provide another access to therapeutic advice.42  No official additional training is required 
for pharmacists to administer or supply medicines according to this model. However, in-
house training is provided in most cases.44  
 
Emergency contraception, antibiotics, combined oral contraceptives and anti-histamines 
are listed as medicines included in the PGD model.38  
 
The PGD names the medicine or its class, dosage frequency and dosage form(s),  route 
of administration, period of administration, relevant warnings, quantity, situations when 




An example of PGD model for cystitis management is presented in Figure 2.1
 
Figure 2.1 Patient group direction for cystitis management. Rothertham Primary 
Care Trust 42 (Figure reproduced with permission of the copyright owner). 
 
 
2.2.1.5  Patient referral 
 
Patient referral is another dependent form of prescribing practised in the UK. According 
to this model, the patient is referred by a physician to the pharmacist for managing an 
agreed drug therapy or to achieve a certain therapeutic outcome. 38,58,61 There are cases 
where patients, medical practice staff or a community pharmacist refer patients to a 




A study assessed the outcomes from patients being referred to one of eight pharmacies 
by a medical practice.38,62 Ailments were identified in medical practice and patients were 
referred to the pharmacist. Pharmacists then prescribed a medicine from the formulary. 
Positive outcomes were reported with this model. However, patients did not accept a 
referral if they felt they needed doctors’ examination or antibiotics, if patients were 









2.2.2 United States of America (USA) 
 
 
In the USA, the role of the pharmacist in prescribing was defined in 1971.57,63 This was 
viewed in the context of pharmacists’ clinical tasks. The prescribing role was described 
as:  
• assisting drug therapy and prescribing at a doctors request;  
• refilling prescriptions on patients request;  
• dispensing ‘standing orders’, which means independently prescribing from a pre-
arranged plan with the doctor;  
• sharing the prescribing role with a doctor based on the pharmacists’ competence; 
• doctors retaining the right of diagnosing the condition first;  
• pharmacist prescribing of over the counter medicines;  
• prescribing in an emergency situation when this is in a patients best interest; 
• replying to patients enquiries which result in a continuation of drug therapy; and  
• in consultation with a doctor, selecting and dispensing a medicine different from 






Several prescribing models are practiced in the USA. These include: collaborative 
prescribing, independent prescribing, protocol prescribing and repeat prescribing.38 
 
 
2.2.2.1 Collaborative prescribing model 
 
US pharmacists are involved in activities described as collaborative drug therapy 
management. 64,65,66 This model requires collaboration between doctors and pharmacists, 
resulting in prescribing authority being given to the pharmacist. 38,58,64,65. Collaborative 
agreements are negotiated and specifically applied. These agreements must be filed with 
either the State Pharmacy or Medical Board.22,38 
 
According to this model the doctor diagnoses, while the pharmacist selects, initiates, 
monitors, modifies and continues or discontinues therapy accordingly.38,65,66 In this 
model both the doctor and pharmacist are responsible for clinical outcomes.61 
  
A collaborative prescribing model has been in place in the US since 1970’s.57,66 
Literature data have suggested that pharmacist prescribing in a collaborative model is 
supported by 38 states in the US as well as the US Public Health Services, armed forces 
and Veterans Health Administration.57,66    
 
Collaborative Drug Therapy Management (CDTM) services offered by pharmacists in 
the US have expanded over the years and they include a variety of professional services 
such as: management of pain and chemotherapy related nausea and vomiting, provision 
of protocol based prescription evaluation and refills, modification and management of 
hyperlipidaemic and psychiatric therapies, reduction of cardiovascular risk, prescribing, 




Hammond et al. have indicated that pharmacists involved in CDTM have demonstrated 
improved drug effectiveness, efficacy and safety and went further to recommend that 
CDTM’s should become the core of healthcare service delivery.66 Additionally, 
beneficial financial effects of CDTMs were reported by Schumock et al. in a study 
evaluating 104 studies, half of which qualified as CDTM. In this critical review, authors 
found that 89% of studies showed positive financial outcomes.74 
 
The main difference between supplementary prescribing employed in the UK and 
CDTM in the US is that in the UK, management plan is customized according to each 





2.2.2.2 Independent prescribing in the US 
 
In some US states pharmacists are permitted to initiate or modify drug therapy but only 
in Florida is independent prescribing practised.39,75 This independent prescribing 
however is done from a limited drug formulary with most prescriptions written for 
topical pediculicides and oral and otic analgesics.75 Independent prescribing was first 
introduced in Florida in 1986, but since its introduction the drug formulary has not been 
updated and most of its drugs are currently available over-the-counter.57  
 
 
2.2.2.3 Protocol prescribing 
 
As a dependent form of prescribing, protocol prescribing is also practised in the US. 
This form of prescribing is characterised by a limitation of prescribing activities through 
a detailed formal agreement describing the activities that pharmacists may perform when 
prescribing. The protocol, which is a written guideline, includes: disease state, drugs and 
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drug categories and the procedures and criteria to be followed by the prescribing 
pharmacist, agreement between the doctor and the pharmacist, agreement time, 
responsibilities of both doctors and pharmacists and feedback procedures for authorising 
prescriber and protocol review policies. 38,58,76 The level of prescribing authority given to 
the pharmacist is competency based.38,77 
 
Utilizing the protocol prescribing model, the Indian Health Service (IHS) pharmacists 
prescribe for patients with disease states such as a limited number of infections (eg. ear 
infections, urinary tract infections and sexually transmitted diseases), hypertension, heart 
failure, seizures, and arthritis.38,77 In 1979, the IHS reported that doctors did not consider  




2.2.2.4 Repeat prescribing 
 
This model allows pharmacists to provide medicine-refills to patients. This model is in 
place in some US States.38,78 This prescribing model is generally practised in pharmacies 
associated with medical centres. The pharmacist through this prescribing model offers 
three main services:  supplies medicines in sufficient quantity to last until a patients’ 
next appointment with a doctor, consults the doctor if there are drug-adherence problems 













In Canada, a survey of its members conducted by the Canadian Society of Hospital 
Pharmacists (CSHP) in 1996, showed that a number of pharmacists were in involved in 
various degrees in prescribing activities. 57 In August 2001, CSHP approved a statement 
on pharmacist prescribing advocating pharmacists as capable prescribers. CSHP 
supported pharmacists’ involvement in a collaborative drug prescribing model. The 
objectives of this model were to improve patients’ health and make and efficient 
delivery of pharmaceutical care. The foundations of this prescribing model, according to 
the CSHP, would be to recognise “doctors’ expertise on disease diagnosis and 
pharmacists’ expertise on pharmacotherapy and disease management”.80 
 
Major developments in the area of pharmacist prescribing have recently occurred in 
Canada with different provinces being in various stages of granting expanded 
prescribing roles to pharmacists. Alberta implemented a three category prescribing 
model. These models are: a) ‘adapting a prescription’, where pharmacists can modify the 
prescription to meet special needs for the patient or expand therapy in cases where 
patients cannot contact the doctor; b) emergency prescribing, in cases where patients 
cannot access a doctor and immediate treatment is necessary and c) pharmacists can 
initiate, modify and extend drug therapy in an interdependent or collaborative 
fashion.81,82,83 Controlled drugs and narcotics are not allowed to be prescribed by 
pharmacists.82 
 
Nova Scotia and Northwest territories allow an extension of prescription medicines by 
pharmacists by up to 30 days, provided the patient is unable to see a doctor. “Adapting 
the prescription” and emergency prescribing have also been approved in Nova Scotia. In 
Quebec, the Pharmacy Act allows pharmacists to initiate or “adjust” medication therapy 
according to a prescription. In Manitoba pharmacists have a broadened prescribing 
authority through “continued care” prescriptions. This allows them to independently 




In British Columbia, pharmacists who have completed an orientation to British 
Columbia College of Pharmacy’s Medication Management Protocol can adapt and 
renew prescriptions.84 They can also substitute a drug within the same therapeutic class. 
New legislation in New Brunswick has also granted expanded prescribing rights to 
pharmacists who are now able to alter the dose, formulation or medication regimen and 
renew a prescription. Emergency and collaborative prescribing is also allowed in New 
Brunswick. Pharmacists in Prince Edward Island can provide continued care 
prescriptions for drugs other than narcotics and they must inform patients’ doctor as 
soon as possible. 84 Pharmacists in Newfoundland and Labrador, Ontario and 
Saskatchewan are in the process of regulatory change to allow expanded prescribing 
roles for pharmacists. Expanded pharmacist prescribing is not allowed in Nunavut and 
Yukon.84 
 
The expanded pharmacist prescribing role in Canada was met by criticism from 
Canadian doctors. In August 2007, the Canadian Medical Association (CMA) approved 
12 principles on collaborative care models to manage patients.85 These principles were 
designed to put the doctors in the core of patient management and enable doctors to 
always be the leaders of any collaborative patient management model. Canadian doctors 
also warned that a collaborative care model should not substitute a one care provider 
only because it may be more cost-effective. The CMA also demanded that the role of 
pharmacists in prescribing be limited and that pharmacists should not be given an 
independent prescribing authority.85 
 
Croskerry has reported that with Canadian pharmacists expanding their prescribing 
rights patient safety could be compromised.86 This author also highlighted the possible 
commercial influence of the pharmaceutical industry on pharmacists.73 The Canadian 
Pharmacists’ Association (CPA) has suggested that the Medical profession in Canada 
still has a long way to go in order to accept enhanced roles for pharmacists. It was also 






Emmerton et al. mapped eight main models of pharmacist prescribing identified 





Figure 2.2  Pharmacist prescribing models identified internationally by 










2.2.4 Continental Europe 
 
Expanded pharmacist prescribing is not practiced in European countries. It is suggested 
that pharmacists in Europe lack authority in the decision-making process for drug 
prescribing and that their active participation in healthcare teams is affected by lack of 
support from physicians.39,87 In this regard, Van Foppe et al. have indicated that 





2.3.5 Other parts of the world 
 
In South Africa there are reports of competition between doctors and pharmacists with 
their continuous attempts to protect professional domains. As reported by Gilbert, due to 
socio-economic factors and the country’s failure to provide adequate health services, 
there has been a growing number of dispensing medical practitioners.88 Therefore, in 
South Africa, pharmacists seem to be in a position where they struggle to defend their 
dispensing role rather than assume more responsibilities such as expanded prescribing.  
 
A significant increase in ’gateway pharmacies’ (i.e. pharmacies owned by GP’s and 
operated by the same clinic that does prescribing) was seen in Taiwan in 2002, after the 
introduction of payment incentives for these pharmacies.89 A dispensing fee increase for 
pharmacists and an increase in doctors’ consultation fee occurred in Taiwan to 
compensate for revenues lost after a dispensing and prescribing separation policy 
introduced in 1997.90 This suggested that until recently Taiwan pharmacists were 





Literature data from Argentina has suggested that to enhance pharmaceutical care, and 
therefore pharmacists’ roles, the main barriers identified by Argentinean pharmacists 






2.3 Pharmacist Prescribing in Australia 
 
Pharmacists in Australia are able to prescribe medicines listed under Schedules 2 and 3 
of the SUSMP.  Schedule 2 medicines are otherwise called ‘Pharmacy Medicines’ and 
Schedule 3 ‘Pharmacist Only Medicines’.92 
 
‘Pharmacy Medicines’ (S2’s) are intended for therapeutic use in minor ailments and for 
which symptoms can be readily recognised by the consumer. 93,94  As such, for  the 
purpose of their use there is no need for medical management or differential diagnosis. 
These medicines are essentially safe to use.  Counselling and advice for ‘Pharmacy 
Medicines’ is available on ‘if necessary basis’.  On the other hand, ‘Pharmacist Only 
Medicines’ (S3’s) are medicines intended for therapeutic use in minor ailments and for 
symptoms which can be readily recognised by the consumer but these symptoms have to 
be verified by a pharmacist. ‘Pharmacist Only Medicines’ are intended for use in minor 
ailments and symptoms which do not require initial medical diagnosis. These medicines 
are essentially safe to use and their provision requires pharmacists’ professional 
counselling, management and monitoring.93,94  
 
The Pharmaceutical Society of Australia (PSA) guidelines for the provision of 
‘Pharmacy Medicines’ and ‘Pharmacist Only Medicines’ state that “all staff members 
who supply Pharmacy Medicines and Pharmacist Only Medicines receive initial and 
ongoing training on products, services, and procedures relevant to their supply”.93 Both 
‘Pharmacy Medicines’ and ‘Pharmacist Only Medicines’ are located in a Pharmacy area 
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separated from those containing other commercial products. ‘Pharmacy Medicines’ are 
located within a ‘professional services area’ which is an area that contains only health 
related products. 93 On the other hand, ‘Pharmacist Only Medicines’ are located in an 
area not accessible or available for self-selection by customers. These medicines are 
placed within “pharmacists’ sight, hearing and supervision”.93 In Australian pharmacies, 
consumers often have access to a private consultation area within the pharmacy. This 
facilitates the provision of ‘Pharmacist Only Medicines’.  It should be noted that some of 
the medicines listed as ‘Pharmacist Only Medicines’ were previously prescription only 
medicines (e.g. Pantoprazole 20mg tablets, Ketotifen eye drops etc). 92 
 
The pharmacy profession in Australia has seen an expansion of pharmacists’ traditional 
roles. In addition to regular medicine reviews conducted by clinical pharmacists in 
hospitals, Home Medicine Reviews (HMR) and Residential Medicine Management 
Reviews (RMMR) have been introduced during the last decade.  These services are 
conducted by Consultant Pharmacists who are accredited following additional training. 
These services are reimbursed under the Pharmaceutical Benefits Scheme (PBS) 95 
 
Australian pharmacists are also able to continue the supply of prescription medicines 
based on ‘emergency supply’ and ‘repeat prescription’ systems. The majority of 
medicines supplied under the ‘repeat prescription system’ are subsidised by the PBS. 96 
However, it should be noted that the ‘repeat prescription’ system is also utilised for 
private prescriptions. 
  
The PBS was established in 1948 and is governed by the National Health Act 1953. It is 
designed to provide a wide range of medicines at a government subsidized price. The 
PBS is a rational formulary and covers around 80% of prescriptions dispensed in 
Australia. It should be noted that in addition to Australian residents, overseas visitors 
from countries having a reciprocal health care agreement with Australia are also eligible 




The ‘repeat prescription’ system is a form of dependent prescribing.38 This model 
enables a continuation of prescription medicine supply without patients having to see a 
doctor to obtain a prescription for each refill. Generally, the number of repeats that are 
authorized by doctors range from one to six.  However, as of 1st of December 2008, the 
PBS has expanded the number of repeats allowed from a maximum of six to a maximum 
of 12 months. This may be regarded as a limited extension of pharmacist prescribing in 
Australia. It should be noted though that the list of medicines for which the PBS allows 
up to 12 repeats is limited.96 The main objective for expanding the number of repeats 
was to provide greater flexibility to access of repeat prescriptions to patients with 
chronic conditions. The PBS also lists other reasons for this repeat extension. These 
include: easing the burden off patients with chronic conditions, simplifying medicine 
access and reducing the need of seeing a doctor just to refill a prescription without 




2.3.1 Prescribing in Australia by other healthcare professionals  
 
Independent prescribing from a limited list of medicines is undertaken by dentists. 
Dentists commenced prescribing medicines under the PBS on 1st of April 1979.99 There 
is a wide range of therapeutic classes listed under the PBS from which dentists can 
prescribe with antibiotics and analgesics being the most abundant classes.96 There are 
limits as to the variety of controlled drugs i.e. narcotics and duration of treatment that 
dentists can prescribe, dependent on the Australian State or Territory. The PBS has also 
set a limitation on duration of treatment that dentists can prescribe with no repeats 
allowed under the PBS for dentist prescribing.96 
 
Dependent on the Australian State or Territory, podiatrists and optometrists have also 
been granted prescribing rights for a limited formulary of prescription medicines. 100,101 It 
is worth mentioning that in addition to medical practitioners only dentists and 
optometrists have access to prescribing items under the PBS. Optometrists accredited to 
50 
 
prescribe under State or Territory legislation gained access to the PBS items from 1st of 
January 2008.96 Under the PBS, optometrists can prescribe medicines for optometrical 
use from the following therapeutic areas: anti-infectives, anti-inflammatory agents, 
antiglaucoma agents, miotics, decongestants and antiallergics.96 Optometrists and 
podiatrists do not have prescribing rights in all Australian States and Territories. 
 
In Australian hospitals, some nurse and midwife practitioners are able to prescribe. Their 
prescribing is limited to selected specialities such as pain management, primary care, 
and emergency medicine. This prescribing is either formulary or protocol based (i.e. 
defined protocols that guide pharmacotherapeutic management). There is also a model 
for remote area nurse prescribing.95,102 Nurse practitioners and midwives will gain 
access to prescribing a limited number of PBS items from 1st of Novemeber 2010. 96 
 
It is worth emphasising that the acquisition of prescribing rights by nurse practitioners 
and optometrists was accompanied by significant efforts made by their professional 
bodies with each profession making submissions justifying their prescribing rights and 
highlighting their contribution to collaborative healthcare work, cost effectiveness and 
patient safety and benefit.103 
 
The Australian Government Productivity Commission recommended that Australia 
should increase the scope for other health professionals undertaking doctor’s tasks.104  
This view is not entirely shared by the Australian Medical Association (AMA).105 
According to the AMA, doctors embrace the idea of allocating clinical responsibilities to 
lesser medically trained health professionals “wherever it can be done safely and 
effectively”.105 The AMA encourages that this should be done in a context of: team care 
where skills are synergised, doctors retain their central role, no fragmentation of care 
occurs and taking into account patient preferences and expectations.  The AMA at the 
same time has warned that a task transfer from doctors to other non-medical health 
professionals could lead to shortages of other healthcare professionals. Ultimately, the 
view of the AMA is that any possible reforms must improve what doctors do and not 




The Royal Australasian College of Physicians (RACP) supports task transfer “both 
across its speciality groups and to other health professionals as long as this transfer if 
evidence-based, safe, cost-efficient and it facilitates patient care.”106 
 
When it comes to transferring the task of prescribing specifically, the AMA has 
signalled that it is opposed to an extension of prescribing rights for pharmacists. 
Reacting to a limited pharmacist prescribing extension proposed by the Pharmacy Guild 
of Australia (PGA), who proposed a list of 20 medicines that pharmacists should be able 
to prescribe, the AMA’s president has pointed out that “doctors must maintain sole 
responsibility for prescribing medicines to patients”. The AMA’s president has 
emphasized patients’ safety, lack of pharmacists’ training and the conflict of interest 
with pharmacists having both dispensing and prescribing rights as the main reasons for 
this stance. 107 However, it should be noted that the view of a separation of prescribing 
and dispensing is also shared by the PSA and the Society of Hospital Pharmacists of 
Australia (SHPA).100,108  In addition, the SHPA’s position on prescribing by non-medical 
professionals is that “only health professionals who have undergone credentialing within 
their defined practice setting, in pharmacology, pharmacokinetics and applied 
therapeutics, meeting the standard core competencies for safe and effective prescribing, 
should be registered to prescribe medicines following diagnosis”.100 
 
The Pharmaceutical Council of Western Australia (PCWA), made a submission to a 
review of WA’s Poisons’ Act endorsing a collaborative drug therapy prescribing model 
for pharmacists provided that the diagnosis for the patient is established and a treatment 
plan was developed for individual patients.109 The PCWA has proposed that part of the 
doctors tasks can be transferred to another health professional. This prescribing model 
would require pharmacists to undergo an accreditation process. According to the PCWA 
this expansion of pharmacist prescribing could be applied to chronic conditions such as 
diabetes, asthma, hypertension, dyslipidaemia, hypothyroidism, heart failure and 
anticoagulation therapies. The PCWA also separately advocated the possibility of 
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pharmacists independently prescribing ‘Prescription Only Medicines’ in specific 
circumstances.109 
 
When exploring the issue of pharmacist prescribing in Australia, it is worth noting that 
there is shortage of doctors and nurses which is driving the task transfer in Australia. 106 
In addition, literature suggests that fewer medical graduates, are choosing general 
practice as a career hence indicating further exacerbation of the general practitioner 
shortage.110 Joyce et al. predicted a continued shortage of general practitioners in 
Australia, hence suggesting that innovative primary medical care policies were 
necessary.111 
 
Extension of the current pharmacist prescribing role in Australia has to be weighed 
against new challenges that the pharmacy profession is facing. These challenges include 
ownership deregulation, increased access to health products, internet pharmacies, 
healthcare reforms and nurse practitioners with prescribing authority.57 Australian 
studies have reported that Australian GP’s are no better at monitoring their patients 
compared to their UK colleges.112,113 Clinical Pharmacists in Australia have an active 
role in drug and dose selection. Patient monitoring and medication reviews are also 
performed by Australian pharmacists. These skills are certainly valuable if pharmacists 
in Australia assume further prescribing responsibilities.113 
 
An extension of non-medical healthcare professionals’ role in prescribing needs to be 
considered in the context of patient harm caused by the provision of medically 
prescribed medicines. There is data suggesting that in Australia, nearly 140 000 hospital 
admissions a year may be linked to drug related adverse effects with half of these being 
preventable. Also, up to 400 000 visits to general practitioners a year are linked to drug 
related adverse effects. In 2002 the cost for medicine related hospital admissions was 
estimated to be $380 million.114,115 Miller et al. have suggested that 10.4% patients 
attending general practices suffered a drug related adverse effect with half of these being 
moderate to severe. Translating these findings to the total number of patients that visit 
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GP’s in Australia it indicated that almost two million people in Australia have a drug 
related adverse effect annually.114,116 
 
As outlined by Kidd et al. new roles for other Australian health professionals need to 
take into account six main principles: “support the relationship between patients and 
their general practitioners, be clearly defined, aligned with competency and with 
relevant professional registration, be supported by practice systems providing safeguards 
against medical error, be underpinned by a system ensuring informed patient consent to 
activities being undertaken by members of the general practice team and be supported by 






2.3.2 Australian studies exploring pharmacist prescribing  
 
There is one descriptive study to date that has assessed the issue of pharmacist 
prescribing in Australia. This study addressed the awareness of international 
developments in pharmacist prescribing and whether respondents would benefit from 
prescribing activities. 118 However, this study was limited by a low response rate (6.4%). 
Also, in this study community pharmacists were represented by consultant pharmacists 
who worked in community pharmacies. It should be noted that a majority of pharmacists 
in Australia work in community pharmacies and most of them are not consultant 
pharmacists. Views of Australian hospital pharmacists were assessed by another study. 
119 The limitation of this study was that it only included 15 hospital pharmacists. Both 





There are currently two trials in the implementation stage being conducted in 
Queensland. These trials are exploring the skills, knowledge and competencies of 
pharmacist prescribers. Both these trials are being conducted in hospital settings.109  
 
Aiming to provide Australians with improved and safe access to prescription medicines,   
utilize pharmacists’ and doctors’ skills better and reduce healthcare costs, a major 
Australian research project has proposed four models in which pharmacists would have 
expanded prescribing roles.120 These proposed models were: 
 
 
1) Medicine maintenance 
 
According to this model pharmacists would prescribe based on an individual patient plan 
designed by doctor. This model in essence is a collaborative approach that would allow 
patient management in Residential Aged Care Facilities (RACFs).120   In this model the 
doctor would initiate the medicine while an accredited pharmacist (i.e. consultant 
pharmacist) would review, monitor, and renew medicines provided the residents’ 
condition was stable. The main advantage of this model highlighted by researchers was 
to overcome current difficulties associated with the ‘emergency supply’ system.  
The authors of this project recommended that in this model the supply of medicines for 
chronic conditions should be prescribed in a way that improves this supply both in terms 
of time and quantity. The authors also recommended that medicines supplied under the 




2) Advanced practitioner 
 
This model is a hospital-focused model in which senior pharmacists could prescribe in a 
supplementary fashion. This model would allow hospital pharmacists to prescribe 
medicines in collaboration with doctors and it has the potential to be applied in ‘pre-
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admission and out-patient clinics, ambulatory care and inpatient clinics. The authors 
recommended that prior to hospital pharmacists assuming this role, they need to reach a 
pre-determined level of competence.120 
 
 
3) Protocol management 
This model would allow pharmacists to prescribe prescription medicines according to a 
‘defined population-based protocol’. With the protocol management model the authors 
have proposed similar responsibilities to other rural health workers for pharmacists in 
rural and remote areas.  In this model pharmacists would have an expanded role 
allowing them to monitor and modify medicines according to evidence-based protocols. 




4) Formulary prescribing 
This model essentially advanced the current formulary prescribing by pharmacists in 
Australia by allowing them to claim ‘Pharmacist Only Medicines’ via the PBS. The 
authors also proposed that non-PBS items should be covered by private health insurance. 
In order to implement this model and ensure appropriate use of medicines, the authors 
recommended introduction of an electronic health record system accessible by doctors, 
pharmacists and patients.106 All medicines prescribed by pharmacists would be recorded 
in this system. The authors also recommended that ‘Pharmacist Only Medicines’ should 
be renamed to ‘pharmacists’ formulary’.120 
 
Some concerns were also raised by the participants (prescribing stakeholders) in this 
project.120 In the ‘medicine maintenance’ the extension of the ‘emergency supply’ 
system from three to 30 days does seem to provide a postponement rather than a solution 
to the supply of medicines to RACFs. Stakeholders in this project also had concerns with 




The second model includes hospital pharmacists only. Stakeholders have raised concerns 
about the availability of pharmacists during weekend discharge of patients, particularly 
in light of hospital pharmacists’ shortages. Given that this model emphasizes a patient-
specific plan, stakeholders had concerns about the disruption of treatment and potential 
errors during the weekend with multiple pharmacists being involved.120  
 
In terms of the third proposed model i.e. protocol management, stakeholders had 
concerns with clarification between doctors’ and pharmacists’ tasks. Main concerns 
raised by stakeholders with the formulary prescribing model were: potential for 
increased consumer demand for medicines, adverse health outcomes and the issue of 





2.4 Benefits and facilitators of pharmacist prescribing 
 
Literature suggests that the main benefits of expanding prescribing for non-medical 
health professionals internationally include: improvement of patients’ care and access to 
medicines, better resource utilization both economical and human, making the 
healthcare system more efficient by reducing waiting times for patients and reducing 
fragmentation of health care.38,43 
 
The main drivers for the expansion of pharmacist prescribing responsibilities in the UK 
have been to provide better health outcomes for patients with chronic diseases in 
particular, and assist GPs to utilize their time more effectively by possibly reducing their 
workload. 121 England’s Department of Health lists improving patient care, medicine 
access, better utilization of pharmacists’ professional skills and team work within the 
healthcare system as the main aims for the introduction of independent nurse and 
pharmacist prescribing.51 England’s Department of Health also suggests that PIPs may 
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also fill geographical and skills shortages in services and manage complex medicine 
regimens and long term medical conditions.51 
 
 
2.4.1 Studies evaluating pharmacists prescribing prescription only    
medicines 
 
Positive clinical outcomes were reported in the literature when pharmacists engaged in 
prescribing prescription only medicines. As early as 1960-1970, in the US there were 
programs that authorized pharmacists to prescribe prescription medicines directly to 
patients and without prior authorization from doctors.57,77  These programs were initiated 
by the IHS, an agency of the US Public Health Service. In these programs, in addition to 
prescribing, pharmacists also monitored patients’ progress and made pharmacological 
alterations accordingly. These programs were so successful that eventually pharmacists’ 
roles were expanded even further to include patients’ physical examination and 
differential diagnosis.77  
 
A study explored the clinical outcomes in a pain clinic with pharmacists having 
prescribing authority.122 In this clinic 90% of patients were treated for chronic non-
cancer pain. This study has reported that patients in this clinic were managed effectively 
by a pharmacist. In addition, cost savings were also achieved.122 
 
Improvement of blood pressure control and anticoagulation therapy were reported by 
studies assessing the clinical outcomes of pharmacist prescribers. 57,64,123,124,125,126  
Hawkins et al. reported significantly lower blood pressure results in a study aimed at 
lowering blood pressure in diabetic patients.127  In terms of anticoagulation therapies a 
few studies showed that fewer warfarin related adverse effects occurred in patients 
managed by pharmacist prescribers.57,125,126,128,129  
 
Literature data also suggests improved compliance achieved in cases where pharmacists 
were involved in prescribing medicines.57 Additionally, studies have shown better 
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resource utilization, reduced outpatient visits to clinics and reduced emergency hospital 
admissions and hospitalization days for  patients receiving warfarin therapy with 
pharmacists engaging in prescribing. 57,124,126,118,130 
 
Simmel et al. compared prescribing by pharmacists and physicians for psychiatric 
inpatients. Pharmacist prescribers only dealt with patients who were already diagnosed 
and treatment was exclusively pharmacologic. Prescribing by both pharmacists and 
physicians was evaluated by a team of clinical judges independently. The result was that 
pharmacists’ prescribing was as safe and appropriate as physicians’ prescribing. 131 
 
Ellenor and Dishman described a successful expansion of hospital pharmacists’ scope of 
practice in psychiatry. 132 The success of pharmacist prescribers as well as the 
acceptance of a psychiatry clinic as a role for pharmacists was demonstrated by 
continuous expansion of this program. By the end of fourth year of this program, 
pharmacists conducted 46% of all psychiatric medicine visits.132 
 
A study conducted in Seattle, US, evaluated pharmacists prescribing hormonal 
contraceptives in a collaborative drug therapy protocol model.133 Prescribing was done 
according to protocol guidelines. This study showed that community pharmacists could 
efficiently monitor patients for safe use of hormonal contraceptives and select 
appropriate therapy. Both patients and pharmacists were satisfied with the services. 
Willingness to pay for this service as well as readiness to visit pharmacist prescribers for 
receiving other services was also displayed by patients.133 
 
Bauer et al. explored the outcomes of expanding pharmacists’ scope of practice in the 
area of venous thromboembolism prophylaxis.134 Pharmacists developed a program 
which would assess all new patients admitted to the hospital for risk of venous 
thromboembolism. Pharmacists accordingly recommended pharmacologic prophylaxis. 
This pharmacist led program resulted in a significant increase in the use of 





Literature data also indicated that a pharmacist directed hypertension clinic resulted in 
improved patients’ blood pressure and prescribing of antiplatelet agents and statins for 
primary prevention of cardiovascular events. 135 In this program, a total of 242 patients 
visited this clinic during a period of 10 months. Pharmacists recommended lifestyle and 
pharmacological alterations with the aim of achieving British Hypertension Society 
(BHS) target blood pressure levels. This study reported that patients who achieved target 
blood pressure level increased from 74 (36%) pre-clinic to 174 (85%) post-clinic. 
During a five months period of time, in this clinic 74 patients (80%) achieved target 
blood pressure level compared to 27 (40%) with standard GP management.135   
 
Till et al. assessed the outcomes of pharmacist managed lipid-lowering therapy in a 
primary care setting. 136 This study specifically focused on examining the difference in 
lipid profile improvement for patients receiving lipid lowering medicines prescribed and 
altered by pharmacists compared to other health care practitioners. In this setting, in 
addition to prescribing, pharmacists were also responsible for ordering and interpreting 
laboratory results and monitoring lipid lowering therapy. Clinical pharmacists with an 
expanded prescribing role in lipid lowering drug therapy achieved a significantly greater  
reduction in low-density lipoprotein cholesterol (LDL), compared to the group which 
did not have a clinical pharmacist managing patients’ dyslipidemia.136 This also 





2.4.2 The UK experience with expanded pharmacist prescribing 
 
Studies are emerging that have evaluated the experiences of PSPs in the UK. Warchal et 
al. suggested that professional challenge, a better use of their skills and patient and 
pharmacy profession benefits were significant reasons for pharmacists commencing 
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supplementary prescribing training in the UK.43,54 Pharmacists’ professional challenges 
and patient benefit by supplementary prescribing were also reported by Weiss et al.137 
 
A cross-sectional survey conducted by George et al. has identified the benefits perceived 
by PSP’s.55 These benefits included: improved patient management, job satisfaction and 
greater confidence and independence for pharmacists. Pharmacists in this study also 
believed that patients were more satisfied under the pharmacist supplementary 
prescribing.55 In addition to job satisfaction and benefits to patients, Lloyd et al. reported 
that doctors believed that pharmacist supplementary prescribing can reduce their 
workload and errors.138 While et al. reported pharmacists’ increased knowledge was a 
benefit to supplementary prescribing.139  
 
Benefits for patients have also been identified with Weiss et al. suggesting improved 
information from and longer consultations with pharmacists, compared to doctors.137   
 
There is a lack of research on clinical outcomes of supplementary and independent 
prescribing practised in the UK. Shulman and Jani conducted a study which measured a 
clinical outcome with supplementary prescribing arrangements.140 These authors 
assessed doctors and pharmacists’ adherence to drug dosing guidelines for 
haemofiltration in an intensive care unit. According to this study, pharmacists were more 
adherent to haemofiltration drug dosing guidelines.140 
 
A good relationship between pharmacists and doctors, which is based on mutual trust, 
has been reported to be a facilitator in the implementation of supplementary prescribing 
in the UK.53 
 
It is worth adding that the IHS pharmacist protocol prescribing model in the US resulted 
in increased patients’ satisfaction. This model also improved pharmacist-physician 





2.5 Barriers to pharmacist prescribing 
 
Literature data have indicated that most pharmacists are reluctant to prescribe due to 
conflict of interest with doctors, drug manufacturers, liability insurance, lack of 
economic incentives, excessive workload, lack of willingness and time pressure.57,142,143 
It has been reported that UK pharmacists were concerned about time pressures without 
prescribing.144 There are also reports stating that fragmentation of care can result in 
increased costs and inefficiencies within the health care system.117 
 
Mrtek highlighted the lack of access to patient’s medical records in a community 
pharmacy as the main barrier to pharmacist prescribing.145  
 
Limitations reported with pharmacist protocol prescribing also included additional 
workload for pharmacist prescribers, complicated financial compensation and 
pharmacists compromising other professional tasks leading to more errors. 38,78,141,146 
 
Privacy during consultations as well as the management of pharmacist only medicines 
were reported to be issues of concern for pharmacists involved in PGD model of 
prescribing.38,60,147 There were some barriers reported with the formulary based 
pharmacist prescribing model as well. 38 Record-keeping and pharmacists’ liability were 
reported to be barriers towards this model. 38,148 
 
Significant barriers in implementing supplementary prescribing have also been 
identified. 36,43,137 Barriers identified in the literature include delays in obtaining 
prescription pads and deficiencies in access to patients’ medical records, information 
technology to print prescriptions, administrative support to run supplementary 
prescribing clinics, time and financial limitations. Furthermore, Candlish et al. have 
suggested that a hospital environment was more suitable for supplementary prescribing 
as there already existed a relationship between doctors and pharmacists and sufficient 




Hobson and Sewell have also suggested that there are more barriers to implementing 
supplementary prescribing in primary care (i.e. health services offered through a local 
medical practice) in comparison to secondary care (i.e. acute health services including 
emergency and specialties that cannot be offered in primary care). 39 It was suggested 
that in hospitals, supplementary prescribing in fact formalized already existing practices. 
39,45 Baird has also identified limitations for supplementary prescribing in a community 
setting. This study reported confusion about the initial patient diagnosis, patient co-
morbidities resulting in part-prescribing and lack of supplementary prescribing by some 
pharmacists.150 
 
Further evidence from the UK confirms barriers such as lack of funding and Information 
Technology (IT) support for the implementation of supplementary prescribing. In 
addition, lack of awareness by other stakeholders has also been reported to be a barrier 
perceived by PSPs.49 The same authors have suggested in another study that only half of 
the pharmacists trained to assume supplementary prescribing were actually practicing.55 
In addition to doctors’ and patients’ lack of awareness with supplementary prescribing, 
Weiss et al. reported communication issues, lack of skills in clinical examination to be 
barriers in the implementation of supplementary pharmacist prescribing. 137 
  
Difficulties in developing relationships with doctors have also been reported.36 Child 
and Cantrill have reported that doctors perceive a lack of pharmacists’ clinical and 
patient knowledge, communication skills and mechanisms for reviewing patients’ 
treatment after doctors initial prescribing, as barriers towards the implementation of 
supplementary prescribing.151  
 
Nurses are more positive to pharmacist prescribing compared to doctors.43 Child reports 
that nurses positively perceived pharmacist prescribing if issues such as liability, 
communication skills and resources are properly addressed.152 It is worth emphasising 
that in a study conducted by Lloyd et al. nurses believed pharmacists were the most 
knowledgeable regarding medicines.153 However, they did not perceive pharmacists to 
be the best in prescribing. This same study reported that pharmacist prescribing was not 
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seen as a threat by nurses but they did consider this role may de-skill doctors.153 Buckley 
et al. reported that hospital stakeholders were supportive of pharmacist prescribing 
despite concerns they had with pharmacists’ lack of diagnostic skills and lack of patient 
knowledge.154 However, in this study some doctors were more defensive professionally 
and suggested a reluctance to relinquish their current medical control.154   
 
Inter-professional barriers were also reported by Hughes and McCann.155 These authors 
highlighted that doctors perceived pharmacists as shopkeepers. In this regard issues such 
as doctors considering pharmacist prescribing to be a threat to the professional hierarchy 
and lack of GP’s awareness of pharmacist supplementary prescribing were also found to 
be significant barriers.155 Lack of doctors’ awareness on pharmacist supplementary 
prescribing was also reported by Lloyd et al.138  
 
A qualitative evaluation of pharmacists’ and their mentors views on supplementary 
prescribing conducted by Lloyd and Hughes revealed that although supplementary 
prescribing was in fact welcomed by both pharmacists and their doctor mentors there 
were still issues such as a perceived threat of independent prescribing and infringement 
of boundaries that surfaced.53 Medical de-skilling was also an issue raised by doctor 
mentors. However, these doctors believed that supplementary prescribing would 
ultimately allow them to retain control of the patient. This same study also reported that 
pharmacists were concerned about the supplementary prescribing limiting their 
professional autonomy.53  
 
Lack of access to patients’ medical records and the threat to supplementary prescribing 
by independent prescribing were also reported to be barriers by Warchal et al. 54 In 
addition to lack of access to patients medical records, While et al. reported time as a 
significant barrier for pharmacists to implement supplementary prescribing.139  
 
Frequently, the involvement of the CMP in supplementary prescribing has been reported 
in the literature to be one of the main barriers for its implementation. This is mainly due 
to its restrictive, inflexible and time consuming nature.43,44,54,55,137  The CMP is a core 
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element in supplementary prescribing and represents a framework designed for the 
management of individual patients. George et al. have suggested that an independent 









2.6 Training of pharmacist prescribers 
 
 
Pharmacists in the UK need to complete an accredited prescribing course at a tertiary 
institution in order to gain any prescribing rights. This is in addition to the undergraduate 
training that leads to registration as pharmacists.157 The RPSGB accredits the training 
and sets the professional requirements for pharmacist prescribers in the UK.  The main 
difference between pharmacists prescribing training in the UK and elsewhere in the 
world is that in the UK this training is nationally recognized and accredited as opposed 
to a local assessment of competencies. 38,156,157  
 
In the US prescribing authority of pharmacists varies between states and there are no 
uniform education requirements for pharmacists providing CDTMs. However, 
pharmacists providing CDTM’s usually have an advanced level of training or clinical 
experience.67 Additionally, many pharmacy schools in the US are now focusing on 
providing specific training on CDTM to new graduates. The state of New Mexico, has 
developed a category of pharmacists providing CDTMs which are trained in physically 
assessing the patient. These pharmacists complete a 60 hour course which is approved 
by the pharmacy board and this is also followed by a nine month clinical experience 




In Canada, pharmacists receive no additional tertiary level training for gaining further 
prescribing responsibilities. 83 There are also no uniform non-tertiary training 
requirements throughout Canada for pharmacists assuming expanded prescribing roles. 
It should be emphasized that prescribing roles vary in different Canadian provinces. 85 In 
the Province of Alberta pharmacists must be familiar with the new practice standards. In 
the Province of British Columbia pharmacists are guided by the “Protocol for 
Medication Management – Adapting a Prescription”, developed by the British Columbia 
College of Pharmacy. They must also in writing declare that they understand this 
orientation guide.83,158 
 
In the UK, pharmacist prescribing training is taught for an equivalent of 26 days and is 
part-time based lasting 3-6 months. Distance learning is also offered by some tertiary 
education institutions.156 Pharmacists also need to have two years of clinical experience 
prior to enrolling into a prescribing course. Upon completion of this course pharmacists 
are also required to undergo a supervised learning experience with a Designated Medical 
Practitioner. 156 
 
Under the new training plans, current PSPs will take extra training, including practice-
based learning in order to become PIPs. However, it should be emphasized that the 
independent prescribing model was not started in order to replace the existing 
supplementary prescribing model but to complement it.   
 
Evidence from the UK suggests that there are concerns that have been identified with the 
actual training for non-medical prescribing, including pharmacists’ prescribing.156  
George et al. reported that Scottish community pharmacists considered that their needs 
for suitable training be emphasised on evidence-based medicine, diagnosis and 
consultation skills before independent prescribing was undertaken.159 Buckley et al. 
suggested that hospital stakeholders considered pharmacists to have sufficient 
pharmacological knowledge, however they lacked diagnostic skills and patient 
knowledge.153 Therefore, suggesting training was to be focused in these areas. Dawoud 
et al. observed how pharmacists undertaking supplementary prescribing considered were 
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knowledgeable in areas such as pharmacology and pharmacokinetics, but they needed 
more training in patient assessment and counseling.160  
 
Cooper et al. explored pharmacists’ experience with supplementary prescribing after 
being trained in England.156 Areas of training such as clinical examination, training in 
consultation skills and practical experience with doctors were valued the most whereas 
training in pharmacology was criticized.157 Pharmacists suggested that training in 
pharmacology was either a ‘waste of time’ or ‘too basic’.  Although supplementary 
prescribers were not involved in patient diagnosis, some respondents still suggested a 
need for training in diagnosis. The authors have attributed this to the intentions of most 
respondents to become independent prescribers. These authors suggested that 
supplementary prescribing training was an important step for pharmacists wishing to 
achieve full independent prescribing authority.156 
 
In evaluating the experiential learning of pharmacists with DMP’s, during 
supplementary prescribing training, George et al. have identified time, attitudinal and 
organisational barriers.161 Alternatively, professional development and teamwork were 
reported to be major positive aspects of this training. These authors have suggested that 
the internet could be used to advance communication during the experiential learning of 
pharmacists with DMP’s. The authors have also concluded that a multidisciplinary 
approach of health professionals, as well as consultation videos, could have a positive 












2.7 Economical implications of pharmacist prescribing 
 
There are limited data directly exploring the economical implications of pharmacist 
prescribing. However, there is evidence that when pharmacists intervened in otherwise 
doctors’ routine prescribing, this has resulted in significant savings.16,136,162-168   
 
Studies have explored the cost-effectiveness of clinical pharmacist interventions in 
prescribing of antibiotics such as tobramycin and vancomycin. These studies showed a 
significant cost reduction was achieved for the hospital. 16,162 Pharmacists’ intervention 
in these studies consisted of promotion of the use of other antibiotics. 
 
Another study showed that when a doctors’ surgery employed a practice pharmacist, 
who monitored and ensured rational prescribing, a reduction in prescribing costs was 
achieved over a three year period.163 
 
A study investigated the effect of two pharmacists providing clinical services on 
prescribing and drug costs for nonsteroidal anti-inflammatory drugs (NSAIDs) and 
salicylates in a primary-care clinic.164 Pharmacists recommended prescribers low-cost 
alternatives and reviewed patients’ medicine profiles. These two pharmacists did not 
reduce the cost of NSAID prescribing while they slightly reduced the cost of salicylate 
prescribing. The operational costs during the first months exceeded those anticipated and 
therefore this program was not self-sustainable economically. 164 However, in addition to 
this study’s limitations in terms of representativeness of pharmacists and primary-care 
clinics, one should take into consideration that availability of NSAIDs in 1987 was 
significantly lower than today and therefore the chances for pharmacists making 
recommendations were reduced compared with today. Therefore, the class of medicines 
that was explored in this study (i.e. NSAIDs) has its own specific limitations, especially 
when compared to contemporary recommendations on adverse gastrointestinal and 




Forstrom et al. studied the effect of clinical pharmacists on antihypertensive therapy in a 
family practice clinic provided by five doctors. Pharmacists reviewed patients’ files and 
placed recommendations to changing drug therapy in patients’ medical records.165 
Pharmacists’ intervention led to a decrease in the cost of antihypertensive therapy from 
33.4 to 27.2 cents per day.  
 
A study which explored the outcomes of a pharmacist with prescribing authority in a 
pain clinic with patients consisting mainly of chronic non-cancer pain also concluded 
that additional cost reduction was achieved.166 Clinical pharmacists’ impact on 
prescribing of parenteral cefalosporins was also reported to result in significant cost 
savings. 167 Pharmacists interventions consisted of publication of a newsletter that 
contained specific recommendations for doctors, emphasizing the primary use of 
cefazolin and personal interaction of pharmacists and doctors promoting the newsletters’ 
recommendations.167 
 
Another study showed an improved lipid profile for patients who were managed by a 
clinical pharmacist with an expanded prescribing role in lipid lowering therapy 
suggesting lower cost to the healthcare system as a result of dyslipidemia consequences 
and long term cardiovascular complications.136 
 
Rodgers et al. showed that when pharmacists were employed in a UK general practice 
clinic it resulted in significant savings.168 Pharmacists did control prescribing costs 
enough to offset their employment costs. In this general practice pharmacists performed 
duties such as: generic substitution of branded medicines, clinical audits, repeat 
prescription and formulary reviews. Pharmacist-run asthma and gastrointestinal clinics 
in order to review patient medicine were also set up. The group of surgeries who had 
pharmacists employed was then compared with surgeries that did not have pharmacists. 






2.8 Pharmacy clients’ perspectives on pharmacist prescribing 
 
Ultimately the process of medicine prescribing is directed towards achieving an optimal 
treatment and management for patients. Therefore one would argue that this puts 





Figure 2.3   An illustration of medicine management pathway 169 (Figure reproduced 
with permission of the copyright owner). 
 
 
Despite the central role that patients have in the process of medicine provision, literature 
on their perceptions of pharmacist prescribing is very limited. This is even despite the 
fact that for example supplementary prescribing involves the use of CMP’s which is an 
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agreement between three parties i.e. doctors, pharmacists and patients.43,45,49 No study 
was identified that explored attitudes of pharmacy clients who had not experienced 
pharmacist prescribing.  
 
One study has evaluated patient's perceptions of a pharmacist-led supplementary 
prescribing model in a hypertension clinic. 170 Of 110 respondents (87% response rate), 
57% reported that the standard of care was better than the previous care and 85% 
indicated they could make appointments more easily. This study was viewed as an audit 
to the services provided by this clinic. No statistical analysis was performed and the 
author specified that it was aimed at finding ways to improve the service provided by the 
clinic. Also, this study did not indicate whether there was an acceptance of patients for 
non-medical staff prescribing.45,170   
 
Another recent study has explored the experiences of eight doctors, nine PSPs and 18 
patients recruited by PSP’s. These patients were purposively sampled.171 Patients 
expressed a high level of satisfaction with PSP’s. Limitations of this study were a) 
selection of patients by service providers i.e. PSP’s and hence the possibility of bias in 
their responses and b) a low number of patients in the sample.  
 
Patients’ attitudes were explored in another study where participants were again 
recruited by nine PSP’s.171 A total of 103 patients was surveyed and researchers 
emphasized the need for larger scale studies exploring patients’ attitudes to pharmacist 
prescribing. Most of these patients consulted PSP’s in a general practice. Patients were 
satisfied with their pharmacist consultation and especially with the information given to 
them about their medicines. These patients also considered that they trusted the 
pharmacist and would recommend a pharmacist prescriber to others. However, those 
patients considered that they would still choose a doctor over a pharmacist if they had 
that option.171 
 
Stewart et al. conducted telephone interviews with nine pharmacist prescribers, eight 
doctors and 18 patients.172 This study reported a general support by stakeholders. 
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Patients in this study did not raise concerns with pharmacist prescribing but they did not 
know “what to expect on their first visit, leading initially to feelings of apprehension”.172 
This study was also limited by representativeness.  
 
A study which used qualitative, semi-structured interviews with 43 UK stakeholders 
including doctors, pharmacist and nurse supplementary prescribers, academics, patient 
group representatives, and policy developers welcomed the introduction of 
supplementary prescribing but also identified barriers to its implementation.173 
 
Weis et al. undertook 10 patient interviews and 15 patient observations. In this study 
patients considered that PSPs may reduce doctors’ workload. Patients in this study 
reported that they received more information and increased consulting time with PSP. 
This study was also limited in terms of representativeness.137  
 
Qureshi et al. assessed whether patients were confident of nurse and pharmacist 
prescribing. However, in this study participants were limited to patients who attended 
ophthalmology clinics.174 
 
Since in the UK nurse prescribing was developed in parallel to pharmacist prescribing, it 
is worth mentioning that one study has evaluated the views of a small convenience 
sample of the general public on nurse supplementary prescribing. These patients had not 
experienced supplementary prescribing.175 This study concluded that participants had 
confidence in nurse supplementary prescribing and they raised issues such as prescribing 
of correct medicine, dose, drug side effects and interactions rather than specific nurse 
concerns. 175 
 
A major study conducted in Scotland in 2006 and published in June 2009 has assessed 
the views and awareness of the general public on non-medical prescribing.176 Stewart et 
al. have indicated that the general public was most comfortable with pharmacist 
prescribing followed by nurses. Respondents agreed that pharmacists should have a 
prescribing role but were concerned with lack of privacy. Safety of pharmacist 
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prescribing seemed to be an issue for respondents as only 39.6% agreed that pharmacists 
would prescribe as safely as doctors.176 Fewer respondents believed that pharmacists 
should prescribe the same medicines as doctors and fewer respondents also considered 
pharmacists equally knowledgeable as doctors in prescribing medicines. In this study 
more than half of the respondents has not visited a pharmacy to get medicines and/or 
advice in the past 12 months.176 Therefore, there may have been a lack of a relationship 
of the respondents with pharmacists which could have affected the overall results.  In 
addition this study did not separate respondents who had already experienced pharmacist 
prescribing in the UK.  
 
Hobson et al. conducted a study which explored patients’ perspectives on nurse and 
pharmacist independent prescribers.177 This study used semi-structured interviews where 
18 patients were recruited in four sites: two by doctors and another two by PSP.  These 
authors focused on whether patients had a preference in terms of consulting a nurse or a 
pharmacist independent prescriber and whether pharmacists were capable of an 
expanded prescribing role. Contrary to Stewart et al., Hobson et al. reported that patients 
had a preference for nurses over pharmacists because they were more trustworthy, caring 
and that their profession had an established relationship with patients. Participants also 
highlighted privacy issues and available space in community pharmacies adopting 
independent prescribing. Clinical governance concerns were also raised. However, 
patients indicated support for pharmacist prescribers.177 Patients also suggested that the 
actual popularity of PIPs will take time until PIPs build a relationship with patients. In 
this study the number of PSP recruited was limited which in turn restricted the sampling 
frame. The fact that participants previously experienced pharmacist supplementary 
prescribing but not nurse supplementary prescribing and were selected for participation 
by prescribers may have had an impact on the findings. Hobson et al. attributed the 
difference in results with Stewart et al. to the difference in percentage of female versus 
males between the studies and the different methodologies used.177  
 
In Australia, the study conducted by Bessell et al. included a patient perspective. Their 
perspectives was based on proposed models of pharmacist prescribing. In this study 
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consumers participated in focus groups and were in favour of improved medication 







2.9 Medicine supply to residential aged care facilities (RACF) 
 
 
2.9.1 General description of residential aged care 
 
An estimated 6% of Australians aged over 65 years and 30% over the age of 85 live in 
RACFs. 178 In terms of gender there is a significant difference only for residents over the 
age of 85 where residents are mainly women.178,179 People with special needs such as 
those with linguistic and cultural diverse backgrounds, and people with intellectual and 
physical disabilities also live in RACF. In addition to pharmacy services, RACF 
residents are also offered other care such as allied health, social services, respite and 




2.9.2 Health workforce in RACFs 
 
There are four main challenges facing the aged care sector. 180 These include: a) building 
a flexible workforce which provides adequate care to RACF residents, despite the 
pressure from anticipated reduction in growth of workforce; b) responding to an 
increased demand for services as the Australian population ages; c) ensuring an upgrade 
of workforce skills and training in order to comply with improved services and d) 
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adapting the workforce in order to reflect the changing needs and preferences of 
consumers.180 
 
GP’s provide primary medical care to residents of RACFs. This care is focused on 
preventing and managing chronic conditions and geriatric syndromes. Rehabilitation, 
palliative and end of life care are also provided by GP’s. In managing complex 
conditions seen in the elderly, GP’s are also provided with specialist advice by aged care 
assessment teams and geriatricians. 178 
 
There are indications suggesting that GP services to RACFs are inadequate to meet the 
current needs. A survey based study conducted in 2004 found that 52% of RACFs had 
difficulties in obtaining services from residents’ GPs. This survey also found that 56% 
of RACFs had difficulties in receiving GPs’ input for services such as: prescription 
writing, reviewing medicine charts and prescriptions. 181,182 Low level of reimbursement, 
time consuming procedures and the lack of interest by younger GP’s, have been reported 
as barriers to the provision of GP services to RACFs.183-188  
 
Pharmacists are closely involved with RACFs and the management of their residents. In 
addition to dispensing and supplying medicines, pharmacists are actively involved in 
providing medicine information and advice. Consultant pharmacists also participate in 
medicine advisory committees (MAC) and perform residential medicine management 
reviews regularly.58,178 As a part of multidisciplinary care, other allied health workers 
are also involved in providing services to residents of RACFs.  
 
Registered nurses (RN) provide a variety of services to RACF residents including 
general nursing care and assessment and monitoring of residents health needs. RNs also 
use evidence based tools in care planning which enables them to assess and manage 
geriatric syndromes. 178,188 Registered nurses supervise carers and have a central role in 
liaising with GP’s. Documentation of residents’ care plans, records and accreditation of 
RACFs is also managed by RNs.178 Residents’ carers (personal care attendants – PCA) 
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make up the largest workforce in RACF’s and while supervised by registered nurses, 
they maintain daily activities and residents’ personal care.178  
 
It should be emphasized that The Hogan Review has identified a greater shortage of 
trained nurses in RACFs and ageing of nurses, compared to other areas. 178,189   This 
review has also identified difficulties in recruitment and retention in the workforce. Job 
satisfaction has also been identified to be an issue with the nursing workforce, especially 
due to low remuneration and high workload. This does not only apply to nurses but to 
personal carers as well.189 
 
2.9.3 Medicine management in RACF 
 
The elderly living in RACFs represent the chronically ‘sickest and frailest’ group of the 
Australian population and they also represent the group with the highest disability rate. 
179 In terms of medical conditions, it is estimated that 90% of this population has sensory 
loss, 40-80% suffer from chronic pain and 60% from dementia. Depression, sleep 
disorders and falls are also quite prevalent in residents living in RACFs.178  
 
 
High prevalence of diseases and co-morbidities implies complex medicine regimens and 
needs in RACFs. Therefore a multidisciplinary approach is needed in order to ensure 
optimal medicine management.178  
 
To ensure the quality use of medicines the Australian Pharmaceutical Advisory 
Committee (APAC) has made a number of recommendations. 190 These include:  
 
1) The establishment of Medicine Advisory Committees (MAC) by facilities. MAC 
should include management, general practitioners, nurses, supplying pharmacist 
or the pharmacist conducting medicine reviews (if different) and residents’ 
advocate(s); 
2) Use of medicine charts for recording administered medicines; 
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3) Review of residents medicines by health professionals;  
4) Except in cases where residents self-administer medicines or a DAA is used, 
medicines should be administered by registered nurses or authorised enrolled 
nurses; 
5) No standing orders  should be used for administering new medicines for a 
changed new clinical condition; 
6) Nurse initiated medicines should be from a list of drugs (including recommended 
doses) according to protocols developed by the MAC and State/Territory and 
Commonwealth legislation; 
7) Self-administration of medicines by residents should be done only after each 
resident is assessed as capable of carrying this task individually; 
8) RACFs should have procedures, endorsed by the MAC, for alteration of 
medicine dosage forms; 
9) Medicines should be retained in original or dispensed packaging. Dose 
Administration Aids (DAA) should be used in cases where it overcomes issues 
with compliance or confusion with medicines. Medicines used on a ‘when 
required’ (PRN) basis should not be packed with regular medicines. All 
medicines packed in a DAA should be included in the residents’ medicine formal 
chart; 
10) The RACF should have resources available, recommended by the MAC, on 
medicines information; 
11) Secure storage of medicines; 
12)  The RACF must have a mechanism for disposal of unwanted, expired and 
returned medicines; 
13) The RACF must have policies in place, approved by the MAC, for 
complementary, alternative and self-selected medicines; 
14) The emergency supply of medicines should be in accordance with legislation and 
approved by the MAC.191 
 
In Australian RACFs medicine supply is negotiated between the RACF and the 
community pharmacy. Medicines in RACFs are prescribed by GP’s, specialists, locum 
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and hospital doctors. In addition, dentists and registered nurse practitioners are also able 
to prescribe medicines.179 RNs are entitled to use their clinical judgment and assessment 
to initiate S2 or S3 scheduled medicine. 
 
Currently pharmacists cannot prescribe medicines to RACF residents. The pharmacy 
supplies the medicines based on the medicine orders which are written by prescribers on 
an individual residents’ medicine chart.  
 
Except for private prescriptions, pharmacists are reimbursed for dispensing and 
supplying medicines to RACFs through the PBS. Therefore, for each medicine 
dispensed pharmacists need a prescription from the prescriber to be entitled for 
reimbursement. After these basic steps in the medicine supply chain, the pharmacy 
supplies medicines to RACF residents, either in original packs or using DAA. In 
situations when residents run out of prescriptions (or repeats), pharmacists may supply 
prescription medicines prior to receiving a new prescription. However, the prescription 
must be received within seven days.191 
 
As per APAC guidelines stated above, RNs and authorized enrolled nurses administer 
medicines. PCAs also administer medicines in cases where DAAs are used.178,190 A 
typical DAA contains doses of medicines packed according to days and weeks of drug 
supply. DAAs allow for medicines to be packed according to doses schedule of the 
day.192 There are two main types of DAAs provided by community pharmacies and 
these include ‘blister packs’ and ‘compartmentalised boxes’.  Medicines in DAAs are 
packed and labeled by the pharmacist or under a pharmacists’ direct supervision. They 
are directly administered to the resident. In cases where the prescriber alters the 







2.9.4 Current difficulties in medicine supply and management  
 
There is a range of barriers to the quality use of medicines in RACFs. These include: 
polypharmacy, resulting in increased prevalence of drug related adverse effects and 
interactions; excessive use of sedatives and psychotropic agents; lack of medicine 
review (required for accreditation); awareness of specific drug requirements in the 
elderly, and administration of medicines by unqualified staff.190 
 
Currently pharmacists need prescriptions supplied by a qualified prescriber for every 
medicine they dispense during the process of medicine provision to RACFs. Legally, the 
‘emergency supply’ system allows pharmacists to supply medicines to RACF residents 
for a period of three days hence theoretically allowing doctors enough time to visit, 
review and write the prescription. Residents are charged privately for this service. 
However, Bessel et al. have suggested that this process is not very feasible because it 
requires a ‘high level of clerical organisation from the doctor, pharmacist and RACF 
staff.120 There is also a cost burden for pharmacists associated with breaking the packs of 
medicines when the ‘emergency supply’ system is used.  
 
Pharmacists in some cases continue the supply of medicines without a prescription using 
the ‘owing prescription’ system.178,191 This system allows the supply of medicines to 
residents while pharmacists have to follow-up with doctors to receive prescriptions for 
medicines supplied. The ‘owing prescription’ system has the advantage of continuing 
the supply of medicines to patients, hence not interrupting the treatment and it also keeps 
patients’ costs down i.e. medicines are reimbursed by the PBS once the pharmacist is 
able to submit the prescription to the PBS. The problem with this system is that it is not 
always legal, it consumes pharmacists’ time in following up prescriptions from doctors 
and it presents pharmacists with a financial burden by waiting until the prescription is 
received from the doctor and hence claiming it after delayed receipt. Furthermore, in 
some cases doctors may decide to discontinue the therapy hence leaving pharmacists 




Working within the boundaries of the Fourth Community Pharmacy Agreement for 
reviewing existing supply arrangements of PBS medicines to RACFs, Healthcare 
Management Advisors (HMA) in association with Pharm Consult, responded to a 
number of existing issues related to medicine supply to RACFs.191 Their final report on 
reviewing existing supply of PBS medicines in RACFs and private hospitals was issued 
in late 2009. This review was provided to the Agreement Consultative Committee 
(ACC) who reported to the Australian Government. This review considered options of 
PBS medicine supply to RACFs which included a prescription-less model, PBS 
authority application of pharmacists for medicines with approved indications and PBS 
authority application by pharmacists for increased maximum quantity for medicines with 
approved indications.  Issues highlighted in this review relating to medication supply to 
RACFs pertained to prescription timing, right of choice, transition of residents between 
RACFs and hospitals, use of DAAs, information technology and infrastructure, right of 
residents’ choice and administrative arrangements.191 
 
1) Prescription timing: It was suggested that doctors generally initiate or modify 
medicines whilst visiting residents in RACFs. As highlighted above, when doctors 
initiate or modify medicines they also need to write and send a prescription to the 
pharmacy. Often doctors need to obtain an Authority approval for certain PBS listed 
medicines that require special authority. This means that currently they need to have a 
PBS prescription pad as well as an Authority prescription pad. In addition, doctors also 
need to have access to the PBS schedule which advises them about maximum allowed 
quantities, repeats, indications approved and restrictions. HMA have suggested that this 
lack of access of doctors may cause delays for doctors writing a PBS prescription. In 
their discussion paper, HMA have suggested that this may be an unnecessary use of 
doctors’ time and skills. As also stated above in description of the ‘owing prescription’ 
system, pharmacies often supply PBS medicines without a prescription, which should 
then be received from the doctor within seven days. However, the HMA have noted that 
sometimes doctors do not send their prescriptions within seven days hence pharmacists 




According to the HMA, the abovementioned issues lead to doctors being concerned 
about the duplication of tasks causing less time to look after residents, pharmacists 
having delays submitting claims to the PBS which resulted in their cash-flow being 
affected, additional tasks performed by pharmacists in requesting prescriptions from 
doctors, additional tasks performed by RACF staff following up these issues and 
therefore pressure on their time. HMA also suggested that these issues do not promote 
good collaboration between doctors and pharmacists. 191 
 
2)  Transition of residents between RACFs and hospitals: There are issues during this 
transition as hospitals generally supply only a limited supply of medicines to residents 
upon discharge. Therefore, generally a prescription is needed to be written by the doctor 
in order for the pharmacy to be able to continue supplying the medicines. Possible lack 
of medicine supply was suggested to be a potential for creating life-threatening 
situations for residents.  HMA have highlighted the issue of lack of information on new 
medicines started in the hospital for residents and the fact that carers in RACFs 
sometimes do not communicate these changes appropriately due to lack of time and 
focus on patient care.191 
 
3) DAAs:  The main issues raised  by HMA on DAAs are the wastage of medicines   that 
results when changes to residents therapy occur and pre-packed DAAs are discarded, 
lack of residents input on the decision regarding the generic or non-generic medicines 
are used and the provision of repeat prescriptions to ensure continuation of DAAs. 191 It 
should be emphasized that the HMA report found that the use of DAAs was well 
supported by RACF staff. 
 
Carruthers et al. have indicated that the rate of medicine related incidents in DAAs is as 
high as 4.3%.192 These authors emphasized incorrect packaging, use of no longer needed 
DAA’s and operational problems. The main reasons for these incidents have included: 
missing medicines, incorrect medicines dispensed including the wrong strength, wrong 
labeling and supply of medicines previously ceased by doctors. Failure to deliver 
medicines to RACFs and incorrect dosing instructions were also reported by these 
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authors.180 It should be emphasized that another study also recognized packaging errors 
but also identified the benefits in using DAAs. These benefits included reduction of 
administration errors, time effectiveness, and easier management of medicines. 192,193 
Another strong rationale for using DAAs was that supplying medicines from a bulk 
stock has resulted in a rate of administration errors of as high as 15-20% in comparison 
to individualized supplies (i.e.  DAAs) which reduced this error to 5-8%.192,194 
 
4)  Infrastructure and IT: Lack infrastructure and IT support was suggested to be a 
barrier towards supporting clinical decisions on medicine use in RACFs resulting in 
non-optimal care for residents and concerns regarding prescribing. Lack of IT support 
and infrastructure may also cause a delay in pharmacies receiving both medicine orders 
and prescriptions.191 
 
5) Residents’ right of choice: In their discussion paper, the HMA have suggested that 
lack of residents decision on which doctor they see, which pharmacy they use and use of 
generic medicines affects their right of choice.191 
 
The HMA has also raised the issue of storage of medicines being affected when 
medicines are delivered from the pharmacy to RACFs as the distance of pharmacies to 
RACF varies.  
 
In their final report, the HMA highlighted a few options to address the current 
difficulties they identified with medicine supply arrangements in RACFs.191 These 
options included: a prescription-less system which would use a medicine chart forming a 
central document for all stakeholders (this model was supported overwhelmingly by 
stakeholders in this review), pharmacists having the authority to apply for increased 
quantities of medicines supplied and/or obtaining PBS authority approval (considered by 
stakeholders as simply shifting of responsibilities from GPs to pharmacists although the 
need for modifying PBS authority arrangements was recognised), removing the 
requirements for obtaining PBS authority for some currently PBS authority required 
medicines when supplied to RACF residents, pharmacists prescribing in a collaborative 
82 
 
fashion hence allowing a continuation of an established therapy regimen (considered by 
stakeholders as an issue needing further separate investigation and being beyond its 
scope), nurse practitioners prescribing in collaborative fashion (some support by 
stakeholders but given a shortage of nurse practitioners it was proposed to be considered 
when their numbers increase), provision of a Patient Medicine Profile (PMP) by 
pharmacies to RACFs, and RACFs entering into a contractual agreement with GP 






2.10 The Agency Theory 
 
The application of the Agency theory was initially described from an economics 
perspective by Jensen and Meckling.195,196 Mott et al. provided a conceptual framework 
for using Agency Theory in pharmaceutical care suggesting that selecting medicines to 
treat medical conditions was in fact a principal-agent relationship.195 The Agency 
Theory was therefore relevant and a useful tool in exploring the issue of pharmacist 
prescribing since it involves the process of medicine selection. According to the Agency 
Theory the principal (i.e. patient) delegates the authority to the agent (i.e. doctor, 
pharmacist) for action on their behalf. 195,196 In this triangular relationship, or dual 
agency relationship, doctors also delegate some decision making authority to the 
pharmacist. In terms of prescribing this is particularly noticeable with the supplementary 
prescribing model which involved an agreement between doctor, pharmacist and patient. 








Table 2.1   The agency relationship between doctors, pharmacists and patients 
 
 
There are assumptions with the Agency Theory. The first assumption is that both 
principals and agents are motivated by self-interest. Agents try to perform their actions 
on agents’ behalf with as little effort as possible but on the other hand the higher the 
effort the better are the chances for favourable outcomes.195,197 Secondly, the functioning 
of agents and principals is arranged in an environment of incomplete information. In this 
regard literature suggests that principals face difficulties with lack of information related 
to agents’ abilities, characteristics as well as the quality and outcomes associated with 
agents’ actions. 195,198,199 Mott et al. suggested that without adequate information agents’ 
actions may not match principals’ desires. These authors also suggest that principals can 
choose to self-select their agents which enable them to demonstrate their abilities to 
perform activities desired by principals.195  
 
The third assumption suggested is that agents and principals differ in the amount of risk 
they are ready to assume. Hence these authors suggest difficulties arising due to risk 
preferences with agents pursuing their own interest rather than principals as there may 
be too much risk involved. 195 Agency Theory also assumes that the outcomes of agents’ 
actions is influenced by external factors such as environment, technology, personal 
beliefs and the economy beyond the agents’ control. 195,198 This makes it difficult for 
principals to evaluate whether outcomes that are less than desirable result from external 
factors or agents actions. 195 
 
Principal Desired action Agent 
Patient Diagnosis and selection of appropriate medicine, 
provision of drug information 
Doctor 
Dispensing and provision of drug information Pharmacist 
Doctor Dispensing, provision of drug information Pharmacist 
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Ensuring the right medicine is selected by agents which is harmonious with a principals’ 
goals and desires is a main agency problem for patients. Mott et al. suggested that 
selection of medicines was associated with conflicts in goals between principals and 
agents and uncertainty generated by decision making during selecting a medicine. 196  
On the other hand, the problem of different goals between principals and agents can be 
reflected through prescribers being influenced by their self-interest as well as the 
interests of patients and others (e.g. manufacturers and insurers) when selecting a 
medicine. According to the literature this can result in differences in type, number and 
cost of medicines prescribed to the patient.195,200,201,202,203 The goal conflict can be 
reduced when principals and agents have a longer relationship. This allows principals to 
learn more about agents and their actions.195 
 
Patients tend to establish control mechanisms to minimize the uncertainty associated 
with whose interest agents consider when performing actions on principals’ behalf. This 
problem arises between one agent and multiple principals (e.g. patients, manufacturers, 
insurers). The control mechanism implemented by patients is done through establishing 
patient-doctor relationships and showing loyalty to the doctor through repeat visiting.195 
The same can apply with patients (i.e. pharmacy clients) establishing a relationship with 
their pharmacist and demonstrating loyalty by using the same pharmacy. However, the 
problem of uncertainty may often be inevitable when introduced if decisions are made 
for conditions which are not diagnosed precisely, uncertainty about signs and symptoms, 












2.11 Data collection methods 
 
This project has utilized questionnaires, telephone interviews and focus groups to collect 
the data. The use of different data collection techniques was done to achieve sound data 
by applying different approaches to studying the issue of pharmacist prescribing in 




The use of questionnaires is a data collection technique that provides a relatively cost-
effective and time-effective tool of information gathering from a large sample. In 
constructing questionnaires it should be assumed that respondents are able to provide the 
relevant information required.205 
 
Smith has suggested that issues of validity and reliability need to be carefully considered 
when using a questionnaire as the research instrument.205 An important step towards 
ensuring content validity is to conduct fieldwork which generally implies organising 
interviews with a small number of potential participants. This should be supported by 
literature review in order to identify issues which are relevant to the objectives of the 
study and hence provide content validity.205  
 
Reliability is an important factor in producing a successful questionnaire. Reliability 
indicates the extent to which “questions lead to reproducible responses that are internally 
consistent”.205 Unreliability is often inflicted with the actual construction of questions 
which may be ambiguous or hard for respondents to answer. Validity of questionnaires 
indicates the “extent to which the questions provide a true measure of what they are 
designed to measure”. 206 There are four main types of validity: face validity- whether 
the responses produce accurate information, criterion validity - if questions correlate 
with the variable, construct validity – if questions present the concept precisely and 




Questions in a questionnaire used may be either closed or open. For closed questions 
there is a limitation on the range of responses that can be given.  Smith has suggested 
that closed questions are often preferred in self-administered questionnaires as they are 
quicker and easier to answer and their use also results in less missing data. 205 Closed 
questions are also more practical for the researcher in terms of coding and data analysis. 
On the other hand, in open questions the respondents can express themselves more. 
These questions are more difficult for the researcher to code and categorize. Smith 
suggested that open questions are usually left at the end of the questionnaire so that 
respondents have the opportunity to add issues not covered in the questionnaire hence 
providing a good check of content validity.205 
 
Questionnaires which assess respondents attitudes rely on respondents expressing their 
opinions based on statements given. 205 Respondents need to have a choice of different 
strengths that best reflects their opinion on particular statements given. For this purpose, 
scales such as the Likert are used. Likert scales usually measure attitudes using: strongly 
agree, agree, neutral, disagree and strongly disagree. 205 This scale was developed in 





Interviews are employed in both qualitative and quantitative research. They are 
categorized as structured, semi-structured and unstructured. 205 A structured research 
interview is run according to structured questions. In comparison to questionnaires 
interviews have more open questions and they may also include instructions for the 
interviewer so that responses are clarified. Semi-structured interviews mainly consist of 
open questions therefore enabling a more detailed exploration of respondents’ views. 
Unstructured interviews only provide a framework for the interview. 205 
 
In conducting interviews, the interviewer has to ensure that they are not influenced by a 
personal agenda and preconceptions. Furthermore, an introduction of preconceived ideas 
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by the interviewer is a source of possible bias when interviews are used.205 It is 
suggested that a skilled interviewer exercising a good interviewing technique will have a 
positive effect on data validity as this would enable adequate reflection of respondents’ 
views.   
 
Interviews can be conducted face to face or by telephone. Telephone interviewing is 
more convenient for structured interviews.205 Using the telephone to interview 
respondents is usually less time-consuming and is a convenient and cost-effective way 
of collecting the data especially when the population is spread over a large geographical 
area. Telephone interviewing also yields higher response rates.207 Some limitations 
include the possibility of less mobile householders not being able to answer the phone 
and the possibility of lack of privacy for respondents for which the interviewer may be 
unaware.208 Computers are increasingly used to facilitate telephone interviewing. 
Computer-assisted telephone interviews (CATI) are increasingly being used in health 





2.11.3 Focus groups 
 
Focus group data collection is a popular qualitative technique that explores the views of 
participants through group discussions.209,210 Focus groups are conducted by an 
interviewer referred to as the focus group facilitator who encourages participants to 
engage in the discussion.205,211 In comparison to one-to-one interviews, focus groups 
allow for interaction between respondents. Exploration and clarification of views that 
can be achieved with focus groups is less accessible to one-to-one interviews.205,211 
Kitzinger has suggested that focus groups are a convenient and quick way of collecting 




In addition to exploratory work, Smith has suggested that focus groups consisting of 
experts are sometimes used in consensus building.205 The main limitation of using focus 
groups is that they are not an effective tool of data collection when issues are sensitive, 
in which case one-to-one interviews are preferred. 205,209,211  This is because the presence 
of other participants can compromise confidentiality.211 However, Kitzinger considered 
that it should not be assumed that focus groups cannot explore sensitive issues as group 
work can lead to discussion of taboo issues through some participants ‘breaking the ice’ 
for shyer participants.211 
 
The majority of studies utilize a few focus groups and some also combine this method of 
data collection with others. The literature also suggests that homogenous groups (e.g. 
same profession participants) are preferred to better capitalize on common experiences. 
Segmentation of focus group participants also facilitates a comparative data analysis. 
211,212 However, lack of diversity in focus group participants may be a limitation in 



























This project aimed to test the following hypotheses:  
 
H1: There is no significant difference between pharmacists’ support for expanded 
prescribing based their professional practice area. 
  
H2: There is no significant difference between pharmacists’ preference for 
supplementary or independent prescribing models. 
 
H3:  There is no significant difference in pharmacy clients’ support for supplementary or 
independent prescribing models.   
 
H4: There is no significant difference in pharmacy clients’ perception of trust in 
pharmacists assuming an expanded prescribing role dependent on doctors continuing to 
diagnose the condition. 
 
H5: There is no significant difference in pharmacy clients’ perception of trust in 
pharmacists assuming an expanded prescribing role dependent on this role’s potential to 
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3.1  Introduction 
 
To date there is a lack of representative studies evaluating the views of Australian 
pharmacists on the issue of pharmacist prescribing.  As highlighted in the literature 
review chapter, one study investigated the awareness of international developments in 
pharmacist prescribing and respondents’ benefit from prescribing activities.1 This study 
was limited by a very low response rate (6.4%) and a significant under-representation of 
community pharmacists. Another study assessed the views of 15 hospital pharmacists on 
pharmacist prescribing.2 Aimed at improving Australians medication access, Bessell et 
al. have evaluated four potential prescribing models for Australian pharmacists.3 
This project evaluated the views of a representative sample of Australian pharmacists on 
different aspects of pharmacist prescribing.  
 
 
3.2  Objectives 
 
The main objectives of this part of the project were to assess pharmacists’ views on 
expanded pharmacist prescribing with a focus on: 
 
1 Current level of support for introducing an expanded prescribing role for 
pharmacists  
2    Pharmacist prescribing models and preferred therapeutic areas of prescribing 
3    Training needs for assuming an expanded role in prescribing and 










3.3  Methods 
 
All data collection instruments and the methodologies used in this project were approved 
by the Human Research Ethics Committee of Curtin University of Technology (See 
Appendix 1 and 2).  
 
3.3.1 Data collection 
 
3.3.1.1 Focus groups and pilot questionnaire 
 
Data were collected using a self-administered questionnaire. The design of the 
questionnaire was initially constructed based on a review of the relevant literature and 
findings from a focus group meeting. The questionnaire was then piloted on 114 
pharmacists in Western Australia. The distribution of this pilot questionnaire was done 
in 2006, electronically or via the Pharmaceutical Council of Western Australia’s 
(PCWA) newsletter (see Appendix 3).  
  
3.3.1.2 Final questionnaire 
 
The pre-piloting resulted in minor changes to the final questionnaire (see Appendix 4). 
The final questionnaire had nine sections related to: 1) expansion of pharmacy 
professional services and pharmacist prescribing, 2) pharmacists perspectives on views 
of their clients, 3) advantages  of expanding the pharmacist’s prescribing role 4) 
prescribing models preferred 5) barriers to expanded pharmacist prescribing 6) 
therapeutic areas in which pharmacists supported expanded prescribing 7) training 
requirements to prescribe 8) infrastructural implications 9) expansion of the current role 
in the management of minor ailments. The questionnaire also had a section which 
gathered basic demographic data. Dependent upon the question, pharmacists were either 
asked to respond Yes/No or to complete a five point Likert scale to assess their level of 
agreement with a particular statement.   
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 3.3.1.3 Questionnaire distribution 
 
The self-administered questionnaire was posted nationally to a random sample of 
pharmacists directly. In the State of New South Wales (NSW) the distribution of the 
questionnaire was done through a random sample of community pharmacies. The 
sample was drawn from Registers obtained from State Pharmacy Boards (South 
Australia, Victoria, Tasmania) and the PCWA. Registers for NSW and Queensland were 
not made available due to privacy issues. The list of pharmacies in the telephone 
directory “Yellow Pages” was used to select a random sample of community pharmacies 
in NSW. In this case the questionnaire was directed to “The Pharmacist”. The sample for 
Queensland was drawn from the list of pharmacists publicly available online at the 
Pharmacy Board of Queensland’s website. An electronic randomiser was used to draw a 
20% sample for each of the abovementioned States. A 20% sample was chosen as it 
allows a representative sample to be drawn from a large number of potential 
respondents. The questionnaires were sent to 2199 pharmacists and in the case of NSW 
503 pharmacies. Therefore, a 20 % sample for each state was drawn from a pool of 
approximately 11000 pharmacists and in the case of NSW all pharmacies listed in the 
“Yellow Pages” directory in December 2007. The Northern Territory (NT) and the 
Australian Capital Territory (ACT) were excluded due to limited number of potential 
respondents and therefore statistical insignificance. The questionnaires were distributed 
by mail in December 2007 and included “replied paid” envelopes. A follow-up 
questionnaire was sent in January 2008 with the aim of increasing the response rate. 
Each potential respondent also received an information sheet which explained the 
project (see Appendix 5 and Appendix 6). 
 








3.3.2 Data analysis 
 
3.3.2.1  Chi-Square testing  
 
Data were coded and analysed using SPSS v17. Initially frequency distributions were 
obtained to summarise the responses to the questions. This included frequencies for 
categorical variables, and means and standard deviations for variables measured on a 
continuous scale.  Chi-square testing was used to evaluate binary variables (i.e. Yes/No 
responses) regarding whether 1) pharmacists should have an expanded prescribing role 
and 2) if they would need further training. Chi-Square testing was purposively used to 
check for differences between samples drawn from different States in relation to the 
above two key questions. Additionally differences in age, gender, professional practice 
setting and pharmacy ownership were also analysed. 
 
 
3.3.2.2 One-Way ANOVA 
 
Analysis of Variance (ANOVA) was employed to evaluate various aspects of 
pharmacists’ attitudes on pharmacist prescribing. One-way ANOVA was used to 
compare the means of Likert scale variables where the independent variables had more than 
two categories.  With the large sample size used in this study, the distribution of the mean 
score for variables based on the Likert scale can safely be assumed to be Normal (Central 
Limit Theorem).  
 
One-Way ANOVA was specifically used to evaluate differences between pharmacists 
working in different pharmacy professional areas and pharmacists from different 
Australian states in relation to their preferences for: 
a) models of prescribing  
b) therapeutic areas of prescribing,  
c) training requirements and  
d) infrastructure implications.  
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The influence of years of pharmacist’s registration on prescribing models was also 
evaluated using One-way ANOVA. Years of pharmacist registration were categorised 
into groups: a) 0-5 years, 6-10 years, 11-20 years and >20 years. The differences 
between pharmacy owners and non-owners in regards to different aspects of pharmacist 
prescribing which measured respondents’ attitudes on a 5-point Likert scale were also 
evaluated using One-Way Anova. Tukey’s post-hoc comparison was used to locate the 
significance identified with One-Way ANOVA.  
 
 
3.3.2.3 Factor analysis 
 
Factor analysis was employed throughout the data analysis process in order to reduce the 
number of variables and hence facilitate the interpretation of results. The method of 
extraction throughout the Factor Analysis of data was Principal Component Analysis. 
The following describes the sections of the questionnaire in which Factor Analysis was 
used: 
 
Section 1 (see Appendix 4): Support for statements related to prescribing and the future 
of the pharmacy profession were grouped and subjected to factor analysis. These 
statements were: 
i) I would like the Pharmacy profession to expand its scope of professional 
services  
ii) I would like the Pharmacy profession to expand its scope of services, by 
expanding the prescribing role 
iii) I see myself in future as having more expanded prescribing 
responsibilities 




Section 3 (see Appendix 4): Support for statements related to potential advantages of an 
expanded prescribing role were grouped and subjected to factor analysis. These 
statements were: 
i) I believe customers would have better access to their medications if 
pharmacists were prescribers 
ii) Expanded pharmacist prescribing would ease the burden from 
overloaded GP’s and hence improve the functioning of our health system 
iii) Expanded prescribing responsibilities is a direction that the Pharmacy 
profession should be headed in order to secure a more important role in 
health care 
iv) Pharmacists are highly regarded by the community and therefore they should 
assume more prescribing responsibilities 
v) Pharmacists have the necessary drug knowledge to assume more 
prescribing responsibilities 
vi) Pharmacists have the necessary patient assessment skills to assume more 
prescribing responsibilities 
vii) Pharmacist prescribing enables better use of pharmacist’s professional 
skills 
viii) Expanded prescribing will contribute to increased Pharmacy profits 
 
Section 5 (see Appendix 4): Support for statements related to barriers for expanding the 
prescribing role were grouped and subjected to factor analysis. These statements were: 
i) Inadequate training in diagnosis of disease (if this were the pharmacist’s 
responsibility)  
ii) Inadequate training in patient assessment and patient monitoring 
iii) Potential for a reduction in the quality of patient care 
iv) Potential for increased patient costs 
v) Potential for increased hospital admissions 
vi) Potential for increased government costs 




viii) Pharmacists’ lack of time 
ix) Increased confusion amongst the public as to the role of GP’s and 
pharmacists 
x) Potential decrease in quality of current services offered by pharmacists 
xi) Pharmacists having commercial interest in prescribing 
xii) Inadequate facilities within pharmacies to allow pharmacist prescribing 
xiii) Increased likelihood of litigation 
 
Section 2 (see Appendix 4): Support related to pharmacists’ perspectives based on their 
clients’ views on pharmacist prescribing were grouped and subjected to factor analysis. 
These statements were: 
i) Customers would accept pharmacists with an expanded prescribing role 
ii) Customers would trust pharmacists as prescribers 
iii) Customers would have safer access to their medications if pharmacists 
were prescribers 
iv) Customers find accessing  their GP’s too difficult and may prefer pharmacists 
having an expanded prescribing role 
v) Customers appreciate pharmacists’ professional advice and may prefer 
pharmacists as prescribers 
 
Internal consistency of the statements within each section was performed using Cronbach’s 
coefficient alpha.  This was done to confirm that the statements within each section were 
measuring different facets of the same theme.  
 
All statements which were subjected to Factor analysis measured respondents’ 
agreement on a five–point Likert scale, where 1 was strongly disagree and 5 was 
strongly agree. Additionally, where appropriate to achieve a clearer interpretation, 
variables were subjected to Principal Component Analysis and Varimax rotation. Kaiser-
Meyer-Olkin measure of sampling adequacy and Bartlett’s test of sphericity were used 
to confirm the suitability for factoring.  
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3.3.2.4 Regression Analysis 
 
Variables extracted during the factor analysis were analysed further with multiple 
regression. Regression analysis was employed to a) identify positive and negative 
predictors of expanding pharmaceutical services through prescribing and b) to assess 
how pharmacy ownership predicts the expansion of pharmacy services through 
prescribing. Section 1 summary score from Factor analysis was used as a dependent 


























3.4  Results 
 
3.4.1 Response rate and demographic characteristics 
 
A total of 1049 of the 2592 questionnaires distributed were returned and useable, 
yielding a response rate of 40.4%. Table 3.1 summarises the demographic characteristics 
of the respondents.  The majority of the respondents practiced in a community pharmacy 
setting and were employee community pharmacists working in larger pharmacies 
(annual turnover ≥ AUD2M).  
 
Table 3.1 Demographic characteristics of respondents (n=1049*) 
Variable Category n (%) 
Gender Male 536 (51.6) 
Female 503 (48.4) 
Mean age (SD)  42.8 years (SD=13.5) 
Mean years of 
registration as 
pharmacist (SD) 
 20.5 years (SD=14.2) 
 
Practice setting 
Community 873 (84.1) 
Hospital 119 (11.5) 
Medication reviews (i.e. 
consultant pharmacists) 
14 (1.3) 
Other 32 (3.1) 
Pharmacy 
ownership  
Owners  359 (41.1% of community 
pharmacists) 







Victoria 422 (40.9) 
New South Wales 199 (19.3) 
Queensland 88 (8.5) 
Western Australia 156 (15.1) 
South Australia 121 (11.7) 
Tasmania 43 (4.2) 




3.4.2 Frequency distributions 
 
3.4.2.1  Prescribing and the future of the pharmacy profession 
 
The majority of respondents agreed about the pharmacy profession expanding 
professional services with most of them supporting this be done through an expanded 
prescribing role. Respondents expressed disagreement with the current prescribing role 
limited to Pharmacist Only Medicines (i.e. S3’s). Table 3.2 shows the level of agreement 
expressed by respondents in regards to prescribing and the future of the pharmacy 
profession (Section 1 of Appendix 4). 
 
 
Table 3.2 Pharmacists’ attitudes on prescribing and the future of pharmacy 
profession  
Statement Level of agreement n(%)* 
SD** 
 
D N A SA 
I would like the Pharmacy 
profession to expand its 
scope of professional 
services 
23(2.2) 14(1.3) 82(7.9) 323(31.0) 599(57.5) 
I would like the Pharmacy 
profession to expand its 
scope of services, by 
expanding the prescribing 
role 
43(4.1) 83(8.0) 160(15.4) 362(34.9) 390(37.6) 
I see myself in future as 
having more expanded 
prescribing responsibilities 
50(4.8) 107(10.3) 220(21.2) 358(34.6) 301(29.1) 
I am happy with the 
current pharmacist’s 
prescribing role limited to 
S3’s 
148(14.2) 369(35.5) 261(25.1) 183(17.6) 78(7.5) 
*For every statement there were some missing responses 




To the YES/NO question “Do you think pharmacists should have expanded prescribing 
rights?” 83.9% answered “YES”. Additionally, 87.3% of respondents wished to take on 
an expanded prescribing role (i.e. responses to questions 5a and 5b in Appendix 4). 
 
3.4.2.2  Pharmacists’ opinion based upon their perceptions of their clients 
 
Respondents expressed high levels of expectations in regards to how pharmacist 
prescribing would be accepted by their clients. Respondents’ level of agreement with 
given statements is shown in Table 3.3. 
 
 
Table 3.3 Pharmacists’ opinion based upon their perceptions of their clients  
 
Statement Level of agreement n(%)* 
SD** D N A SA 
Customers would accept 
pharmacists with an 
expanded prescribing role 
14(1.4) 39(3.8) 116(11.2) 554(53.5) 312(30.1) 
Customers would trust 
pharmacists as prescribers 12(1.2) 35(3.4) 149(14.4) 526(50.8) 314(30.3) 
Customers would have 




36(3.5) 142(13.7) 408(39.4) 303(29.3) 146(14.1) 
Customers find accessing  
their GP’s too difficult and 
may prefer Pharmacists 
having an expanded 
prescribing role  
27(2.6) 32(3.1) 123(11.8) 487(46.9) 369(35.5) 
Customers appreciate 
pharmacist ‘s professional 
advice and may prefer 
pharmacists as prescribers 
24(2.3) 81(7.8) 285(27.6) 463(44.9) 179(17.3) 
*For every statement there were some missing responses 
**SD=strongly disagree, D=disagree, N=neutral, A=Agree, SA=strongly agree 
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3.4.2.3  Potential advantages of expanding pharmacist prescribing 
 
Better utilization of pharmacists’ skills followed by easing the burden from overloaded 
GP’s and pharmacists’ drug knowledge were the areas for which respondents showed 
highest level of support in answering statements related to reasons why pharmacists 
should have expanded prescribing rights. These attitudes are summarised in Table 3.4. 
 
Table 3.4 Potential advantages of expanding pharmacist prescribing 
 









I believe customers would have better 












Expanded pharmacist prescribing would 
ease the burden from overloaded GP’s and 












Expanded prescribing responsibilities is a 
direction that the pharmacy profession 
should be headed in order to secure a more 











Pharmacists are highly regarded by the 
community and therefore should assume 











Pharmacists have the necessary drug 












Pharmacists have the necessary patient 












Pharmacist prescribing enables better use 










Expanded prescribing will contribute to 










*For every statement there were some missing responses 
*SD=strongly disagree, D=disagree, N=neutral, A=Agree, SA=strongly agree 
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3.4.2.4  Pharmacist prescribing barriers 
 
Respondents were given 13 statements which involved potential barriers of expanded 
pharmacist prescribing. Inadequate training in disease diagnosis followed by 
pharmacists’ inadequate training in patient assessment and monitoring were the two 
main barriers perceived by respondents. On the other hand, for potential barriers such as 
decreased quality of services offered to patients, increased hospital admissions, 
increased government and patient cost, respondents did not indicate high levels of 
agreement. Respondents’ attitudes on potential barriers to pharmacist prescribing are 
summarised in Table 3.5. 
 
Table 3.5 Potential barriers to expanded pharmacist prescribing 
 
Statement Level of agreement n(%)* 
SD** D N A SA 
Inadequate training in diagnosis of disease 












Inadequate training in patient assessment 










Potential for a reduction in the quality of 
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   Table 3.5     Potential barriers to expanded pharmacist prescribing (continued) 
 
Statement Level of agreement n(%)* 
SD** D N A SA 
Increased confusion amongst the public as to 










Potential decrease in quality of current 





















Inadequate facilities within pharmacies to 




















*For every statement there were some missing responses 

















3.4.2.5  Pharmacist prescribing models 
 
Respondents were given statements which described five prescribing models. These 
models were: independent prescribing, supplementary prescribing, expanded repeat 
prescribing, formulary prescribing and emergency prescribing (see Section 4 statements 
in Appendix 4). Respondents could respond to all these models and not only the one 
preferred. Respondents were also asked if expanded prescribing should apply to hospital 
pharmacists only. Respondents indicated highest support for the supplementary model of 
prescribing followed by the formulary model. Lower levels of support were shown for 
























Table 3.6      Pharmacists attitudes on different models for expanded prescribing  
 
Statement Level of Agreement n(%)* 
SD** D N A SA 
Pharmacists should be able to prescribe 
independent of medical practitioners, 
this includes assuming the 
responsibility of clinical assessment of 
the patient, establishing diagnosis and 
clinical management for a range of 












Pharmacists should be able to prescribe 
in a supplementary fashion through a 
partnership with an independent 
prescriber (a doctor or dentist) 
implementing an agreed patient-
specific management plan. In this 
model the doctor diagnoses and 
initiates therapy while the pharmacist 
continues prescribing as long as 
patient’s condition is within agreed 











Pharmacists should be able to prescribe 
from a limited drug formulary which 
would include current S2’s, S3’s and 
additional drugs depending on 











Pharmacists should be able to prescribe 
for 30 day emergency supply, rather 











I believe any possible future expanded 












*For every statement there were some missing responses 
**SD=strongly disagree, D=disagree, N=neutral, A=Agree, SA=strongly agree 
 
 
Cross-tabulation analysis revealed that the vast majority of respondents who answered 
agree/strongly agree to the independent prescribing model also answered agree/strongly 




*SD=strongly disagree, D=disagree, N=neutral, A=Agree, SA=strongly agree 
 
The exclusion of respondents who answered agree/strongly agree to both supplementary 
and independent models resulted in much less support for the independent prescribing 













Table 3.7    Cross-tabulation of pharmacists’ attitudes on supplementary vs. 
independent prescribing model 
 
  Pharmacists should be able to 
prescribe in a supplementary 
fashion n=1022 
Total   SD D N A SA 
Pharmacists should be able to 
prescribe independently of 
medical practitioners 
SD* 20 14 25 84 62 205 
D 1 10 29 198 77 315 
N 3 4 23 131 65 226 
A 0 7 10 99 88 204 
SA 1 5 7 11 48 72 
Total 25 40 94 523 340 1022 
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Table 3.8    Respondents who supported either a supplementary only or an 
independent prescribing model only 
 
Statement Level of agreement n(%) 




Pharmacists should be able to 












Pharmacists should be able to 
















3.4.2.6  Therapeutic areas for expanded pharmacist prescribing 
 
Respondents were given the choice of indicating the level of support for different 
therapeutic areas of prescribing, based on whether they supported an independent or a 
supplementary prescribing model (see Section 6A and 6B in Appendix 4). Many 
respondents who answered Section 6A also answered Section 6B and vice versa. 
Therefore, in order to gain a clearer interpretation of results, Statement 1 and 2 of 
Section 4 were cross-tabulated with Section 6A and 6B so that three groups of 
respondents could be clearly identified: 1) those that agreed to supplementary 
prescribing model only, 2) those that agreed to independent prescribing model only and 
3) those that agreed to both models. Therapeutic areas included in Section 6A and 6B for 
respondents to choose were the main chronic conditions as well as infections and pain 




Respondents favouring the independent prescribing model only showed strongest 
support for a limited range of infections and pain management. Respondents who 
preferred only the supplementary prescribing model, showed strongest support for 
expanded prescribing for asthma and a limited number of infections followed by 
hypertension, pain management and diabetes. Lower levels of support by all groups 
were seen for an expanded role in anticoagulation and heart failure. These preferences 
are summarised in Tables 3.9 and 3.10 respectively. 
 
Table 3.9 Therapeutic area preferences of respondents who supported either a 
supplementary or an independent prescribing model 
 
 
* Missing is from the data set for these questions 
** Missing is from the data set for these questions 
*** A/SA=Agree/Strongly agree; N=neutral; D/SD=Disagree/Strongly disagree 
****      Treatment of a limited number of infections 
 
 Supporters of 
supplementary  model only 
n(%)* 
Supporters of independent 
model only 
n(%)** 
Therapeutic areas A/SA * ** N 
 


























































































Respondents who supported both models showed remarkable preference consistency with 
those that only preferred either supplementary or independent prescribing. This indicated 
that pharmacists supporting an independent prescribing model showed strongest support 
for prescribing in a limited number of infections and pain management. Pharmacists who 
preferred supplementary prescribing showed strongest support for prescribing in asthma. 




Table 3.10  Therapeutic area preferences of respondents who supported both a 
supplementary and an independent prescribing model 
 
* Missing is from the data set for these questions 
** A/SA=Agree/Strongly agree; N=neutral; D/SD=Disagree/Strongly disagree 











Therapeutic area A/SA **  N 
 


























































































3.4.2.7  Training requirements for pharmacist prescribing 
 
Almost all respondents (97.1%) considered they would need further training if they 
assume additional prescribing responsibilities. 
 
In terms of therapeutic areas, pathophysiology of conditions was the area for which 
respondents agreed more that they need further training.  These attitudes are summarised 
in Table 3.11. 
 
 
         Table 3.11    Training preferences for therapeutic areas 
 
Training area Level of agreement n(%)* 
SD** D N A SA 





















Adverse drug reactions and 










Pathophysiology of conditions 




















Physiological changes and 












  *For every statement there were some missing responses 
  *SD=strongly disagree, D=disagree, N=neutral, A=Agree, SA=strongly agree 
 
 
Respondents were given additional statements specifically related to the practice of an 
expanded prescribing role. Highest levels of support were indicated for training areas 
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such as principles of diagnosis, principles and methods of patient monitoring, and legal 




Table 3.12    Training preferences for expanded pharmacist prescribing 
 
Training area Level of agreement n(%)* 
SD** D N A SA 
Patient consultation and 





























































Principles and methods of 
patient monitoring (physical 
examination, laboratory results, 





















*For every statement there were some missing responses 
*SD=strongly disagree, D=disagree, N=neutral, A=Agree, SA=strongly agree 
 






           Ranked training preferences are also illustrated in Table 3.13  
 
Table 3.13   Ranked training area preferences for expanded pharmacist  
prescribing 
 














           *For every statement there were some missing responses 
           *A/SA=Agreed/Strongly agreed 
 
The majority of respondents (93.2%) agreed/strongly agreed that continuing education is 
needed in order to keep their prescribing skills up to date.  Of the respondents, 88.3% 
considered that pharmacists needed to specialise in specific clinical areas in accordance 
with their prescribing rights. Most respondents (84.5%) also considered that pharmacist 
prescribers need a specialist registration as prescribers with the registering body. Just 
over half of respondents (58.9%) agreed/strongly agreed that training of pharmacist 
prescribers should also include a period of supervision by a medical practitioner. 
 
Training area  Agreement level n(%)* 
%A/SA ** 
Pathophysiology of conditions  890(91.2) 
Principles of diagnosis  864(87.8) 
Patient monitoring  863(87.6) 
Legal and ethical aspects of prescribing  787(80) 
Selection of drug regimen  736(75.9) 
Physiological changes and drug response in 
different age groups  
726(74.6) 
Psychology of prescribing  726(74.2) 
Evidence based practice  694(70.7) 
Public health issues  681(69.5) 
Clinical pharmacology  655(67.7) 
Patient consultation and decision making  537(55) 
Pharmacodynamics and pharmacokinetics  484(50.4) 
Adverse drug reactions and drug interactions  474(49.3) 
Communication skills  270(27.8) 
140 
 
3.4.2.8 Infrastructure implications for pharmacist prescribing 
 
Respondents were given statements which pertained to the potential impact of 
pharmacist prescribing on pharmacy infrastructure. Most respondents considered that in 
order to support an expanded pharmacist prescribing role, additional IT resources were 
needed and that prescribing in the pharmacy should be separated from dispensing. 
Pharmacists did not consider that current staff arrangements and access to patient 
information were adequate to support this role. Respondents’ attitudes exploring 
infrastructural implications of pharmacist prescribing are summarised in Table 3.14. 
 
Table 3.14  Implications of pharmacist prescribing on pharmacy infrastructure 
 
Statements related to 
infrastructure implications 
Level of agreement n(%)* 
SD** D N A SA 
I believe additional IT resources 
in the pharmacy would be needed 











I believe I have access to 
sufficient patient information in 
order to make prescribing 











I believe prescribing and 
dispensing should be carried out 











I believe a separate quiet 
consulting area for pharmacist 












I believe current staff 
arrangements in the pharmacy can 












I believe independent prescribing 
by a pharmacist should NOT 












*For every statement there were some missing responses 




3.4.2.9 Pharmacists’ role in the management of minor ailments 
 
As mentioned in Chapter I and II, currently pharmacists in Australia manage clients’ 
minor ailments through prescribing ‘Pharmacy Medicines’/‘Pharmacist Only Medicines’ 
i.e. S2/S3s. A potential extension of pharmacists’ current roles in the management of 
minor ailments was also explored in this study. Just over half of respondents considered 
that a more defined consultation system should be set up for the provision of S3s. Most 
respondents considered that expanding the role of pharmacists in the management of 
minor ailments would require remuneration and that medicines prescribed under this role 
should be claimable from the Medicare. These attitudes are summarised in Table 3.15. 
 
Table 3.15  Expanding pharmacists’ role for managing minor ailments 
 
Statements related to 
management of minor ailments 
Level of agreement n(%)* 
SD** D N A SA 
I believe a more defined 
consultation system should be set 
up for provision of Pharmacist 











I believe such a defined 
consultation system would require 
a separate consultation room and 
possibility for customers to make 
appointments with the pharmacist 











I believe that any extension of 
current role in the management of 












I believe medicines prescribed 
from an expanded role and 












I believe current staff 
arrangements in the pharmacy can 
support an expanded pharmacists’ 












*For every statement there were some missing responses 
**SD=strongly disagree, D=disagree, N=neutral, A=Agree, SA=strongly agree 
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Most respondents (62.6%) considered 10 minutes would be needed for pharmacists’ 
consultations under a potential new expanded role for managing minor ailments. This is 
as opposed to 34.3% of respondents who considered that five minutes was needed and 
3.2% who considered that only three minutes was needed for such a consultation. 
The remuneration of AU$22.3 was the mean amount that respondents considered 
pharmacists should be paid (excluding medication cost) for their services in an expanded 






3.4.3 Chi-Square testing  
 
Chi-square testing was done to identify any differences between pharmacists from 
different Australian states, pharmacists working in different professional settings (i.e. 
community, hospital, consultant pharmacy, other), pharmacists’ years of registration 
(divided in four groups: 0-5 years, 6-10 years, 11-20 years and >20 years), gender and 
pharmacy ownership versus key categorical variables in the questionnaire that measured 
pharmacists’ agreement with YES/NO statements. These statements were: 
 
1)  For the YES/NO statement “Do you think pharmacists should have expanded 
prescribing rights”, the following were the Chi-square test results: 
a) No significant difference (p=0.095) was found between pharmacists’ samples 
from different Australian states. 
b) No significant difference (p=0.139) was found based on pharmacists’ 
professional practice settings. 
c) No significant difference (p=0.998) was found based on pharmacists’ years of 
registration. 




e) No significant difference (p=0.431) was found between pharmacy owners and 
non-owners. 
 
2) For the YES/NO statement “If I assume additional prescribing responsibilities, 
I would need further training”, the following were Chi-square test results:  
 
a) No significant difference (p=0.293) was found between pharmacists’ from 
different Australian states. 
b) A significant difference (p=0.001) was found based on pharmacists’ professional 
practice setting. Compared to other groups, consultant pharmacists responded 
that they needed less training in order to assume further prescribing 
responsibilities. 
c) No significant difference (p=0.321) was found between pharmacists with 
different years of registration. 
d) No significant different (p=0.894) was found between male and female 
pharmacists 





3.4.4 One-Way ANOVA 
 
One-Way ANOVA was used to evaluate differences between pharmacists from different 
Australian states, professional settings (i.e. community, hospital, consultant pharmacy, 
other), pharmacists’ years of registration (0-5 years, 6-10 years, 11-20 years and >20 
years), gender and pharmacy ownership. Continuous variables measured pharmacists’ 
agreement on a five-point Likert scale. Significance found with ANOVA was located 
using Tukey’s post-hoc comparison. Where a result of p≤0.05 occurred it was 
considered significant.  The following is a summary of the ANOVA results. 
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3.4.4.1  Prescribing models 
 
 
a) Respondents from Australian states 
 
No significant difference was found in attitudes of pharmacists practising in different 
states for statements measuring the agreement level for supplementary and formulary 
prescribing models (p=0.172, p=0.338). However, a significant difference was found in 
attitudes regarding the respondents’ agreement levels for independent and emergency 
prescribing models (p=0.005, p<0.001). Tukey’s test identified respondents from SA to 
favour the independent prescribing model less in comparison to respondents from WA 
(p=0.023) and NSW (p=0.011). In terms of the emergency prescribing model, Tukey’s 
test identified significant differences between respondents from SA in comparison to 
those from WA (p<0.001), NSW (p=0.001) and VIC (p=0.043). Again, SA respondents 
indicated significantly lower levels of agreement for the emergency prescribing model. 
Mean values and standard deviations (SD) for these differences are given in Table 3.16.  
 
 
Table 3.16 Mean and standard deviation values of respondents from 





WA NSW VIC QLD SA TAS 
I * 
(SD) 
2.81(1.22) 2.82(1.20) 2.58(1.22) 2.49(1.10) 2.36(1.18) 2.53(1.16) 
S≠ 
(SD) 
4.15(0.84) 4.12(0.85) 4.14(0.85) 4.07(1.04) 3.93(0.97) 3.91(0.95) 
E# 
(SD) 
3.83(1.16) 3.77(1.21) 3.56(1.27) 3.40(1.30) 3.18(1.17) 3.79(1.18) 
F†  
(SD) 
4.04(0.91) 3.94(0.95) 4.00(0.89) 3.83(1.10) 3.87(0.95) 4.09(0.87) 




a) Pharmacists’ professional practice setting 
 
No significant difference was found between pharmacists working in different 
professional settings in regards to their preferences for independent, supplementary, 
formulary or emergency prescribing model given in the questionnaire (p=0.115, 
p=0.087, p=0.922, p=0.159).  
 
b) Pharmacists’ years of registration 
 
No significant difference was found between pharmacists’ years of registration and their 
agreement levels for independent, supplementary, formulary and emergency prescribing 




c) Pharmacy Ownership 
 
No significant difference was found in attitudes of pharmacy owners and non-owners in 
regards to their preferences for supplementary and formulary prescribing models 
(p=0.644, p=0.360). However, a significant difference was found in attitudes regarding 
the independent and emergency prescribing models. Mean values of responses suggested 
that pharmacy owners were more supportive of both the independent and emergency 
prescribing models in comparison to pharmacy non-owners [independent model (
=2.75±1.21 vs. =2.57±1.20, p=0.024), emergency model ( =3.74 ±1.25 vs. 







3.4.4.2  Advantages for pharmacist prescribing 
 
 
a) Respondents from different Australian states 
One-Way ANOVA levels of significance for advantages of pharmacist prescribing 




Table 3.17 One-Way ANOVA results for advantages of pharmacist prescribing 
vs. pharmacists’ state of practice 
 




S1)* Patients’ better access to their medications  0.063 
S2) Easing the burden from overloaded GP’s and  0.003 
S3) A direction which secures a more important role in health 
care 0.010 
S4) Pharmacists are highly regarded by the community and 
therefore they should assume more prescribing responsibilities 0.006 
S5) Pharmacists have the necessary drug knowledge  0.012 
S6) Pharmacists have the necessary patient assessment skills  0.009 
S7) Better use of pharmacist’s professional skills 0.007 
S8) Contribution to increased Pharmacy profits 0.073 
*For more details refer to sub-group of statements in Section 3, Appendix 4 
 
Tukey’s test located the significant difference in attitudes of respondents from WA and 
SA, in regards to whether expanded pharmacist prescribing: a) eases the burden off 
overloaded GP’s (p<0.001); b) is a direction by which pharmacy profession secures a 
more important role in healthcare (p=0.006); c) should occur as pharmacists are highly 
regarded by the community (p=0.005) and d) enables a better use of pharmacists’ skills 
(p=0.002). WA respondents were more in favour of those statements.  Additionally, in 
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comparison to WA (p=0.024) and NSW (p=0.008) respondents, SA pharmacists were 
significantly less in supportive of pharmacists having the necessary drug knowledge to 
assume more prescribing responsibilities. Furthermore, SA pharmacists in comparison to 
NSW pharmacists were less convinced of pharmacists having the necessary patient 
assessment skills to assume more prescribing responsibilities (p=0.002).  Mean values of 
statements in which a significant difference was found are summarised in Table 3.18. 
 
 
Table 3.18   Mean and standard deviation values of statements where significant 
differences were found between respondents from different states in relation to 




Mean and standard deviation values of statements measuring the 
agreement levels for advantages of pharmacist prescribing 
S2* S3 S4 S5 S6 S7 
 SD  SD  SD  SD  SD  SD 
WA 4.21 0.82 4.04 0.96 3.90 0.94 3.92 0.97 3.32 1.01 4.13 0.83 
NSW 3.98 1.04 3.87 1.09 3.76 1.02 3.94 0.90 3.50 1.10 3.97 0.98 
VIC 3.98 0.94 3.88 1.05 3.72 1.00 3.83 0.95 3.27 1.06 3.94 0.90 
QLD 4.00 0.89 3.84 1.08 3.63 1.03 3.94 0.91 3.23 1.07 3.92 1.06 
SA 3.73 1.04 3.59 1.03 3.46 1.05 3.56 1.06 3.03 1.16 3.69 1.02 
TAS 3.91 0.89 3.60 1.18 3.47 0.93 3.91 0.95 3.19 1.04 3.81 0.91 




b) Pharmacists professional practice setting 
 
One-Way ANOVA significance values for potential advantages of pharmacist 
prescribing (i.e. Section 3 statements in Appendix 4) versus pharmacists’ professional 
practice setting are summarised in Table 3.19. 
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Table 3.19   One-Way ANOVA significance values for reasons for pharmacist 
prescribing vs. pharmacists professional practice setting 
 
Statements measuring agreement level for advantages 
of pharmacist prescribing 
ANOVA 
significance 
S1)* Patients’ better access to their medications  0.496 
S2) Easing the burden from overloaded GP’s and  0.314 
S3) A direction which secures a more important role in 
health care 0.001 
S4) Pharmacists are highly regarded by the community and 
therefore they should assume more prescribing responsibilities 0.011 
S5) Pharmacists have the necessary drug knowledge  0.025 
S6) Pharmacists have the necessary patient assessment 
skills  0.053 
S7) Better use of pharmacist’s professional skills 0.002 
S8) Contribution to increased Pharmacy profits 0.094 
*For more details please refer to sub-group of statements in Section 3, Appendix 4 
 
 
Mean values of statements in which a significant difference was found are summarised 
in Table 3.20. 
 
Table 3.20   Mean and standard deviation values of statements where a significant 
difference was found between pharmacists’ practice setting and advantages of 
pharmacist prescribing 
Practice setting Mean and standard deviation of statements measuring the 
agreement levels for advantages of pharmacist prescribing 
 S3* S4 S5 S7 
 SD  SD  SD  SD 
Community 3.87 1.04 3.73 1.00 3.85 0.96 3.95 0.93 
Hospital 3.58 1.17 3.48 1.02 3.71 1.00 3.76 1.02 
Consultancy 4.57 0.65 4.29 0.73 4.43 0.65 4.71 0.61 
Other 4.09 0.86 3.69 0.96 4.06 0.88 4.03 0.68 
*Please refer to Table 3.19 for a description of statements 
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The Tukey’s test identified hospital pharmacists to be less in favour of expanding 
prescribing so that pharmacists secure a more important role, in comparison to 
community (p=0.026) and consultant pharmacists (p=0.005). Hospital and consultant 
pharmacists also had differences in attitudes for the statement that prescribing should be 
introduced because pharmacists are regarded highly by the community (p=0.023) and 
that pharmacists have the necessary drug knowledge (p=0.038). Hospital pharmacists 
were less in favour of these statements. In terms of better use of pharmacists’ skills, 
consultant pharmacists had significant level of differences in attitudes with both 
community (p=0.013) and hospital pharmacists (p=0.002). Consultant pharmacists 
agreed significantly more with this statement.  
 
 
c) Pharmacists’ years of registration 
 
No significant differences in responses were identified using One-way ANOVA based 
on pharmacists’ years of registration for statements regarding advantages of pharmacist 
prescribing in section 3 of Appendix 4: Statement 1, p=0.74; Statement 2, p=0.677; 
Statement 3, p=0.418; Statement 4, p=0.692; Statement 5, p=0.307; Statement 6, 




d)  Pharmacy ownership 
 
The results of the One-way ANOVA to assess the influence of pharmacy ownership on 
pharmacists’ perceptions of the advantages of expanded pharmacist prescribing are 
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Table 3.21 One-Way ANOVA significance values for advantages of pharmacist 
prescribing vs. pharmacy ownership 
 




S1)* Patients’ better access to their medications  0.014 
S2) Easing the burden from overloaded GP’s and  0.059 
S3) A direction which secures a more important role in health care 0.284 
S4) Pharmacists are highly regarded by the community and 
therefore should assume more prescribing responsibilities 0.041 
S5) Pharmacists have the necessary drug knowledge  0.075 
S6) Pharmacists have the necessary patient assessment skills  <0.0001 
S7) Better use of pharmacist’s professional skills 0.050 
S8) Contribution to increased Pharmacy profits 0.220 
*For more details refer to sub-group of statements in Section 3, Appendix 4 
 
 
The interpretation of mean values shows that for statements 1, 4, 6 and 7 significant 
differences were found. Pharmacy owners compared with non-owners more strongly 
favoured a) patients’ better access to medicines ( =3.89±1.02 vs. =3.73±0.97), b) 
pharmacists highly regarded role by community being a reason for expanding their 
prescribing role ( =3.79±1.02 vs. =3.66±1.00) c) better use of pharmacist’s 
professional skills ( =4.02±0.90 vs. =3.90±0.95) and d) pharmacists having the 
necessary patient assessment skills to assume further prescribing responsibilities (









3.4.4.3 Pharmacist prescribing barriers 
 
a) Pharmacists working in different Australian states 
 
The results of the One-Way ANOVA to assess the influence of the pharmacists’ state of 
practice on perceived barriers to pharmacist prescribing are summarised in Table 3.22. 
 
Table 3.22 One-Way ANOVA significance levels for pharmacist prescribing 
barriers vs. pharmacists’ state of practice 
 




S1) Inadequate training in diagnosis of disease (if this were the 
pharmacist’s responsibility)  0.131 
S2) Inadequate training in patient assessment and patient 
monitoring 0.010 
S3)Potential for a reduction in the quality of patient care 0.533 
S4)Potential for increased patient costs 0.026 
S5)Potential for increased hospital admissions 0.167 
S6)Potential for increased government costs 0.044 
S7)Conflict of interest with pharmacists acting both as prescribers 
and dispensers  0.007 
S8)Pharmacists’ lack of time 0.015 
S9)Increased confusion amongst the public as to the role of GP’s 
and pharmacists 0.123 
S10)Potential decrease in quality of current services offered by 
pharmacists 0.002 
S11)Pharmacists having commercial interest in prescribing 0.009 
S12)Inadequate facilities within pharmacies to allow pharmacist 
prescribing 0.001 
S13)Increased likelihood of litigation 0.778 





The Tukey’s test located a significant difference between respondents from SA, NSW 
and VIC in regards to their agreement levels for the statement pertaining to inadequate 
training in patient assessment and patient monitoring. Respondents from NSW agreed 
significantly less than those of SA (p=0.017) and VIC (p=0.023) with that statement. 
WA respondents agreed significantly less than SA respondents that a) increased 
government cost (p=0.047), b) conflict of interest between pharmacists acting both as 
prescribers and dispensers (p=0.006), c) pharmacists lack of time (p=0.003), d) decrease 
of quality of current pharmacy services (p=0.007) and e) pharmacists commercial 
interest in prescribing (p=0.038) are reasons why pharmacists should not assume 
expanded prescribing roles. Respondents from SA also agreed significantly more than 
respondents from WA (p=0.013) and NSW (p=0.001) that inadequate facilities within 
pharmacies is a barrier towards an expanded prescribing role. 
A summary of mean values for statements where One-Way ANOVA identified a 
significant difference (and also confirmed with Tukey’s post-hoc) is given in Table 3.23. 
 
Table 3.23 Mean values of statements where significant difference was found 
between respondents’ state of practice and attitudes on pharmacist prescribing 
barriers 
 
State Mean and standard deviation values of statements measuring 
the agreement levels for barriers to pharmacist prescribing 
S2* S6 S7 
 SD  SD  SD 
WA 3.74 1.06 2.34 1.00 3.07 1.21 
NSW 3.56 1.11 2.38 1.08 3.19 1.15 
VIC 3.85 1.03 2.53 1.07 3.37 1.18 
QLD 3.62 1.26 2.56 0.97 3.38 1.04 
SA 3.96 0.94 2.71 1.15 3.58 1.10 
TAS 3.74 0.93 2.55 0.92 3.44 1.20 




Table 3.23 Mean values of statements where significant difference was found 




State Mean and standard deviation values of statements 
measuring the agreement levels for barriers to pharmacist 
prescribing 
S8 S10 S11 S12 
 SD  SD  SD  SD 
WA 3.09 1.32 2.51 1.17 3.14 1.18 3.40 1.17 
NSW 3.34 1.16 2.60 1.10 3.17 1.13 3.32 1.12 
VIC 3.39 1.22 2.79 1.18 3.43 1.19 3.59 1.13 
QLD 3.36 1.17 2.65 1.08 3.38 1.07 3.58 1.20 
SA 3.64 1.11 3.07 1.19 3.56 1.06 3.86 0.98 




b) Pharmacists’ professional practice setting 
The results of the One-Way ANOVA to assess the influence of the pharmacists’ 
professional practice setting on perceived barriers to pharmacist prescribing are 










Table 3.24 One-Way ANOVA levels of significance for pharmacist prescribing 
barriers vs. pharmacists’ professional practice setting 
 




S1*) Inadequate training in diagnosis of disease (if this were the 
pharmacist’s responsibility)  0.142 
S2) Inadequate training in patient assessment and patient 
monitoring 0.025 
S3)Potential for a reduction in the quality of patient care 0.440 
S4)Potential for increased patient costs 0.294 
S5)Potential for increased hospital admissions 0.149 
S6)Potential for increased government costs 0.082 
S7)Conflict of interest with pharmacists acting both as 
prescribers and dispensers  0.003 
S8)Pharmacists’ lack of time 0.007 
S9)Increased confusion amongst the public as to the role of GP’s 
and pharmacists 0.035 
S10)Potential decrease in quality of current services offered by 
pharmacists 0.373 
S11)Pharmacists having commercial interest in prescribing <0.001 
S12)Inadequate facilities within pharmacies to allow pharmacist 
prescribing 0.027 
S13) Increased likelihood of litigation 0.708 
*For more details please refer to sub-group of statements in Section 5, Appendix 4 
 
The Tukey’s test located a significant difference between community and hospital 
pharmacists in regards to a) pharmacists’ inadequate training in patient assessment and 
monitoring (p=0.029), b) conflict of interest with pharmacists acting both as prescribers 
and dispensers (p=0.001), c) pharmacists having a commercial interest in prescribing 
(p<0.001) and d) inadequate facilities to allow pharmacist prescribing (p=0.031). 
Community pharmacists agreed less with these statements. Community pharmacists in 
comparison to pharmacists working in other professional settings agreed more that 
pharmacists’ lack of time (p=0.017) was a reason why they should not have expanded 
prescribing rights. A summary of mean values of statements for which One-Way 
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ANOVA identified a significant difference (and also confirmed with Tukey’s test) is 
given in Table 3.25. 
 
Table 3.25 Mean and standard deviation values of statements where a 
significant difference was found between respondents practice setting and attitudes 
on pharmacist prescribing barriers 
 
Practice setting Mean and standard deviation values of 
statements measuring the agreement level 
on barriers to pharmacist prescribing 
S2* S6 S7 
 SD  SD  SD 
Community 3.73 1.08 2.48 1.06 3.27 1.17 
Hospital 4.03 0.90 2.72 1.08 3.71 1.07 
Consultancy 3.86 1.10 2.21 0.97 3.07 1.23 
Other 3.53 1.07 2.39 1.12 3.41 1.21 
 
Table 3.25 Mean and standard deviation values of statements where a 
significant difference was found between respondents practice setting and attitudes 
on pharmacist prescribing barriers (continued) 
 
Practice setting Mean and standard deviation values of 
statements measuring the agreement level 
on barriers to pharmacist prescribing 
S8* S11 S12 
 SD  SD  SD 
Community 3.39 1.20 3.28 1.16 3.51 1.13 
Hospital 3.48 1.14 3.78 1.02 3.82 1.02 
Consultancy 2.86 1.15 3.43 1.16 3.21 1.48 
Other 2.75 1.21 3.25 1.22 3.41 1.04 
  *Please refer to Table 3.24 for a description of statements 
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c) Pharmacists’ years of registration 
In terms of differences in attitudes regarding the barriers of expanded pharmacist 
prescribing versus pharmacists’ years of registration, inadequate facilities to expand 
pharmacist prescribing was the only statement for which One-Way ANOVA indicated a 
significant difference (p=0.035). The Tukey’s test found that the group of pharmacists 
registered for less than 5 years were more strongly in favour of this statement in 
comparison to pharmacists’ registered for more than 20 years (p=0.023). Mean values 
for responses to the statement “inadequate facilities to expanding pharmacist 
prescribing” are presented in Table 3.26. 
 
 
Table 3.26  Mean and standard deviation values of statement for which Tukey’s 
test located a significant difference 
 
Years of registration Mean and standard deviation values for the 
statement “ inadequate facilities within pharmacies to 
support pharmacist prescribing” 
  SD 
0-5 3.72 1.08 
6-10 3.59 1.12 
11-20 3.51 1.11 





d) Pharmacy ownership 
The results of the One-Way ANOVA to assess the influence of pharmacy ownership on 




Table 3.27 One-Way ANOVA significance values for pharmacist prescribing 
barriers vs. pharmacy ownership 
 




S1*) Inadequate training in diagnosis of disease (if this were the 
pharmacist’s responsibility)  0.001 
S2) Inadequate training in patient assessment and patient 
monitoring 0.066 
S3)Potential for a reduction in the quality of patient care 0.595 
S4)Potential for increased patient costs 0.215 
S5)Potential for increased hospital admissions 0.590 
S6)Potential for increased government costs 0.049 
S7)Conflict of interest with pharmacists acting both as 
prescribers and dispensers  0.147 
S8)Pharmacists’ lack of time 0.001 
S9)Increased confusion amongst the public as to the role of GP’s 
and pharmacists 0.484 
S10)Potential decrease in quality of current services offered by 
pharmacists 0.049 
S11)Pharmacists having commercial interest in prescribing <0.001 
S12)Inadequate facilities within pharmacies to allow pharmacist 
prescribing <0.001 
S13Increased likelihood of litigation 0.001 
*For more details please refer to sub-group of statements in Section 5, Appendix 4 
 
 
The interpretation of mean values shows that for statements 1, 6, 8, 10, 11, 12 and 13 
significant differences were found with ANOVA. Compared to pharmacy owners, 
pharmacy non-owners more strongly favoured the following barriers to expanded 
prescribing rights: a) inadequate training in disease diagnosis ( =3.96±0.965 vs. 
=4.16±0.932), b) potential for increased government cost ( =2.41±1.101 vs. 
=2.55±1.038), c) pharmacists’ lack of time ( =3.20±1.168 vs. =3.40±1.214), d) 
potential decrease in quality of current services offered by pharmacists ( =3.64±1.00 
vs. =2.79±0.99), e) pharmacists having a commercial interest in prescribing (
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=3.16±1.00 vs. =3.44±1.00), inadequate facilities within pharmacies to allow 
pharmacist prescribing ( =0.26±1.00 vs. =3.69±1.00) and f) increased likelihood of 




3.4.4.5  Training requirements for expanded pharmacist prescribing 
 
a) Respondents from different Australian states 
 
One-Way ANOVA performed on these data showed no significant difference (p>0.05) 
between respondents practicing in different Australian states for any of the statements 
that measured attitudes of respondents on training requirements (see Section 7A,7B and 
7C statements in Appendix 4) for an expanded prescribing role for pharmacists. 
 
 
b) Pharmacists’ professional practice setting 
 
From statements related to training requirements for expanded pharmacist prescribing, 
One-Way ANOVA identified a significant difference in attitudes of pharmacists 
working in different professional practice settings for the following three statements: 
1) Selection of drug regimen (p=0.005) 
2) Specializing in clinical areas in accordance with additional prescribing rights 
assumed eg. Diabetes, Cardiology, Asthma, Anticoagulation, Pain management, 
Infections (p=0.003) 
3) Specialist registration as prescribers with the registering body (p=0.004) 
 
The Tukey’s test identified consultant pharmacists involved in medication reviews 
needed less training for selection of drug regimens in comparison to community 
(p=0.009) and hospital pharmacists (p=0.003). The Tukey’s test also identified 
community pharmacists, in comparison to hospital pharmacists, to be less in favour of a) 
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pharmacist prescribers to specialise in specific clinical areas in accordance with 
additional prescribing rights assumed (p=0.008) and b) specialist registration as 
prescribers with the registering body (p=0.009). A summary of mean and standard 
deviation values for statements where One-Way ANOVA identified significant 
difference (and also confirmed with Tukey’s test) is given in Table 3.28. 
 
Table 3.28 Mean and standard deviation values of statements where significant 
difference was found between respondents’ practice setting and training 




Mean and standard deviation values of statements measuring the 
agreement level on preferred therapeutic area training preferences  
Selection of drug 
regimen 
Specialising in clinical 
areas 
Registering with a 
registering body 
  SD*  SD  SD 
Community 3.93 1.06 4.23 0.85 4.15 0.92 
Hospital 4.06 0.98 4.50 0.81 4.44 0.81 
Consultant 2.91 1.64 4.64 0.50 4.64 0.67 
Other 3.74 0.89 4.45 0.57 4.03 0.87 
 
 
c) Pharmacists’ years of registration 
The results of One-Way ANOVA on the influence of pharmacists’ years of registration 








Table 3.29 One-Way ANOVA levels of significance for training preferences for 
therapeutic areas vs. pharmacists’ years of registration 
 
Statements measuring agreement levels on training needs 
for therapeutic areas 
ANOVA  
significance 
S1*)Clinical pharmacology <0.0001 
S2)Pharmacodynamics and pharmacokinetics <0.0001 
S3)Adverse drug reactions and drug interactions <0.0001 
S4)Pathophysiology of conditions that you would prescribe for 0.010 
S5)Selection of drug regimen 0.037 
S6)Physiological changes and drug response in different age 
groups 0.002 
S7)Patient consultation and decision making 0.069 
S8)Communication skills 0.753 
S9)Principles of diagnosis 0.133 
S10)Evidence based practice  0.063 
S11)Legal and ethical aspects of prescribing 0.116 
S12)Psychology of prescribing  0.018 
S13)Principles and methods of patient monitoring (physical 
examination, laboratory results, patient compliance)  
0.070 
S14)Public health issues 0.098 
S15)A period of supervision by a Medical Practitioner 0.213 
S16)Demonstration of relevant Continuing Education that 
ensures their prescribing skills are kept to date 0.431 
S17) Specializing in clinical areas that conform with additional 
prescribing rights assumed (eg. Diabetes, Cardiology, Asthma, 
Anticoagulation, Pain management, Infections) 
0.113 
S18)Specialist registration as presribers with the registering body 0.192 
  *For more details please refer to sub-group of statements in Section 7, Appendix 4 
 
The Tukey’s test identified pharmacists registered for >20years compared to those 
registered for 0-5years and 11-20years to need more training in pharmacology (p=0.012 
and p=0.001). Compared to respondents registered for 0-5years, 6-10years and 11-
20years, respondents registered for >20years also needed more training in 
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pharmacokinetics and pharmacodymanics (p<0.001, p=0.043 and p=0.001), adverse 
drug reactions and drug interactions (p=0.012, p=0.008 and p=0.002).  
Pharmacists registered for 11-20 years felt they needed less training in pathophysiology 
of conditions, compared to pharmacists registered for 0-5 years and 6-11 years (p=0.045 
and p=0.011).  
Pharmacists registered for 11-20 years felt they needed less training in selection of drug 
regimen compared to pharmacists registered for 6-10 years (p=0.045).  
Pharmacists registered for >20 years, in comparison to those registered for 0-5 years, 
considered they needed more training in physiological changes and drug response in 
different age groups in comparison (p=0.001). No significant difference between 
different groups was located using Tukey’s test (p>0.05), for training in psychology of 
prescribing although ANOVA alpha-level was significant (p=0.018).  
 
A summary of mean values for statements where One-Way ANOVA indicated 
significant differences is given in Table 3.30.  This table illustrates with exception of 
area of selection of drug regimen (S4), pharmacists registered for >20 years showed 
stronger levels of agreement with all statements. 
 
 
Table 3.30 Mean and standard deviation values of statements for which One-




Mean and standard deviation values of statements measuring the 
agreement level on preferred therapeutic area training preferences 
S1* S2 S3 
 SD  SD  SD 
0-5 3.58 1.22 3.07 1.17 3.14 1.25 
6-10 3.65 1.20 3.26 1.27 3.09 1.32 
11-20 3.52 1.24 3.17 1.23 3.09 1.32 
>20 3.90 1.05 3.56 1.14 3.48 1.20 
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Table 3.30 Mean and standard deviation values of statements for which One-




Mean and standard deviation values of statements measuring the 
agreement level on preferred therapeutic area training 
preferences 
S4 S5 S6 
 SD  SD  SD 
0-5 4.39 0.81 3.98 1.09 3.66 1.15 
6-10 4.44 0.81 4.11 0.95 3.91 1.11 
11-20 4.17 0.96 3.81 1.13 3.80 1.09 
>20 4.33 0.72 3.87 1.05 4.00 0.95 
 *please refer to Table 3.29 for description of statements 
 
 
d) Pharmacy ownership 
 
One-Way ANOVA identified significant differences between the attitudes of pharmacy 
owners and non-owners only on the need for a) a period of supervised training by a 
medical practitioner (p=0.001), b) specializing in clinical areas in accordance with 
additional prescribing rights assumed (p<0.001) and c) specialist registration as 
prescribers with a registering body (p=0.001). In comparison to pharmacy owners, 
pharmacist non-owners agreed significantly more with the above statements. Mean and 
standard deviation values for these three statements where the difference was significant 







Table 3.31  Mean and standard deviation values for statements where a 















 3.4.5 Factor Analysis 
 
Factor analysis was performed on four sections of the questionnaire in order to reduce 
the number of variables and hence facilitate further analysis of results. Principal 
Component Analysis was the extraction method. In each section, sub-group of 
statements measured attitudes of respondents on one particular theme related to 
expanded pharmacist prescribing. Results of factor analysis for these four sections of the 
questionnaire are presented below:    
 
Section 1: Factor analysis of questionnaire statements related to prescribing and the 
future of the pharmacy profession (please refer to sub-group of statements in Section 1 
of Appendix 4) was successful in reducing the number of variables. One factor was 
extracted for this group of statements. Factor loadings for these statements were 0.77, 
0.93, 0.88, 0.79. Percentage of variance explained was 71.4%. Kaiser-Meyer-Olkin 
measure of sampling adequacy (0.783) and Bartlett’s test of sphericity (<0.0001) 
Pharmacy 
ownership 








 SD  SD  SD 
Owners 3.44 1.14 4.13 0.91 4.04 1.00 
Non-owners 3.68 1.15 4.34 0.79 4.25 0.86 
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confirmed the suitability for factoring. This was additionally supported by the screeplot 
(Figure 1). 
 
Cronbach’s alpha was performed for the group of statements related to prescribing and 
the future of pharmacy profession to confirm their internal consistency. Cronbach’s 
alpha result was 0.86.  
 






Figure 3.1 Screeplot illustrating 
variables extracted from groups of 
statements related to prescribing 




Section 3: Factor analysis of questionnaire statements related to potential advantages for 
pharmacists expanding their prescribing role (please refer to sub-group of statements in 
Section 3 Appendix 4 for statement details) was successful in reducing the number of 
variables. 
One factor was extracted for this group of statements. Factor loadings for these 
statements were (0.76, 0.82, 0.85, 0.85, 0.77, 0.69, 0.87, 0.38). Percentage of variance 
explained was 58.2%. Kaiser-Meyer-Olkin measure of sampling adequacy (0.903) and 
Bartlett’s test of sphericity (<0.0001) confirmed the suitability for factoring. This was 
supported by the screeplot as well (Figure 3.2). Internal consistency of statements was 
performed and Cronbach’s alpha result was 0.89. 
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Figure 3.2 Screeplot illustrating variables extracted from groups of statements 
related to potential advantages why pharmacists should have expanded prescribing 
rights 
 
Section 5: In factoring the group of questions related to barriers for expanding 
pharmacists’ prescribing role (please refer to sub-group of statements in Section 5, 
Appendix 4), three factors emerged with eigenvalues of more than 1.0. Kaiser-Meyer-
Olkin measure of sampling adequacy (0.867) and Bartlett’s test of sphericity (<0.0001) 
confirmed the suitability for factoring. This was supported by the screeplot as well 
(Figure 3.3). Clearer interpretation was obtained by using Varimax rotation as shown in 
Table 3.32. Three factors extracted explained 64.3% of the variance. Factors extracted 
(i.e. variables) were named according to what the groups of statements pertained to: i) 
“Other barriers”; ii) “Increased cost and deterioration of patient care” and iii) 




Cronbach’s alpha internal consistencies were as follows: i) other barriers 0.83; ii) 
increased cost and deterioration of patient care 0.87 and iii) inadequate training in 
diagnosis, patient assessment and monitoring 0.83. 
 











Figure 3.3 Screeplot illustrating variables extracted from groups of statements 


















Section 2: Factor analysis of questionnaire statements related to pharmacists’ 
perspectives on their clients’ views on pharmacist prescribing (please refer to sub-group 
of statements in Section 2, Appendix 4) was successful in reducing the number of 
variables. One factor was extracted for this group of statements. Factor loadings for 
these statements were (0.82, 0.83, 0.71, 0.72, 0.75). Percentage of variance explained 
was 59.3%. Kaiser-Meyer-Olkin measure of sampling adequacy (0.772) and Bartlett’s 
test of sphericity (<0.0001) confirmed the suitability for factoring. This was supported 
by the screeplot as well (Figure 3.4) 
Internal consistency of statements in Section 2 was checked using Cronbach’s alpha and 
the result was 0.82. 
 
Table 3.32  Rotated Component Matrix for statements related to 




Reasons for which pharmacists should not have expanded prescribing rights i ii iii 
Increased confusion amongst the public as to the roles of GP's and pharmacists 0.752   
Pharmacists’ having commercial interest in prescribing 0.727   
Pharmacists' lack of time 0.716   
Potential decrease in quality of current services offered by pharmacists 0.663   
Increased likelihood of litigation 0.662   
Inadequate facilities within pharmacies to allow pharmacist prescribing 0.659   
Conflict of interest with pharmacists acting both as prescribers and dispensers 0.642   
Potential for increased hospital admissions  0.854  
Potential for increased patient costs  0.824  
Potential for increased government costs  0.816  
Potential for a reduction in the quality of patient care  0.731  
Inadequate training in patient diagnosis   0.896 
Inadequate training in patient assessment and monitoring   0.864 
Extraction Method: Principal Component Analysis.  
 Rotation Method: Varimax with Kaiser Normalization. Rotation converged in 5 iterations 
(a)factors: i)other barriers, ii)increased cost and deterioration of patient care and iii) 



















Figure 3.4  Screeplot illustrating variables extracted from groups of statements 




3.4.5.1  Summary of variables created with Factor Analysis models 
 
Factor analysis reduced the number of questionnaire items and facilitated further 
interpretation of the data. New variables created as a result of this analysis are 
summarised below: 
 
1) Expanding pharmaceutical services through prescribing; 
2) Pharmacist prescribing drivers; 
3a) Other barriers;  
3b) Increased cost and deterioration of patient care  
3c)  Inadequate training in diagnosis, patient assessment and monitoring; 
4) Pharmacists’ perspectives on their clients’ views of pharmacist prescribing 
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3.4.6  Regression Analysis 
 
From the variables extracted during the factor analysis two models were developed 
using linear regression. The two regression analyses performed used the factor summary 
score obtained from Section 1 (Appendix 4) as the dependent variable (“Expanding 
pharmaceutical professional services through prescribing”). The first regression model 
examined the association between the independent and supplementary prescribing 
model, in relation to the dependent variable used. This model explained only 36.7% of 
variance. Both independent and supplementary prescribing were positive predictors of 
expanding pharmaceutical services through prescribing (p<0.001). Pharmacists who 
preferred supplementary prescribing showed a stronger association (based on the 
regression coefficient β) compared to pharmacists who preferred independent 
prescribing (β=0.52, p<0.0001 versus β=0.18, p<0.0001).  
 
In the second regression model, the independent variables included the five summary scores 
found through the factor analyses performed on Sections 2,3 and 5 of Appendix 4. The 
dependent variable (“Expanding pharmaceutical professional services through 
prescribing”), used the factor summary score obtained from Section 1 (Appendix 4). This 
model explained 62.2% of variance. This model, shown in Table 3.33, indicated that 
both pharmacist prescribing drivers (i.e. advantages) and their opinions based upon their 
clients’ perspectives on pharmacist prescribing were important positive predictors of an 
expansion of pharmacist services through prescribing (β=0.74, p<0.001 and β=0.12, 
p=0.005). The model also showed patient diagnosis, assessment and monitoring were 
more negatively associated with expanding services through prescribing as opposed to 
other barriers or increased cost and deterioration of patient care [(β=-0.098, β=-0.091 
and β= -0.075; p<0.001, p=0.003 and p=0.004) see Table 3.33].  
 
Regression analysis for the effect of pharmacy ownership on expanding pharmaceutical 
services through prescribing revealed that pharmacy ownership is also a positive 





Table 3.33  Beta values for Model 2: The relationship between the variables of 
pharmacist prescribing drivers, barriers and pharmacists opinions based upon 
their experience with clients against expanding pharmaceutical services through 
prescribing.† 
 
†Dependent variable: Expanding pharmaceutical services through prescribing; *Negative coefficients indicate a significant barrier 
 
 
Figure 3.5 encapsulates the factors and weightings that had significant positive and 
negative impact on pharmacists considering moving towards an expanded prescribing 
role. The weightings are assigned based on the parameters in the regression models 
showing the extent to which variables predicted the expansion of pharmaceutical 

























Standardized Coefficients* Probability 
Beta T 
1.432 6.820 <.0001 
Prescribing drivers .747 18.847 <.0001 
Experience with clients .127 2.796 0.005 
Diagnosis and Assessment -.098 -4.094 <.0001 
Cost & deterioration of patient care -.075 -2.913 0.004 







Other barriers Increased 
cost, 
deterioration 
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Figure 3.5 Graphical illustration of a relationship model between positive and 

























This study has explored perspectives of a large sample of Australian pharmacists on 
expanded pharmacist prescribing. Respondents were from all areas of pharmacy practice 
and all Australian states. To our knowledge this is the first major study on the attitudes 
of Australian pharmacists to expanded pharmacist prescribing. Respondents place of 
professional practice in this study was reflective of the Australian Bureau of Statistics 
(ABS) Population Census data 2006 (i.e. Community pharmacists 84.9%, Hospital 
11.2% and Industrial 3.8%). 4 This study achieved a response rate of 40.4%, which 
although adequate for a postal survey, leaves a possibility of some non-respondents not 
sharing the same views as respondents. However, it should be emphasized that the 
respondents’ highly supportive views for expanded pharmacist prescribing (83.9%) 
suggested that non-respondents’ views would not markedly influence the findings.   
 
Pharmacists who participated in this study were clearly in favour of expanding the scope 
of pharmaceutical services through expanding their prescribing role. Almost all 
respondents indicated that further training was needed to assume such a role. This study 
has indicated that Australian pharmacists strongly preferred a supplementary prescribing 
model. This support for the supplementary model might suggest this model should be 
initially introduced. Respondents also indicated a strong level of support for pharmacists 
prescribing from an expanded list of drugs included in a drug formulary (i.e. an 
expanded S2 and S3 drug list) according to their area of specialisation. The level of 
support for independent prescribing in this study was less than reported in a previous 
Australian study.1 However, that study was limited by a low response rate (6.4%) and an 
under-representation of community pharmacists.16 Given the strongest level of support 
for a supplementary prescribing model, this study focused more on comparing this 
prescribing model with the independent one. For example, although both supplementary 
and independent prescribing were positive predictors of expanding pharmaceutical 
services through prescribing, pharmacists who were in favour of supplementary 
prescribing showed a stronger association towards this expansion. Respondents who 
favoured the independent model showed support for less therapeutic areas of prescribing 
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compared to supporters of supplementary prescribing. This was probably because 
supplementary prescribing does not involve the initial diagnosis and prescribing. It is 
worth emphasising that pharmacists’ opinions based upon their perceptions of their 
clients was shown to be an important predictor of expanding pharmaceutical services 
through prescribing. To date there is a lack of literature exploring this particular 
relationship. 
 
This study found no significant differences between pharmacists from different states in 
regards to key questions such as support for expanded pharmacist prescribing and 
training requirements. However, there were differences in attitudes in regards to sub-
questions such as those related to prescribing models, advantages of and barriers to 
pharmacist prescribing. These differences could have been due to key opinion leaders in 
various states as the impact of different educational foci in various pharmacy schools 
would dissipate with time. There were also differences identified between pharmacists’ 
professional practice area and their attitudes on issues such as training. In this regard 
consultant pharmacists were less supportive. However, they were more supportive of 
pharmacist prescribing enabling a better use of their skills. These differences may be due 
to consultant pharmacists receiving additional training to become accredited to enable 
them to perform medication reviews.  
 
The positive attitude towards a supplementary prescribing model found in this study is 
supported by the views of pharmacists reported elsewhere. This was shown in the UK by 
Hobson and Sewell who suggested pharmacists had a positive attitude towards 
supplementary prescribing and wished to assume this role, despite concerns.5 Better use 
of pharmacists’ skills, easing the burden from overloaded GPs and pharmacists’ drug 
knowledge were the main reasons for Australian pharmacists supporting an expanded 
role in prescribing. In this regard it is worth mentioning that in several ‘Crown Reports’ 
in the UK a better utilisation of pharmacists’ skills in order to develop a more flexible 
system of prescribing, administration and supply of medicines was identified as the main 
driver for expanding pharmacist prescribing. 6,7  Additionally, improvement of patient 
care, medication access and team work within the healthcare system were considered the 
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main objectives by England’s Department of Health for introducing independent 
pharmacist prescribing. 8  
 
As mentioned above, the vast majority of respondents considered pharmacists needed 
further training for pharmacists to assume additional prescribing roles. Strongest 
preferences for such training were shown for areas of pathophysiology of conditions, 
principles of diagnosis and patient monitoring. Training in clinical pharmacology as well 
as pharmacodynamics and pharmacokinetics was supported more by pharmacists who 
were registered for longer than 20 years. Dawoud et al. also suggested that training in 
patient assessment was valued highly by pharmacists undertaking supplementary 
prescribing training in the UK.9 
 
In terms of infrastructural implications of expanded pharmacist prescribing, respondents 
in this study indicated that additional IT resources are needed for pharmacists to assume 
this role. Respondents were also supportive of the fact that prescribing and dispensing 
should be separated in the pharmacy. Respondents did not consider that current staff 
arrangements in the pharmacy can support an expanded role in prescribing and they also 
were not supportive of pharmacists having sufficient access to patient information. 
 
Inadequate training in patient diagnosis, assessment and monitoring were the main 
barriers to expanded pharmacist prescribing identified by respondents of this study. At 
the same time these potential barriers were also the strongest negative predictors of 
expanding pharmacists’ prescribing role in Australia.  These areas were the ones that 
pharmacists also strongly believed that they needed further training. This illustrates the 
readiness of Australian pharmacists to go ahead with assuming an expanded prescribing 
role despite perceived barriers. This should be taken into consideration when expanded 
pharmacist prescribing is considered in Australia. Additionally, Australian policymakers 
should also consider early experiences from supplementary prescribing in the UK 
suggesting inadequate funding to be a major limitation for delivering this service. 10 
Restrictive, inflexible and time consuming nature of CMP involvement in supplementary 
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prescribing was also reported to be a major limitation during the implementation of this 
role in the UK.10 
 
Other studies have revealed a variety of other limitations to expanded pharmacist 
prescribing. These included potential conflict with doctors, need for greater liability 
insurance, excessive workload and time pressures.11,12,13,14 A possibility for 
fragmentation of care resulting in increased costs and inefficiencies within the health 
care system has also been reported.9 Conflict of interest with pharmacists having a 
commercial interest in prescribing with supply and inadequate access to patient records 
were also reported to be obstacles towards the adoption of this role.14,15 Increased health 
care cost was not considered to be a limitation to pharmacist prescribing by respondents 
of this study. Additionally, only about half of the respondents agreed that increased 
litigation and commercial interest in pharmacists both prescribing and dispensing were 
barriers to expanded pharmacist prescribing. Just over half of respondents agreed that 
pharmacists lack of time is a barrier towards expanded pharmacist prescribing in 
Australia. 
 
Support for expanded pharmacist prescribing indicated by respondents in this study 
should be interpreted having in mind other studies Australian studies which, although 
limited in representativeness, also confirmed that an expanded role in prescribing was 
supported by Australian pharmacists.1,2 Results of this study should be taken into 
consideration when constructing policies and recommendations towards future 
pharmacist prescribing in Australia. They are also valuable elsewhere, given the global 
interest on this issue and the lack of literature exploring pharmacists’ views outside of 
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Patients have a central role in the process of medicine prescribing. However, the 
literature exploring their attitudes towards pharmacist prescribing is limited with most 
studies focusing on perspectives of pharmacists and doctors.1,2,3 No study has thus far 
investigated the attitudes of pharmacy clients (i.e. patients who regularly receive doctor 
prescribed prescription medicines from a pharmacy) who have not experienced 
expanded pharmacist prescribing. 4,5,6,7  
 
This project investigated the attitudes of pharmacy clients with no experience with 
expanded pharmacist prescribing. This study describes the relationships between 
pharmacists, doctors and pharmacy clients in the domain of pharmacist prescribing from 
an Agency Theory perspective.  Mott et al. have provided a conceptual framework for 
using Agency Theory in pharmaceutical care in suggesting that selecting medications to 
treat medical conditions invoked a principal-agent relationship.8 According to the 
agency relationship, in a pharmaceutical care setting, the principal (patient) delegates the 
authority to the agent (doctor, pharmacist) for performing actions on his/her behalf. 8,9,10 
Since the process of prescribing involves selection of medication(s) for treatment, the 
Agency Theory provides valuable insight into the relationship between patients (i.e. 











The main objectives of this study were to: 
• Explore pharmacy clients’ perceptions on pharmacists assuming an expanded 
role in prescribing 
• Identify therapeutic areas that pharmacy clients would prefer pharmacists to 
assume expanded prescribing roles 
• Identify drivers that contributed to pharmacy clients perception of trust in 
pharmacists assuming expanded prescribing roles  
• Examine the relationships between doctors, pharmacists and pharmacy clients, 
regarding pharmacist expanded prescribing, using the Agency Theory post-hoc 







This study was approved by the Human Research Ethics Committee of Curtin University 
of Technology (See Appendix 7). 
  
4.3.1 Data collection 
 
4.3.1.1 Interview questionnaire development  
 
An interviewer-administered questionnaire was used to conduct a structured interview 
utilizing Computer Assisted Telephone Interviewing (CATI). This method has been 
recommended in primary care research data collection.11 It enables instant recording of 
answers and it is more efficient than face-to-face interviews when respondents are 
widely spread geographically.11,12 This advantage of the CATI method was important for 
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this study given the geographical expanse of Australia. The development of the 
questionnaire was initially aided by a literature review. Expanded pharmacist prescribing 
was the focus of this literature review while question design was aided by the previous 
part of this study assessing the attitudes of Australian pharmacists using the pre-piloted 
questionnaire. A UK based study on patients’ perceptions of nurse and pharmacist 
prescribing also informed the design of questions.7 
 
Structured questions were used since they were suitable to administer by telephone 
interviewing due to time restrictions.13 The questionnaire was then checked for face and 
content validity by a small pharmacist focus group. The questions were also checked for 
suitability of administration by the telemarketing company that conducted interviews. 
They were from lay public not related to the pharmacy industry and experienced in this 
form of surveying. 
 
 
4.3.1.2 Final interview questionnaire 
 
The final interview questionnaire had a total of 23 questions (see Appendix 8). The 
content of this interview-questionnaire can be divided into three main sections: 1) 
demographic characteristics, b) statements related to the respondent’s satisfaction with 
current services provided by pharmacists and c) statements specifically related to the 
respondent’s attitudes on pharmacist prescribing. Respondents (i.e. pharmacy clients) 
were asked either to respond Yes/No or on a five point Likert scale in order to express 
their level of agreement with statements provided by the interviewer. Reliability of 





4.3.1.3 Participants eligibility 
 
Eligible participants needed to be self-administering at least ONE prescription medicine 
dispensed in a pharmacy regularly and be over the age of 18 years. These were the first 
two screening questions for eligibility of respondents used at the start of CATI (See 
Appendix 8). Respondents needed to be able to converse in English. Identification of 
eligible participants and their structured interviews were conducted by trained staff of an 
experienced telemarketing company not linked to the pharmacy industry or any of the 
researchers conducting this study. This was employed in order to minimise potential bias 
introduced by pharmacists, persons related to the pharmacy industry or researchers of 
this study, interviewing pharmacy clients.   
 
4.3.1.4 Sample distribution 
 
A telephone number list was generated via a random number generation function in 
Microsoft Excel with sequences of likely number combinations where the first two digits 
corresponded to Australian area codes, were created according to the required Australian 
State and Territory breakdowns rather than using  a publicly available telephone number 
list. These were then incorporated into a predictive dialler system to eliminate probable 
invalid number sequences. Distribution targets of connected calls were based on 
Australian Bureau of Statistics Population data as at end June Quarter 2008, with the 
following distribution: New South Wales (NSW) 33%, Victoria (VIC) 25%, Queensland 
(QLD) 20%, Western Australia (WA) 10%, South Australia (SA) 8%,  Tasmania (TAS) 
2%, Australian Capital Territory (ACT) 2%, Northern Territory (NT) < 1%. The target 
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was to interview 400 pharmacy clients who were regularly taking at least one 
prescription medicine from their pharmacy. This target was chosen as it enabled a 
precision of no greater than ± 5% in prevalence estimation. 
 
4.3.2 Data analysis 
 
Data collected were coded and analysed using SPSS v17. Basic descriptive statistics 
were used to summarize demographic data and responses (i.e. frequency distributions, 
means and standard deviations).  Chi-square testing and One-Way ANOVA were also 
employed to analyse the data. In order to reduce the number of items, the scores of four 
questions related to respondents’ satisfaction with their pharmacists roles were 
combined and subjected to reliability analysis using Cronbach’s alpha. Factor analysis 
was employed to confirm item reduction and obtain a summary score. Principal 
Component Analysis was the extraction method. Regression analysis was used to 
explore the impact of factors on pharmacy clients’ perception of trust in pharmacists 
assuming an expanded role in prescribing. “Trust” was used in the context of 
respondents’ confidence in pharmacists’ capability to prescribe. 
 
The relationships between the main stakeholders i.e. doctors, pharmacists and pharmacy 
clients affected by expanded pharmacist prescribing, was evaluated from the perspective 
of the Agency Theory.8 The Agency Theory was applied post hoc on results. In 
particular, this theory was employed to identify how an introduction of expanded 
pharmacist prescribing could potentially disrupt the current relationship of the 




4.4  Results 
 
4.4.1 Response rate and demographic characteristics 
 
A telephone list with 5072 entries was generated. The predictive dialler system 
eliminated 1628 likely invalid number sequences. There were a total of 1980 failed calls 
(i.e. answering machines, busy line, disconnected, fax machines, no answer, and ring 
errors). In order to interview 400 consenting pharmacy clients around Australia, a total 
of 1464 successfully connected calls were made. Of the successfully connected calls, 
311 contacted persons did not meet the eligibility criteria. This gives a response rate of 
34.7% of eligible pharmacy clients who participated in the survey. Demographic 















Table 4.1 Demographic characteristics of respondents (n=400, no missing 
responses) 
Variable Category n(%) 
Gender Male 155 (39%) 
Female 245 (61%) 
 
Age 
<30 44 (11%) 
30-50 108 (27%) 
51-65 116 (29%) 
>65 132 (33%) 
 
Education 
Primary 25 (6%) 
Secondary 231 (58%) 
University 97 (24%) 
Other 43 (11%) 




Full Time 142 (36%) 
Part Time 44 (11%) 
Casual 31 (8%) 
Retired 127 (32%) 
Not Employed 53 (13%) 
Prefer not to disclose 3 (1%) 
Household 
income 
Less than AU$ 20,000 38 (10%) 
AU$20,000 to AU$50,000 150 (38%) 
AU$50,001 to AU$100,000 110 (28%) 
Greater than AU$ 100,000 28 (7%) 





NSW 122 (31%) 
VIC 98 (25%) 
QLD 85 (21%) 
SA 32 (8%) 
WA 42 (11%) 
TAS 11 (3%) 
NT 4 (1%) 
ACT 6 (2%) 
 
Approximately one third of respondents (35%) obtained one prescription per month 
from a pharmacy, 46% obtained two to five prescriptions per month and 17% of 
respondents obtained more than five prescriptions per month. Most respondents (81%) 
had their prescriptions dispensed at the same pharmacy. In addition to having 
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prescriptions dispensed, most respondents (73%) also purchased over-the-counter 
medicines from their pharmacy (i.e. ‘Pharmacy Only Medicines’ and ‘Pharmacist  
Only Medicines’). These data are given in Table 4.2. 
 
 
Table 4.2 Characteristics of respondents regarding number of prescription 
medicines, OTC medicines and use of the same pharmacy 
 
Q1: How many prescriptions do you approximately obtain from 
your pharmacy? n(%) 
1 per Month 141(35) 
2 to 5 per month 185(46) 
> 5 per Month 69(17) 
Other 5 (1) 
Q2: Do you also purchase OTC medicines (e.g. pain relievers-
Panadol®, vitamins, herbal products) from your Pharmacy, in 
addition to obtaining your prescription(s)? n(%) 
Yes 292(73) 
No 108(27) 













4.4.2 Pharmacy clients responses (frequency distributions) 
 
4.4.2.1  Pharmacy clients’ current satisfaction with pharmacists professional 
services provided by pharmacists 
 
High satisfaction levels were indicated by a vast majority of respondents in regards to 
pharmacists’ drug knowledge and the professional services provided. These data are 
summarised in Table 4.3. 
 
 
Table 4.3 Respondents current satisfaction with their pharmacists’ 
professional roles (n=400) 
 






Interviewer administered statements Level of agreement n(%) 
SD* D N A 
 
SA  
I am satisfied with my pharmacists’ 























I am satisfied with the level of assistance my 
pharmacist provides  when I purchase 











I am satisfied with how my pharmacist 
diagnoses minor ailments such as cold & flu, 














4.4.2.2 Pharmacy clients’ general attitudes on pharmacist expanded prescribing 
 
Most respondents (71%) agreed/strongly agreed that they would trust pharmacists 
prescribing medicines that they currently need repeat prescriptions from their doctor. On 
the other hand, most respondents (77% agreed/strongly agreed) only felt comfortable 
with pharmacists prescribing medicines if the condition is first diagnosed by their 
doctor.  
Almost half of respondents (47%) agreed/strongly agreed they had difficulties accessing 
their doctor and therefore would prefer pharmacists writing prescriptions for medicines 
they currently needed repeat prescriptions from their doctor. However, most respondents 
(64%) agreed/strongly agreed that they would find it easier to access medicines without 
delay if prescriptions were also written by pharmacists.  
 
Most respondents (68%) agreed/strongly agreed that pharmacists would need further 
training if they assumed additional prescribing roles. Almost one half of respondents 
(46%) were willing to pay a fee for pharmacists prescribing medicines for which they 
























Table 4.4 Respondents attitudes regarding pharmacist prescribing (n=400) 
 
Interviewer administered statements Level of agreement n(%) 
SD* D N A 
 
SA 
I would trust my pharmacist to write 
prescriptions for medicines that I currently need 











I would only feel comfortable to have my 
pharmacist write prescriptions for my medicines, 











I find it difficult to access my doctor, therefore I 
would prefer my pharmacist writing 
prescriptions for medicines for which I currently 











I would find it easier to access my medicines 
without delay if prescriptions were also written 











I think that if pharmacists were to assume the 
expanded role of writing prescriptions, they 











I would be willing to pay a fee for my 
pharmacist to write prescriptions for medicines 












*SD=strongly disagree, D=disagree, N=neutral, A=Agree, SA=strongly agree 
 
Approximately one half of the respondents (51%) preferred that pharmacists who write 
prescriptions be located in the community pharmacy as opposed to 33% of respondents 
who preferred pharmacist prescribers be located in their own office and 16% who 








4.4.2.3 Prescribing model and preferred therapeutic areas of pharmacist 
prescribing 
 
Less than one third of respondents (29%) preferred pharmacists prescribing all 
medicines for which they needed prescriptions from their doctor. A similar percentage of 
respondents (33%) would accept pharmacists both diagnosing and prescribing for the 
condition diagnosed. These data are reported in Table 4.5. 
 
Table 4.5    Pharmacy clients’ attitudes on the extent of pharmacist prescribing 
(n=400) 
 
Interviewer administered statements Level of agreement n(%) 
SD* D N A SA  
I would prefer my pharmacist write prescriptions 
for ALL medicines that I currently need a 











I would accept my pharmacist diagnosing a 
condition (e.g. asthma) and writing prescriptions 















Respondents who did not prefer (strongly disagree/disagree and neutral) pharmacists 
prescribing all medicines for which they currently needed a prescription from doctors 
and those that preferred pharmacists diagnosing and prescribing for the condition 
diagnosed were separately asked to indicate therapeutic area preferences for pharmacist 
prescribing. In both groups, pain management followed by anti-infectives were the most 
preferred therapeutic areas for pharmacist prescribing. These data are summarised in 



































a) Preferred therapeutic areas of pharmacist 
prescribing for respondents not supporting 
pharmacists prescribing all medicines that 
they currently need a prescription from their 
Doctor [n(%), n=251] 
 SA* A N D SD 
Antibiotics 1(0) 115(46) 23 (9) 89 (35)  23(9) 
Diabetes 0(0) 43(17) 44(18) 139(55) 25(10) 
Blood pressure 0(0) 51(20) 29(12) 145(58) 26(10) 
Heart conditions 0(0) 13(5) 27(11) 173(69) 38(15) 
Asthma  0(0) 64(25) 29(12) 130(52) 28(11) 
Pain management 6(2) 192(76) 25(10) 24(10)  4(2) 
b) Preferred therapeutic areas respondents 
supporting pharmacists diagnosing  a 
condition and prescribing for it [n(%),n=130] 
 SA* A N D SD 
Antibiotics 2(2) 95(73) 14(11) 18(14) 1(1) 
Diabetes 2(2) 40(31) 15(12) 69(53) 4(3) 
Blood pressure 0(0) 45(35) 15(12) 67(52) 3 (2) 
Heart conditions 0(0) 17(13) 13(10) 93(72) 7(5) 
Asthma  1(1) 57(44) 20(15) 48(37) 4(3) 
Pain management 8(6) 107(82) 9(7) 6(5) 0(0) 
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4.4.3 Statistical Analysis 
 
4.4.3.1 Chi-Square testing 
 
Chi-square testing was used evaluate the relationships between categorical variables 
such as: respondents’ age, gender, education level, income, employment status, number 
of prescriptions filled, whether respondents also used OTC medicines and whether they 
used the same pharmacy. In cases where data violated assumptions of Pearson’s 
correlation, Spearman’s rank order correlation was conducted. 
 
Pearson’s chi-square testing indicated no significant difference between respondents age 
and whether they obtained their prescriptions at the same pharmacy and whether they 
also purchased OTC medicines (p=0.357 and p=0.094). A significant difference was 
found between different age-groups in terms of the number of medicines they purchased 
(Spearman’s rho=0.254, p<0.001). As expected, younger age-groups obtained fewer 
medicines in comparison to age-groups of 51-65years and >65years. These data were 


























Table   4.7 Comparison between respondents’ age groups and number of 





No significant difference was found between male and female respondents in terms of 
whether they obtained their medicines at the same pharmacy (p=0.421). No significant 
difference was found between male and female responds in terms of the number of 
medicines they obtained (Spearman’s rho=0.04, p=0.422). However, Pearson’s chi-
square testing suggested that male respondents used OTC medicines more than female 
respondents (p=0.01). 
 
No significant difference was found between respondents’ level of education completed 
and use of the same pharmacy and use of OTC medicines (Spearman’s rho = 0.054 & 
p=0.281, Spearman’s rho= -0.011 & p=0.825). However, a significant difference was 
found for respondents’ level of education and number of prescriptions obtained 
(Spearman’s rho= -0.156, p=0.002). These findings are illustrated in Table 4.8. 
 
 
  Age group Number of prescriptions obtained from Pharmacies 
Total    1 per month 2-5 per month > 5 per month Other 
 < 30 n 22 13 7 2 44 
% 50.0 29.5 15.9 4.5 100 
30-50 n 57 38 12 1 108 
% 52.8 35.2 11.1 0.9 100 
51-65 n 38 59 17 2 116 
% 32.8 50.9 14.7 1.7 100 
>65 n 24 75 33 0 132 
% 18.2 56.8 25.0 0.0 100 
Total              n 141 185 69 5 400 




No significant difference was found between respondents’ household income and 
whether they also used OTC medicines (p=0.411) and whether they used the same 
pharmacy (p=0.365). However, Spearman’s correlation indicated a significant difference 
(Spearman’s rho= -0.120 & p=0.017) between respondents’ household income and 
number of medicines obtained. Respondents with lower household income indicated 
they obtained more medicines compared to those with higher household income. These 





Table 4.8     Comparison of respondent’s education completed and number of 
prescriptions obtained  
 









> 5 per 
month Other 
 Primary n 5 11 9 0 25 
% 20.0 44.0 36.0 0.0 100 
Secondary n 73 113 40 5 231 
% 31.6 48.9 17.3 2.2 100 
University n 43 41 13 0 97 
% 44.3 42.3 13.4 0.0 100 
Other n 18 19 6 0 43 
% 41.9 44.2 13.9 0.0 100 
Prefer not to 
disclose 
n 2 1 1 0 4 
% 50.0 25.0 25.0 0.0 100 
Total n 141 185 69 5 400 






To further explore the issue of level of education, household income and age versus the 
number of prescriptions obtained, since significant differences were found for these 
categories,  respondents’ age, education level and household income were cross-
tabulated. Given that Pearson’s assumptions were violated by the data, Spearman’s 
correlation was obtained in order to interpret the results.  
 
As expected, a significant difference was found (Spearman’s rho= -0.174 and p<0.0001) 
between respondent’s age group and their level of education completed with older 
respondents being more often educated at a primary level and less often at a university 
level. Also, it was found that younger respondents (i.e. <30yrs of age & 31-50 yrs of 
Table 4.9  Comparison between respondent’s household income and number of 
prescriptions obtained 
 
 Household income 
in $1000s 
 Number of prescriptions obtained 
from your Pharmacies 
Total 




> 5 per 
month Other 
 < 20 n 8 18 12 0 38 
% 21.0 47.4 31.6 0.0 100 
20-50 n 41 85 23 1 150 
% 27.3 56.7 15.3 0.7 100 
50-100 n 52 42 13 3 110 
% 47.3 38.2 11.8 2.7 100 
> 100 n 10 11 6 1 28 
% 35.7 39.3 21.4 3.6 100 
Prefer not to 
disclose 
n 30 29 15 0 74 
% 40.5 39.2 20.3 0.0 100 
Total n 141 185 69 5 400 
% 35.2 46.2 17.2 1.25 100 
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age) had higher household incomes compared to older respondents (i.e. 51-65yrs of age 
& >65yrs of age), Spearman’s rho= -0.292 and p<0.0001. These findings indicated that 
education and household income did not determine the number of medicines respondents 
obtained but age was the main determinant. These data were cross-tabulated and are 
illustrated in Tables 4.10 and Table 4.11. 
 
 
Table 4.10  Comparison of respondent’s age and education completed 
 
   Education completed 
Total 
  Age group 




 < 30 n 0 23 16 5 0 44 
% 0.0 52.3 36.4 11.3 0.0 100 
30-50 n 2 60 33 13 0 108 
% 1.8       55.6 30.6 12.0 0.0 100 
50-65 n 4 74 21 15 2 116 
% 3.4 63.8 18.1 12.9 1.7 100 
>65 n 19 74 27 10 2 132 
% 14.4 56.1 20.5 7.56 1.5 100 
Total n 25 231 97 43 4 400 


















Table 4.11  Comparison of respondent’s age and their household income 
 
  Age group Household income in $1000s 
Total 
   
< 20 20-50 50-100 > 100 
Prefer not 
to disclose 
 < 30 n 2 14 17 2 9 44 
% 1.9 31.8 38.6 1.9 2.2 100 
30-50 n 2 23 50 10 23 108 
% 1.8 21.3 46.3 9.3 21.3 100 
50-65 n 13 41 25 12 25 116 
% 11.2 35.4 21.6 10.3 21.6 100 
>65 n 21 72 18 4 17 132 
% 15.9 54.5 13.6 3.0 12.9 100 
Total n 38 150 110 28 74 400 
% 9.5 37.5 27.5 7.0 18.5 100 
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4.4.4 One-way ANOVA 
 
4.4.4.1 Satisfaction with current professional services offered by pharmacists 
 
One-way ANOVA was used to explore the differences between categorical variables in 
the interview questionnaire (see Appendix 8) in relation to continuous variables 
(measuring the level of agreement on a five point Likert scale), which pertained to 
respondents’ satisfaction with pharmacists’ current roles i.e. 
• S9* (*Statement 9 in Appendix 8): I am satisfied with my pharmacists’ 
professional advice I receive for medicines 
 
• S10: I am satisfied with my pharmacists’ level of drug knowledge 
• S11: I am satisfied with the level of assistance my pharmacist provides when I 
purchase medicines from the Pharmacy 
• S12: I am satisfied with how my pharmacist diagnoses minor ailments such as 
cold & flu, indigestion, hayfever, headache, conjunctivitis. 
 
a) Respondents’ Age 
One-Way ANOVA identified no significant difference between respondents age groups 
(<30, 30-50, 51-65 and >65years) and their level of satisfaction with pharmacists’ 
professional services offered and current level of drug knowledge [i.e. statements 
9,10,11 in Appendix 8; (p>0.05)]. The only significant difference identified with 
ANOVA was for the level of satisfaction with how pharmacists diagnosed minor 
ailments (i.e. Statement 12 in Appendix 8; p=0.043) with respondents >65years of age 
showing a lower agreement level. However, this significance was not confirmed with 
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Tukey’s post-hoc comparison (p>0.05). Mean and standard deviation values for each age 
group in relation to their agreement level for satisfaction of with pharmacists’ diagnosis 
of minor ailments are summarised in Table 4.12. 
 
Table 4.12 Mean and standard deviation values for the influence of age on the 
level of satisfaction with pharmacists’ diagnosis of minor ailments 
Age group Mean and standard deviations  values  
 SD 
<30 3.86 0.67 
30-50 3.88 0.61 
51-65 3.89 0.61 




a) Gender, education level, employment status, number of prescriptions 
obtained, use of the same pharmacy and use of OTC medicines 
No significant differences were found between respondents’ gender, level of education, 
employment status, number of prescriptions obtained, use of the same pharmacy and use 
of OTC medicines in relation to respondents’ level of satisfaction with pharmacists’ 
current level of drug knowledge and professional services provided [i.e. Statements 
9,10,11,12 in Appendix 8; (p>0.05)]. 
201 
 
4.4.4.2 Respondents’ perception of trust on pharmacist expanded prescribing  
 
One-way ANOVA was used to explore the differences between categorical variables in 
the interview questionnaire and the continuous variable measuring the agreement levels 
on a Likert scale i.e.: respondents’ perception of trust for pharmacists assuming an 
expanded prescribing role (i.e. Statement 14 in Appendix 8) 
 
a) Respondents’ age, gender, education level, household income and 
employment status, number of prescriptions obtained, use of the same 
pharmacy and use of OTC medicines 
 
One-way ANOVA identified no significant differences between respondents’ age 
(p=0.592), gender (p=0.255), level of education (p=0.802), household income (p=0.998), 
employment status (p=0.476), number of prescriptions obtained (p=0.272), use of the 
same pharmacy (p=0.838) and use of OTC medicines (p=0.084) in relation to 
respondents’ perception of trust for pharmacists assuming an expanded prescribing role.  
 
4.4.4.3 The extent of expanded prescribing 
 
One-way ANOVA was used to explore the differences between categorical variables in 
the interview questionnaire and the continuous variable measuring the agreement level 
on a Likert scale i.e. whether pharmacists should prescribe all medicines (i.e. the extent 
of expanded prescribing) for which respondents currently needed a prescription from 




a)  Respondents’ age, gender, education level, household income and 
employment status, use of the same pharmacy and use of OTC medicines 
 
One-way ANOVA identified no significant differences between respondents’ age 
(p=0.173), gender (p=0.185), level of education (p=0.215), household income (p=0.119), 
employment status (p=0.647), use of the same pharmacy (p=0.439) and use of OTC 
medicines (p=0.528) in regards to whether pharmacists should prescribe all medicines 
for which they currently needed a prescription from their doctor. 
  
b) Number of prescriptions obtained  
One-way ANOVA indicated a significant difference between respondents’ number of 
prescriptions obtained (p=0.05) and whether pharmacists should prescribe all medicines 
for which they currently needed a prescription from their doctor. However, this was not 
conferred by Tukey’s test (p>0.05). Mean and standard deviation values are summarised 
in Table 4.13. 
Prescription number Mean and standard deviations  values  
 SD 
1 per month 2.40 1.03 
2-5 per month 2.57 1.05 
>5 per month 2.59 1.14 
other 3.60 0.89 
203 
 
4.4.4.4  Pharmacists diagnosing and prescribing medicines for conditions diagnosed 
 
One-way ANOVA was used to explore the differences between categorical variables in 
the interview questionnaire and the variable measuring the agreement levels on a Likert 
scale i.e.: whether pharmacists should diagnose medical conditions and also prescribe 
medicines for those conditions diagnosed (Statement 19 in Appendix 8). 
 
a) Respondents’ age  
 One-way ANOVA indicated a significant difference (p=0.03) between respondents’ age 
groups in regards to their preferences for pharmacists diagnosing and prescribing 
medicines for conditions diagnosed. However, Tukey’s post-hoc comparison did not 
identify a significant difference between age groups (p>0.05). Mean and standard 




Table 4.14  Mean and standard deviation values for preferences of different age 
groups regarding whether pharmacists should both diagnose and prescribe. 
 
Age group Mean and standard deviations  values  
 SD 
<30 2.95 0.96 
30-50 2.68 0.96 
51-65 3.03 0.96 





A significant difference was found between female respondents and their preference for 
pharmacists diagnosing and prescribing for conditions diagnosed. Female respondents 
indicated a stronger support for pharmacists diagnosing and prescribing compared to 
male respondents ( =2.81, SD=1.0 vs. =2.59, SD=1.04, p=0.035). 
 
 
c) Education and Household income 
No significant difference was identified between respondents’ level of education 
(p=0.279) and household income (p=0.801), and their preference for pharmacists 
diagnosing and prescribing for conditions diagnosed. 
 
 
d) Employment status 
One-Way ANOVA indicated a significant difference (p=0.005) between respondents 
employment status and their preferences for pharmacists diagnosing and prescribing 
medicines for conditions diagnosed. Tukey’s post-hoc comparison identified 
respondents working part-time to significantly more favour pharmacists both diagnosing 
and prescribing for conditions diagnosed, in comparison to respondents working full-
time (p=0.023) and those retired (p=0.005). Mean and standard deviation values are 




Table 4.15 Mean and standard deviation values for preferences of respondents 
with different employment status regarding whether pharmacists should both 
diagnose and prescribe. 
 
 
Employment status Mean and standard deviations  values  
 SD 
Full-time 2.66 1.05 
Part-time 3.20 0.98 
Casual 2.55 0.96 
Retired 2.57 0.97 
Unemployed 2.94 1.09 




d) Number of prescriptions obtained, use of the same pharmacy and use 
of OTC medicines 
One-way ANOVA indicated no significant differences between respondents’ number of 
prescriptions filled (p=0.571), use of the same pharmacy (p=0.516) and use of OTC 
medicines status (p=0.511) in regards to whether pharmacists should both diagnose and 







4.4.4.5  Access to medicines 
 
One-way ANOVA evaluated whether respondents would find it easier to access their 
medicines without delay if pharmacists were involved in expanded prescribing 
(Statement 17 in Appendix 8). 
 
a) Age, Gender, Education and Employment status 
One-way ANOVA found a significant difference between respondents’ age groups and 
their attitudes on whether pharmacist prescribing can lead to easier access without delay 
to medicines (p<0.0001). Tukey’s post-hoc comparison identified that pharmacy clients 
under 30 years of age were more in favour of this  as opposed to pharmacy clients over 
65 years of age (p=0.001). Tukey’s post-hoc comparison also identified a significant 
difference between pharmacy clients aged 50-65 years and those over 65 years of age 
with the younger population sub-group being more in favour of improved access to 
medicines with pharmacist prescribing (p=0.003). Mean and standard deviation values 
are summarised in Table 4.15. 
 
Table 4.16 Mean and standard deviation values for preferences of age groups in 
regards to whether pharmacist prescribing enables easier access to medicines.   
 
Age group Mean and standard deviations  values  
 SD 
<30 3.82 0.84 
30-50 3.52 0.93 
51-65 3.62 0.83 




The results of One-way ANOVA indicated that there was no significant difference 
between respondents’ gender, level of education, household income and employment 
status in regards to their attitudes on whether expanded pharmacist prescribing enables 
an easier access to their medicines without delay (p=0.351, p=0.311, p=0.402 and 
p=0.082).   
 
 
b) Number of prescriptions obtained, use of the same pharmacy and use of 
OTC medicines 
One-way ANOVA indicated no significant difference between respondents’ number of 
prescriptions obtained and the use of the same pharmacy in regards to whether 
pharmacist prescribing would enable them an easier access to medicines  without delay 
(p=0.452 and p=0.787). 
 
A significant difference was identified between respondents who also used OTC 
medicines in comparison to those who did not, in terms of whether pharmacist 
prescribing leads to an easier access to medicines without delay (p=0.044). Respondents 
who also obtained OTC medicines, in addition to their prescription medicines, were 
more in favour of pharmacist prescribing leading to easier access to medicines without 














4.4.5 Reliability and Factor Analysis 
 
With the aim of reducing the number of questionnaire items and hence facilitating the 
regression analysis, scores of four statements related to pharmacy clients’ satisfaction 
with pharmacists’ current roles were combined (i.e. Statements 9, 10, 11 and 12 in 
Appendix 8). These statements were: 
i) I am satisfied with my pharmacists’ professional advice I receive for 
medicines 
ii) I am satisfied with my pharmacists’ level of drug knowledge 
iii) I am satisfied with the level of assistance my pharmacist provides when I 
purchase medicines from the Pharmacy 
iv) I am satisfied with how my pharmacist diagnoses minor ailments such as 
cold & flu, indigestion, hayfever, headache, conjunctivitis 
 
The result of reliability analysis for combining scores of statements using Cronbach’s 
alpha was 0.63. Item reduction was confirmed using Principal Component Analysis 
which extracted one factor. Kaiser-Meyer-Olkin measure of sampling adequacy (>0.695) 
and Bartlett’s test of sphericity (<0.0001), confirmed the suitability of factoring these 
variables. 
The variable extracted using the Principal Component Analysis and Cronbach’s alpha 








4.4.6 Regression analysis 
 
The regression analysis examined key factors that positively predicted pharmacy clients’ 
perception of trust on pharmacists expanding their prescribing role (i.e. the dependent 
variable). Factors examined (i.e. independent variables) were: 
 
a) Improved access to medicines, i.e. easier access without delay (statement number 
16 in Appendix 8); 
b) Pharmacists diagnosing and prescribing (statement number 18 in Appendix 8) 
c) Respondents being comfortable with pharmacist prescribing only if doctors make 
the diagnosis first (statement number 17 in Appendix 8) 
 
This model explained 19.8% of the variance and the F value (32.6) indicated 
significance (p<0.0001).  
 
Pharmacists diagnosing and prescribing (β=0.099, p=0.027), diagnosis of the condition 
by a doctor (β=0.160, p=0.003) and improved access to prescription medicines 
(β=0.368, p<0.0001) were positive predictors of pharmacy clients showing trust in their 
pharmacists to assume an expanded role in prescribing. These drivers were ordered on 
how strongly they predicted pharmacy clients’ perception of trust in pharmacist 
expanded prescribing and hence potentially leading to their acceptance of this role. This 

























Figure  4.1   Key factors contributing to pharmacy clients’ perception of trust in 
pharmacists assuming an expanded prescribing role.  
 
 
Linear regression was used to see how ‘pharmacy clients’ satisfaction with pharmacists’ 
current roles’ (i.e. summary score extracted with principal component analysis) 
separately predicted pharmacy clients’ perception of trust in pharmacists assuming an 
expanded role in prescribing. Satisfaction with pharmacists’ current roles positively 
predicted pharmacy clients’ perception of trust (dependent variable) in pharmacists’ 








Improved access to medicines         
β=0.368, t=7.508, p=<0.0001 
 
Condition diagnosed by doctor first (i.e. 
supplementary model) β=0.160, t=2.947, p=0.003 
 
Pharmacists diagnosing and prescribing (i.e. 




4.4.7 Agency Theory implications 
 
 
Agency theory defines a relationship between the three main stakeholders regarding a 
change to expanded pharmacist prescribing. Pharmacy clients’ preference for doctors to 
retain their role in diagnosis illustrates a strong agency relationship already exists 
between doctors and patients. Furthermore, findings of this study indicated that a doctor 
diagnosing the condition was a positive predictor to pharmacy clients’ perception of 
trust in pharmacist prescribing. This makes the agency relationship between doctors and 
patients an important component in an expanded pharmacist prescribing domain. 
However, in introducing expanded pharmacist prescribing, particularly the 
supplementary model which involves an agreement between a doctor, pharmacist and 
patient, Agency Theory would predict disruption of the agency relationship that already 
existed between doctors and patients. As illustrated in Figure 4.2, this disruption 
involves the introduction of a decision making authority of a second agent (i.e. 
pharmacist) into an already established relationship between patients and doctors. 
Independent prescribing by pharmacists requires establishment of new stakeholder 











   




* Prescribing authority delegation prior ( ) and after ( ) introducing the 
supplementary prescribing model. Potential disruption of the existing relationship ( ).    
Prescribing authority delegation after introducing an independent prescribing model        
( ). 
 
Figure 4.2  An illustration of prescribing authority delegation between patients, 




























This is the first study that has investigated views of pharmacy clients who had not 
previously experienced expanded pharmacist prescribing on pharmacist prescribing. 
These patients accessed prescription related services in pharmacies across Australia. 
This study has applied a theory to explain the potential influence of expanded 
pharmacist prescribing on relationships between doctors, pharmacists, and pharmacy 
clients. 1,2,3   
 
The respondents’ locations around Australia were reflective of the end of June Quarter 
2008 Australian population distribution obtained from the Australian Bureau of 
Statistics.  14 While the spread of respondents’ locations around Australia improved the 
study representativeness, it was limited by a low response rate (34.7%). The fact that 
respondents were only those that had not experienced expanded pharmacist prescribing 
may also be a limitation in terms of a broader exploration of patients’ perspectives. 
However, an expanded role in prescribing for pharmacists in Australia is not yet 
established. It should also be emphasized that the interview questionnaire was 
previously validated by a small pharmacist focus group and the company administering 
it which were members of the lay public and experienced in this form of surveying. 
However, the face validity and questionnaire piloting was not done with target 
respondents and key study findings relied on pharmacy clients’ interpretation of terms 
such as ‘trust in pharmacist prescribing’. These potential limitations should be taken into 
consideration by future policymakers when the findings of this study are considered.  
 
Most respondents supported pharmacists prescribing medicines for which doctors 
currently write repeat prescriptions. These attitudes are consistent with results reported 
by Stewart et al.5 and Hobson et al.6 where expanded pharmacist prescribing was 
generally supported by patients regardless of the fact that not all respondents they 




Respondents of this study also indicated that pharmacists would need further training if 
additional prescribing responsibilities were assumed. In this regard, pharmacy clients 
and pharmacists shared similar views (see Chapter III for views of pharmacists on 
training requirements). Furthermore, pharmacy clients’ support for expanded prescribing 
was reflected from the fact that less than one third (32%) were unwilling to pay 
pharmacists when prescribing medicines. 
 
A majority of respondents opposed pharmacists prescribing all of the medicines for 
which they currently needed a prescription from their doctor (29% agree/strongly agree). 
These findings were similar to those of Stewart et al. who have also reported that only 
25% of respondents agreed/strongly agreed to pharmacists prescribing the same range of 
medicines as doctors. Furthermore, our respondents indicated that they supported 
pharmacists’ expanded prescribing only if the diagnosis was first made by a doctor. This 
is an indication that, although supporting an expanded role for pharmacists in 
prescribing, pharmacy clients did not support pharmacists engaging widely in disease 
diagnosis.    
 
Respondents who supported pharmacists carrying out diagnosis of the disease and 
prescribing, most strongly favoured this for infections and pain management.  
Interestingly, pharmacists who preferred the independent prescribing model (see Chapter III 
results), which involved pharmacists making the diagnosis and prescribing for the condition 
diagnosed, showed strongest prescribing support for the areas of a limited number of 
infections and pain management.   
 
Improved access to medicines was a significant driver to the introduction of expanded 
pharmacist prescribing in the UK.2 Bessell et al. have proposed prescribing models for 
pharmacists in Australia with the aim of improving patients’ access to prescription 
medicines.15 The issue of accessing doctors and medicines was also considered in this 
study. Almost half of respondents (47%) agreed/strongly agreed that they had 
difficulties in accessing doctors and therefore would prefer pharmacists prescribing. 
However, the majority of respondents (64%) considered that their medicine access 
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would be improved if pharmacists had expanded prescribing rights with younger 
respondents being more in favour of this.  
 
Improved access to medicines positively contributed to an increased respondents’ 
perception of trust in pharmacists performing an expanded role in prescribing, as shown 
in Figure 4.1. Accessibility to medicines was also identified by Hobson et al. to be an 
important reason for patients accepting pharmacist as prescribers.6 Doctors making the 
diagnosis, and improved access to medicines positively contributed to an increased 
patients’ perception of trust in pharmacists performing an expanded role in prescribing. 
It should be emphasized that in comparison to doctors diagnosing the disease (i.e. a 
supplementary model of prescribing), pharmacists diagnosing and prescribing (i.e. an 
independent model of prescribing) was a weaker contributor to an increased patients’ 
perception of trust in pharmacist expanded prescribing. These findings are consistent 
with a previous finding in Chapter III of this project where an independent prescribing 
model was a weaker predictor than a supplementary model to expanding pharmaceutical 
services through prescribing. 
 
Respondents of this study indicated high levels of satisfaction with pharmacists’ current 
professional roles. This satisfaction also had a positive effect on predicting pharmacy 
clients’ perception of trust in pharmacist expanded prescribing, therefore placing 
pharmacists in Australia in a good position in terms of patients’ acceptance of expanded 
prescribing. No significant difference was found between pharmacy clients’ level of 
satisfaction with pharmacists’ professional roles dependent on their level of prescription 
use, use of OTC medicines and use of the same pharmacy. This may indicate similar 
quality level services offered by pharmacists and pharmacies regardless of the number of 
medicines per patient, as pharmacists overall professional role is similar for single or 
multiple medicines, although more interventions are possible with an increased number 
of medicines.  
 
Stewart et al. found that the general public supported pharmacists having an expanded 
prescribing role.5 As mentioned above, this is consistent with findings of this study 
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which suggest respondents’ support for this role. However, in the study conducted by 
Stewart et al. only 40.5% of respondents had confidence in pharmacists’ abilities to 
prescribe as opposed to 71% of respondents in this study who trusted their pharmacists 
to prescribe medicines for which they currently need repeat prescriptions from the 
doctor. The explanation for this difference in attitudes may be due to the fact that less 
than half of respondents in the Scottish study had visited a pharmacy in the past 12 
months, in comparison to the respondents of this study who were obtaining at least one 
ongoing prescription medicine in a pharmacy and therefore were all regular pharmacy 
clients. 
 
These differences in findings can be explained using the Agency Theory given that 
pharmacy clients have an established principal agency relationship with their 
pharmacist. According to this theory, there is an assumption that principals encounter 
problems with the lack of information about agents’ abilities and interests to perform 
actions on their behalf (information asymmetry). 8,9 Mott et al. have emphasized that the 
longer the relationship between agents and principals the more the principals learn about 
their agents. This in turn enables the principal to more easily assess agents’ 
capabilities.8,9 Therefore, Agency Theory suggests that information asymmetry between 
principals and agents is greater with the general public than regular pharmacy clients. 
This would apply to respondents of this study (i.e. pharmacy clients) who already have 
an established relationship with their pharmacists. The information asymmetry identified 
with Agency Theory, may also explain why the majority of pharmacy clients in this 
study preferred pharmacist prescribers to be located in community pharmacies in 
contrast to patients recruited by Hobson et al. who had an established relationship with 
prescribers in a clinical setting. Hobson et al. have concluded that, when it comes to 
pharmacist prescribing, the public may be hesitant of clinics in community pharmacies 
regarding their standards of professionalism, quality and clinical governance.6  
 
This study found through application of Agency Theory that expanded pharmacist 
prescribing would cause a disruption of the relationship that currently exists between 
doctors and patients. Findings from this study have suggested that the existing 
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relationship between doctors and patients is in fact a positive predictor of patients’ 
perception of trust and therefore acceptance of expanded pharmacist prescribing. This 
indicates that pharmacist expanded prescribing should be introduced in a form that it 
does not negatively affect the existing principal-agent relationship between doctors and 
patients. Such a change should be facilitated by addressing issues with patients that 
highlight access to medicines, easing the current high workload of doctors and better 
utilizing pharmacists’ skills.  This study demonstrates that pharmacy clients would then 
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5.1   Introduction 
 
A significant number of Australia’s’ elderly population currently live in RACFs.1 Most 
of the RACFs’ residents are on multiple medications and have a high prevalence of 
disease and co-morbidities.1 Furthermore, as the Australian population ages, there is an 
increased demand for services delivered to RACFs.2 There are signals suggesting that 
there are difficulties in current medication supply systems. These include difficulties in 
obtaining services from residents’ GPs, low level reimbursements as well as time 
consuming procedures. 2-9 
 
There is a lack of literature exploring new models of medication supply to RACFs 
especially those which also consider expanded pharmacist prescribing. The HMAs have 
suggested some models to address current difficulties in medication supply to RACFs 
while Bessell et al. suggested the ‘medication maintenance’ model. 8,9 In this model the 
doctor would initiate the medication while an accredited pharmacist would review, 
monitor, and renew medicines provided the residents’ condition was stable. Bessel et al. 
also proposed that medicines supplied under the ‘emergency supply’ system should be 
increased from three to 30 days duration or otherwise one ‘unbroken’ pack.8 
 
This study focuses on identifying current difficulties with medication supply systems in 
RACFs and potential models that could address these difficulties. It has explored the 





5.2    Aims 
 
The main aims of this part of the project were to:  
 
1. Explore and analyse pharmacists, doctors and nurses/carers views on current 




2. Explore and analyse pharmacists, doctors and nurses/carers views on improved 
medication supply models, including expanded pharmacist prescribing, which 





5.3    Methods 
 
This study was approved by the Human Research Ethics Committee of Curtin University 
of Technology (See Appendix 7). 
 
Focus groups were used as the model to collect the data. As a qualitative technique, this 
method allows exploratory work in order to meet the research aims. This method was 
also chosen because it allowed a timely and cost effective collection of information and 
it generated interaction between participants.10 Individual interviews were not used for 
data collection since a synergistic effect of different participants in a focus group can 




5.3.1 Study participants 
 
All focus group participants were currently working with at least one RACF. The aim 
was to capture the views of the main healthcare professionals involved in medication 
provision to RACFs therefore doctors, pharmacists and nurses/carers were recruited. 
Focus groups were organised separately with doctors, pharmacists and nurses/carers. 
Every focus group was homogenous in terms of participants. The literature has 
suggested that homogenous groups (e.g. same profession participants) are preferred to 
better capitalize on common experiences.13 Two focus groups were organised with 
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doctors, two with pharmacists and three with nurses/carers. The reason for organising 
three focus group discussions with nurses and carers was to ensure a wide representation 
of ideas was captured since these groups, unlike pharmacists and doctors, contained both 
nurses and carers.13 
 
 
5.3.2 Focus group location 
 
Focus groups with doctors were organised and conducted in two different areas of Perth 
i.e. Fremantle and Osborne Park. This was done in order to have a wider range of 
doctors who work with RACFs across the Perth metropolitan area. Focus groups with 
pharmacists were conducted in facilities of the Curtin University of Technology, School 
of Pharmacy. However, participants came from different areas of the Perth Metropolitan 
Area. Each focus group had pharmacists who were not working in the same pharmacy. 
The two biggest pharmacy groups that work with multiple RACFs had one pharmacist 
participant in each focus group. This was done to ensure a wider representation of 
pharmacies involved in supplying medications to RACFs. Focus groups with 
nurses/carers were conducted in respective RACF facilities. The first focus group was 
conducted with nurses/carers in Bicton. The second group was conducted at in Myaree 
and the third group was conducted in Belmont. Nurses had experienced working at 
different RACFs around Perth Metropolitan Area. The RACFs were purposely chosen in 
different locations to ensure a wider representation of participants. For this purpose 




5.3.3 Recruiting focus group participants 
 
Participants for the doctors focus groups were recruited through contacting the 
respective Divisions of General Practice (GP) aged care panels in the Fremantle and 
Osborne Park areas. All potential doctor-participants received an information letter and 
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invitation to attend the focus group. Eight doctors from the Fremantle area and 12 
doctors from Osborne Park area were contacted via telephone. 
  
Participants for the pharmacists focus groups were recruited through contacting 
pharmacies that supply medicines to at least one RACF. This task was difficult as there 
was no official available list of pharmacies that worked with RACFs. Therefore, 
pharmacies were identified by contacting pharmacies initially known to researchers that 
provide services to RACFs. From these pharmacies information was gathered about 
other pharmacies that service RACFs. This process was continued until a sufficient 
number of pharmacists agreed to participate in the focus groups. A total of 14 different 
pharmacies were contacted. Two of them included major groups that deal with multiple 
RACFs. All potential pharmacist-participants were contacted via telephone to seek 
agreement to participate and received an information letter and invitation to attend the 
focus group (see Appendix 9).  
 
Participants for the nurses/carers focus groups were recruited through contacting the 
manager of RACFs who then gave the information letter and invitation (see Appendix 9) 
to attend the focus group to potential participants. The manager who invited nurses and 
carers to participate was informed about the approximate preferred number of 




5.3.4 Focus group design and protocol 
 
The focus group questions and protocol were designed with the aid of the relevant 
literature. This was also assisted by a consultation meeting with researchers involved 
and the facilitator of the focus group. This resulted in minor changes to focus group 
questions. The focus group facilitator was a staff member of School of Pharmacy but 
was not part of research team of this study. This was done to ensure a degree of 
neutrality and avoid bias. The final focus groups questionnaire had an opening question 
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(icebreaker), six transition questions and three key questions (See Appendix 10). The 
opening question pertained to participants’ opinion on current medication supply 
systems in RACFs. Transition questions pertained to difficulties with current medication 
supply systems, potential improvements and potential new models of medication supply, 
including pharmacist prescribing. Key questions pertained to model preference and 
additional training needed (see Appendix 10). 
 
Before commencement of each focus group meeting, the facilitator made a brief 
introduction of the project and also asked participants’ agreement for audio-recording.  
All focus group meetings were audio-recorded using a digital recorder. To ensure 
effective audio-recording and to take notes about contributions made by each 
participant, one of the main investigators attended all focus group meetings and acted as 
an observer and did not participate. 
 
All participants signed a consent form to participate in the focus group (see Appendix 
11). Participants were also reimbursed for their time to participate in the focus group. 
Reimbursement rates were as follows: doctors AU$200, pharmacists AU$100 and 




5.3.5 Data analysis 
 
Audio-recorded data from the focus group meetings was transcribed into Microsoft 
Word. In order to perform a secondary content analysis, audio-recorded data was re-
listened to and also compared with field notes taken. Transcribed data was analysed 
using NVivo® v8 software. This data was imported and thematically coded into the 
NVivo® program and was organized according to topics. This assisted the management 
of a large amount of data and aided further analysis and interpretation of participants’ 
views and experiences. The main themes identified are listed in the results section. 
Selected comments are also given to illustrate participants’ views.  
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5.4    Results  
 
The focus group with Fremantle area doctors had four participants out of eight doctors 
contacted. One of the doctors agreed to participate but cancelled just before the meeting. 
The focus group with Osborne Park area doctors had seven participants, out of 12 
doctors contacted. A total of 11 pharmacists agreed to participate in focus group 
meetings out of 14 pharmacies contacted. One pharmacist cancelled his participation 
before the meeting due to an emergency. Pharmacists were divided in equal focus 
groups consisting of five participants. The two biggest pharmacy groups with multiple 
RACFs had one pharmacist participating in each focus group. The focus group with 
nurses/carers at Bicton RACF location had six participants. The focus group with 
nurses/carers of Myaree RACF location had five participants. The focus group with 
nurses/carers of Belmont RACF location had five participants.  
 
The main themes and sub-themes identified using NVivo® v8 are given in Table 5.1. 
Potential improved models of medication supply to RACFs are given in Table 5.2.  
 
The relevance of each sub-theme was ranked according to their appearance in focus 
group meetings. A sub-theme which has appeared in at least one focus group meeting in 
all three health professional groups (i.e. nurses/carers, pharmacists and doctors) has been 
ranked with ‘high relevance’ and assigned . A sub-theme that was appeared in at 
least one focus group meeting of two different health professional groups or in more 
than one focus group meeting of one health professional group was ranked  with 
‘medium relevance’ and assigned . A sub-theme that has only appeared in one focus 
group meeting of one health professional group was ranked with ‘low relevance’ and 
assigned . A comment that appeared more than once in another focus group meeting 
consisting of same health professionals was marked with an additional †.  
It should be noted that positive aspects of current medication supply systems have not 




Table 5.1 Themes and sub-themes identified from data collected in focus 
groups 
 
Main theme Sub-themes Ranking 
Difficulties with 
medication supply systems  
Medication wastage   
After hours/weekends   
Communication   
Medication charges to the residents  
Delivery of medication   
Difficulties after hospital discharge   
Medication changes   
When required (PRN) and short term 
medications  
 
Packaging – the sachet system   
Inaccurate packaging and discrepancies  
Faxed orders  




Authority prescriptions   
‘No script no supply’  
Owing prescriptions  
Backdating prescriptions  
Paperwork with writing prescriptions   
Missing prescriptions   
Overprescribing  
Difficulties with doctors in obtaining 
prescriptions 
 
Labeling and instructions of medications 
dispensed 
 
Low care facilities   





















Main theme Sub-themes Ranking 
Medical Director  General assessment NA* 




Reviewing the medication chart NA 
Current problems with medication 
profiles and potential disadvantages of 
using medication chart system 
NA 
Repeat extension General assessment NA 
Non-medical prescribing Comments in favour of non-medication 
prescribing 
NA 
Comments against non-medical 
prescribing 
NA 
Additional training NA 
Other proposed solutions to 
improving medication 
supply and management in 
RACFs 
Sharing PRN medications/Imprest 
system 
 
Pharmacist on site  
Using the local pharmacy  
The government taking over the supply 
of medications to RACFs 
 
The ‘best’ model General assessment NA 






5.4.1 Difficulties with current medication supply systems 
 
Focus groups participants indicated a number of difficulties they are facing with the 




a) Medication wastage  
 
Wastage of medication was identified to be one of the most significant concerns raised 
by all three groups of health professionals that participated in focus group meetings. The 
main reason for this wastage generation was that generally the pharmacy does not repack 
medication which comes back from RACFs, since accreditation requirements do not 
allow medication repackaging. Nurses and carers indicated wastage of medication 
seemed to occur in different instances. For example, when a resident goes to the hospital 
on Monday, they have a medication supply until Sunday and the following week they 
come back with new medications while previous medication is discarded and therefore 
wasted i.e. when there are changes to residents’ therapy. Additionally, the residents have 
to pay for discarded medication since the pharmacy has already supplied and they cannot 
be repacked. This was illustrated by a participant in nurses/carers focus group: “…if 
there are any changes you have to take the whole pack away, three or four days worth of 
medication. It is a waste of medication ††”. Nurses and carers also highlighted the issue 
when residents refuse generic brands of medications and because of that all medications 
packed for that week are wasted because the DAA has to go back to the pharmacy and 
medication replaced. 
 
Pharmacists explained how all sachets which come back from RACFs have to be 
discarded due to storage requirements. This especially becomes an issue when in those 
discarded packs there are medications for which doctors need authority approval prior to 
prescribing. Medications that are prescribed for short term use as well as broken packs 
that come from RACFs are also discarded. This is illustrated by one of the pharmacists: 
“One day a month we have two staff members that go through the Drugs of Dependence 
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(DD) returns and write them up. Broken boxes and short dated products that go through 
the DD inspector get destroyed and there are full boxes of morphine in date that come 
back…etc. Currently there is massive wastage ††”. In some cases pharmacists send 
medications for short term or PRN use to RACFs and unfortunately residents pass away 
very soon after. In these cases those short-term or PRN medications are sent back to the 
pharmacy and discarded, even if not used at all. 
 
Doctors indicated they think they are writing more prescriptions than their patients 
require because of the system generating large amounts of wastage. In some instances 
medications are also stopped by the pharmacy as a result of doctors not being able to get 
authority prescriptions for medications which have been wasted (i.e. discarded) by the 
pharmacy. This is illustrated by a doctor who said: “Medications are stopped without me 
saying so. I have written the last prescription in November so there was three months (of 
medication supply) left. With sachets system they say, and I don’t know whether it is 
true, that they throw away old sachets they get back and replace them all again so 
basically what they are doing is they are chewing patients’ drugs. They can’t do that 
because that is patients’ property.  That is a huge waste ††”. 
 
Doctors also highlighted the issue of medication wastage as a result of changes made to 
residents’ therapy. Medications are usually packed for a week at a time and when 
changes are made to residents’ therapy old packs are discarded. Again, medication 
wastage seemed to be particularly an issue of concern with authority medications which 
are often very expensive. This is illustrated by a doctor “…if you make a change, one 
day after the medication pack arrives, some not all pharmacies, will not repack the 
medication so a whole weeks’ supply is thrown away. So you are losing a lot of 
medication. Some are authority medications and very expensive. Sometimes you can 







b) After hours/weekends  
Accessing pharmacies after hours and weekends was identified as causing major 
difficulties in supplying medications to RACFs. Nurses and carers highlighted the 
difficulty with weekend pharmacists which are often different to pharmacists they deal 
with during the week. This seems to be when mistakes happen because “…pharmacies 
got no (regular) pharmacists and training †”. Nurses and carers were stressed on 
occasions when therapy changes occurred during the weekend and the update with new 
medication profile and signing sheets’ did not occur until Monday. In these scenarios 
they find discrepancies between medications given and their signing sheets and they 
would not have the updated profile to compare.  
 
Pharmacists also indicated how after hours work tended to be more difficult because in 
some instances medications were supplied by other pharmacies. This would be the case 
with pharmacies that were not open late and/or during the weekend. In this regard, 
pharmacists were particularly concerned with DDs i.e. “…the main problem, weekend or 
during the week (after hours), is with DDs if we run out and we have an urgent change 
to make †”.  
 
For doctors, the issue of accessing pharmacies after-hours was mainly a concern when 
they need to introduce a therapy change when seeing patients at night for acute 
conditions such as urinary tract infections (UTI) and the pharmacy not being available to 
supply the medication. In these cases medication is sent the next morning by the 
pharmacy. This is illustrated by a doctor who said that “…if you are called on the 
weekend or after hours to see a patient, you issue the script today but the pharmacy 
cannot supply. You are restricted to what the pharmacy can supply. There is a lapse 
between doctors willing to respond and the pharmacy willing to supply. So this part is 







c) Communication  
Difficulties which pertained to communication between staff in RACFs, doctors and 
pharmacists were identified. Participants in nurses and carers focus groups emphasized 
how it was better when the pharmacy was smaller. In those cases when the pharmacy 
was contacted you could get a more personalized response unlike today when “the 
pharmacist is on duty and then when you ring back to find out what has happened, you 
get a different pharmacist. A bit like the agency nurses in a hospital, you don’t get the 
response to your questions until three days later †”. Nurses and carers also highlighted 
some other issues which pertained to a potential lack of good communication between 
them and the pharmacy staff. When medication orders are sent to the pharmacy, the 
pharmacist sometimes has difficulties in interpreting what the nursing staff has requested 
and according to nurses and carers the pharmacist often has the same information that 
the nursing staff has and still rings to clarify instructions. This is illustrated by a 
comment from a RACF carer “…they don’t seem to know what we are requesting when 
it is there written in black and white and they deal with this sort of thing every day ††”. 
This issue tends to be more problematic when nurses and carers are outside their office 
performing other duties and dealing with residents. In these cases they would not have 
direct access to their office so they cannot immediately communicate the information 
requested back to the pharmacist. One of the carers also mentioned the pharmacy not 
passing the information on residents’ current safety net status. This could also be solved 
through a better communication between the pharmacy and RACFs. 
 
Communication between the main stakeholders involved was also a significant issue for 
pharmacists. They emphasized a breakdown in this communication when residents use 
GPs that do not normally deal with that RACF. Another communication difficulty 
appeared when pharmacists were not informed on the urgency of new medication to be 
delivered when these medications are not usually indicated for urgent conditions. A 
pharmacist mentioned that this issue depends on the experience of the nursing staff, for 
example an experienced nursing staff (if the medication is not urgent) will tell the 
pharmacy to deliver the medication with the next delivery but an inexperienced staff 
member or an agency will ask for the medication to be sent immediately hence creating 
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a delivery problem for the pharmacy. This issue is more complex when pharmacists do 
not have the information on the particular indication of that medication and they do not 
know the urgency of it so they are not in a position to make a clinical decision. 
According to a pharmacist, many of those changes can be done within the next two to 
three days. This is illustrated by a pharmacist who said: “You ring the nursing home and 
say the doctor has ordered the drug X he hasn’t indicated when he wants it…†”. 
 
Pharmacists sometimes have to pay overtime and extra delivery cost for their staff to 
deal with after-hours changes because requests come much later than when the doctor 
has seen the resident. This is illustrated by a pharmacist comment: “patient got a UTI 
and has seen the doctor. The fax comes to us at around 5.30 pm. Better communication 
(needed) I suppose †”. Pharmacists also mentioned how sometimes the doctor cannot be 
contacted to clarify potentially incorrect instructions on medications requested. This 
problem could also be addressed through better communication access between 
pharmacists and doctors.   
 
Doctors suggested difficulties which pertain to inadequate communication between them 
and pharmacists. A doctor mentioned instances when the medication was about to run 
out and then they got a fax from the pharmacy saying ‘we need this script now, could 
you fax a copy and then send the script to us in the mail’. This creates problems for 
doctors as it consumes a lot of their time and they have to leave other duties to address 
pharmacists’ prescription request. This becomes more complex in cases when doctors 
have already written a prescription being requested. This is illustrated by a doctor who 
mentioned that “…sometimes you write the script and a week later immediately you get 
the request for the same script, in a mass they send you. I have about 150 patients and 








d) Medication charges to the residents  
 
Nurses and carers, as well as doctors and pharmacists were all concerned with how the 
current medication supply system to RACFs allows for certain medication charges to the 
residents. A nurse stated that dealing with residents’ accounts is the biggest issue they 
have with residents. The problem arises when pharmacy supplies the medication but 
actually receives the prescription and claims it much later. As a result, this owed 
prescription is dispensed within a time interval that is too close to the next due 
prescription for that drug. This creates confusion for the residents and their families who 
query their accounts, as illustrated by a nurse: “…some of the tablets are for 28 days in 
the month and they want to know why they have been charged twice for the month ††”.  
Another issue which emerged in nurses and carers’ focus groups is charging of the 
residents for medications which accidentally get dropped from DAAs before their actual 
administration. In these cases often the whole sachet gets discarded, replaced and 
residents are charged for it. In some cases nursing staff cannot identify medication 
spilled out accidentally. Complaints of family and residents about their accounts are 
frequent. 
         
Pharmacists highlighted the issue of lack of residents’ information when they are 
admitted to the facility. As a result residents get overcharged because the pharmacy does 
not have their concession details at the time of dispensing. There are also cases when 
doctors charge residents for writing prescriptions. The pharmacy passes on this charge to 
the resident. A pharmacist mentioned an amount of AU$2 or more per script. Another 
issue which emerged in pharmacist focus groups was charging patients for authority 
prescriptions which are not approved, especially in situations when residents were 
discharged from hospitals. This was illustrated by a pharmacist: “often there are hospital 
situations requesting authority items (eg. 21 augmentin forte, ciprofloxacin). We put that 
through as an authority and three months down the track when the authority does not 
become possible we have to charge the patient and then we hear from the family: ‘you 
have billed me for mum who died three months ago and what is this charge of $90 for 




There are situations where patients complain to the doctor about their accounts querying 
the amount of medications charged by the pharmacy. A doctor suggested how his 
patients call asking “…How can I have 100 Panadol tablets this week and next day have 
another 100 †”. This is the same issue also reported by nurses which in essence results 
from pharmacy receiving the owed prescription late, claiming it and then charging the 
resident within a time interval which is too close to the next allowed regular supply. 
Another doctor was concerned when medications which are not subsidised by the PBS 
are prescribed because according to this doctor patients are forced to pay a high price set 
by the pharmacy.  
 
 
e) Delivery of medications  
 
Difficulties with delivery of medications from the pharmacy to RACFs were raised by 
nurses/carers, doctors and pharmacists. Nurses and carers were concerned with 
residents’ health being compromised in situations when medications are needed after the 
cut off pharmacy delivery time. A comment from a nurse illustrates this “…anything 
after that time is not delivered. But then the residents care is compromised, they might 
be in pain ††”. A nurse also mentioned problems with courier drivers sometimes giving 
the medication directly to the resident and not the RN and considered this to be very 
dangerous. 
 
For pharmacists delivery of medication did not seem to be an issue when the medication 
was for an acute condition as this was considered to be a straightforward decision for 
delivering the medication. However, delivery problems seemed to emerge when 
pharmacists did not have clear instructions from doctors when the medication should be 
started, particularly in cases when that medication was not usually indicated for an acute 
condition. There was a perception that RACF staff have different opinions on the 
urgency of that delivery dependent on their experience, with less experienced staff 
usually requesting the medication (even when it is not usually indicated for an acute 
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condition) to be delivered immediately. Pharmacists highlighted the need for doctors to 
clarify when the medication should start. This was illustrated by a pharmacist comment: 
“…you ring the nursing home and say the doctor has ordered the drug X he hasn’t 
indicated when he wants it. The nursing home always says we need it now because they 
don’t want to take the risk. So you have a delivery issue to deal with yourself. The doctor 
should say to the patient: ‘You’ll get the medication tomorrow afternoon and will sort it 
out but they don’t, they just sign the script…†”. 
 
Doctors considered it was difficult if they go to see a patient in the middle or later in the 
day since the medication cannot be delivered to the resident immediately. A doctor did 
emphasize the issue of difficulty with delivery when changing residents’ therapy in 
dealing with a pharmacy which was actually located interstate.   
 
 
f) Medication changes  
 
Nurses and carers as well as pharmacists and doctors identified difficulties during 
changes to residents’ therapy. For nurses this was when mistakes occurred including 
incorrect paperwork with signing sheets and residents’ profile. This was illustrated by a 
nurse comment: “I think (medication) changes are always difficult. That is where you 
can get mistakes or incorrect paperwork which comes from the pharmacy ††”. 
 
A few issues were raised by pharmacists when changes were made to residents’ therapy. 
They identified lack of doctors’ specification on the urgency of medication initiated or 
changed to be an issue. Additionally, changes to residents’ therapy seem to be more 
difficult when residents are taken by their family to see their own GP not at the RACF 
and they get the prescription somewhere else. The pharmacy usually finds out about this 
when they get a call from carers asking the pharmacy to include the medication they 
have in their hands in DAAs. However, the pharmacy or RACFs do not have any 
documentation about it. The frequency of changes made to residents’ therapy was also 
identified in a pharmacist focus group to be an issue. This is illustrated by a pharmacist 
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who said: “We got one doctor who continually accuses us over using medication. He 
makes ten changes a week. What physically he wants us to do. We can’t do everything 
†”. It should be noted that every time a change is made, the DAA goes back to the 
pharmacy and is often discarded and medication therefore wasted.  
 
Doctors identified delays for changes to residents’ therapy to be implemented. 
Additionally, doctors were also concerned with medication wastage which occurs when 
changes are made to residents’ therapy. This is illustrated by a doctor who said: 
“Medications have been packaged for quite a number of weeks at a time and if you make 
a change, one day after the medication pack arrives, some, not all pharmacies, will not 
repack the medication so a whole weeks supply is thrown away, so you are losing a lot 
of medication, some very expensive ††”.  
 
 
g) Difficulties after hospital discharge  
 
Difficulties with residents discharged from hospitals were identified by all three groups 
of health professionals. Nurses and carers highlighted how there are problems in cases 
when residents are discharged from hospitals and the pharmacy does not have the 
information on residents discharge medication. Sometimes residents are discharged with 
medications not packed in a DAA. In these cases carers cannot administer that 
medication and send it back to the pharmacy for packaging. Accreditation requirements 
prevent the pharmacy from packing medications which were not dispensed by the 
pharmacy hence compounding this problem. This seemed to be more complex when 
RACFs do not have after-hours access to the pharmacy since the abovementioned 
procedure causes delays and often residents’ therapy is not given until the next day or 
over the weekend. This is illustrated by a carer comment:  “The biggest problem in 
hostels is the medication control when people are returning from hospitals because they 
don’t let the pharmacy know what scripts they are on. They give them (carers) bottles. 
They cannot give them Webster packs and they think there is trained staff to dispense the 
medication. That is a big problem. They come back with a box of antibiotics. Staff here 
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cannot give it to them. Even this week we had tablets from the hospital.  We had to send 
them back to the pharmacy. We are okay because we have 24/7 service but small hostels 
using a local pharmacy which is shut. The medication is required to be given  doesn’t 
occur until the next day, over the weekend or Monday. The pharmacy does not pack if 
medications are sent in boxes ††”.  
 
Pharmacists also highlighted the lack of residents’ medication discharge summary when 
they are transferred from hospitals to RACFs. This seems to waste a lot of time for 
pharmacists who then have to follow up and contact the hospital to find the information. 
Pharmacists often get prescriptions instead of the residents’ discharge summary. These 
prescriptions sometimes are given to the residents or their family which also creates 
confusion because often they are filed away in RACFs and get lost. Receipt of incorrect 
medication discharge summaries were also pointed out by a pharmacist. This is 
illustrated by a pharmacist comment who said:  “From Hospitals the biggest issue is 
with residents’ medication discharge summary. They are incomplete or doctors’ notes 
do not match the discharge summary and when you call them sometimes they cannot tell 
you exactly what patients are on so there is a lot of chasing around ††”. A pharmacist 
also pointed out that once she could not obtain residents discharge summary due to 
confidentiality issues. Pharmacies often supply medications prescribed in the hospitals 
assuming that an authority prescription will be approved and given to them. When the 
medication supplied does not get approved the pharmacy ends up charging the resident 
full price for the medication supplied. This may suggest lack of PBS knowledge by 
hospital doctors prescribing PBS items ‘off-label’. 
 
A doctor also pointed out the problem with hospitals supplying medications which then 
doctors cannot continue to prescribe as they were initially prescribed ‘off-label’ by the 
hospital. This is illustrated by his comment “patients come out from the hospital and 
have their own medications ‘off label’…there is no indication on PBS for it and you are 
now asked for a script for it, which is not legal and it doesn’t seem to be any way around 
that…there should be an easier path for the hospitals prescribing “off label” and for the 





i) When required (PRN) and short-term medications  
 
All three groups of health professionals in focus group meetings highlighted concerns 
with PRN and short-term medications. Nurses and carers pointed out the wastage of 
PRN medications and difficulties with identifying PRN medications from antibiotics and 
short term medications. 
 
Pharmacists’ appeared concerned with charging the resident for short-term medication 
which may only be used a few of times or none. This is illustrated by a pharmacist who 
said: “We have someone who is written up for morphine, hyoscine and midazolam. We 
sent them down at 10 o’clock at night and unfortunately the patient dies the next 
morning and they send the medication back and you can’t do anything with it. You have 
to charge the patient †”.  
 
Doctors pointed out how sometimes they want to give the patient a PRN medication and 
there may be availability of that medication at that facility but under the current system 
the facility will not use any medication that has not got a resident’s label on it i.e. a new 
medication has to come up from the pharmacy. This is illustrated by a doctor who said: 
“…terminal patients who just need morphine at the end of life and they might only get 
one dose e.g. 2mL out of 200mL bottle Ordine and that is just discarded after and then 
when you do need it, it would be useful to be just be there at the facility †”. The current 
system of with PRN medications, in addition to potential wastage, may also be 
unnecessarily consuming doctors’ time in writing prescriptions. A doctor pointed out: “I 
would spent nearly two hours during the week just doing prescriptions and the annoying 







j) Packaging – the sachet system  
 
In both nurses/carers and doctors focus group meetings, the sachet system of packing 
medication came up as a potential difficulty with medication supply to RACFs. 
However, it should be noted that not all comments compared this system with the blister 
system of packaging implying that these difficulties are not necessarily excluded with 
the blister method of packaging. Nurses and carers highlighted the issue of perforation 
with sachets i.e. how the sachets do not tear out very easily so when it is opened the 
medication spills out. This is illustrated by a nurse who said: “I think the sachets in 
themselves are very good. I think the perforations on the sachets cause quite a few 
incidents when we were opening medications because the sachets are torn and the 
medication spills out †”. The issue of difficulties with identification of antibiotics, PRN 
and short term medications from packs containing regular medication was also raised by 
nurses and carers. 
 
Doctors identified the sachet system of packaging to be an issue when changes are made 
to residents’ therapy. This is illustrated by a doctors’ comment: “Most of the places I 
work supply sachets. The sachet system is good, neat, it reduces errors, but there is a 
problem, sachets are meant for no changes, for those who continue with the supply †”. 
A doctor pointed out how when changes to residents’ therapy are made and pharmacies 
use the sachet to repack the medication it generates errors and confusion. 
 
 
k) Inaccurate packaging and discrepancies  
 
Nurses/carers highlighted issues related to inaccurate packaging of medications in 
DAA’s. Sometimes there is less or more medications packed in DAAs than is supposed 
to be and often the nursing staff cannot identify the medication. This is illustrated by a 
carer who said: “…sometimes medication is missing from certain sachets. We have to 
make sure that the correct number of medications is given and because we don’t know 
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particular tablets we find it difficult. So, when one tablet is missing we don’t know which 
particular tablet that is ††”.  
 
Nurses and carers also highlighted issues with discrepancies between patients’ profile 
and medications supplied. Paperwork discrepancy is illustrated by a carer who said: 
“The sachet may say it has Panadol but it actually has a dose of Panadol Osteo and then 
underneath it will have 500mg but the actual paperwork will say it is Panadol Osteo (i.e. 
665mg), so there is that discrepancy ††”.  
 
 
l) Faxed orders  
 
Nurses and carers emphasised that they were having difficulties with faxing orders and 
prescriptions through to the pharmacy. These difficulties pertained to faxed orders going 
missing between RACFs and the pharmacy. This is particularly an issue when DD’s or 
antibiotics are ordered because they are expected to arrive at RACFs within a certain 
time frame. Nurses reported getting frustrated with chasing up faxed orders and they 
indicated that doctors are frustrated with this as well. This is particularly relevant with 
DD patches which are required to be replaced within a specific period of time. This is 
illustrated by a comment which emerged from nurses and carers’ focus groups: “we 
know that we have sent it to the pharmacy because we will get a report saying that it has 
gone through but then we ring up and they say we haven’t received it ††”. Another 
problem for nurses and carers with faxed orders is that once orders are faxed through 
they get constant calls from the pharmacy to confirm their order. 
 
 
m) Medication brands    
 
Nurses/carers identified difficulties with use of different brands of medications in 
RACFs. In this regard, they did report difficulties in explaining to the residents the 
equivalence of brands which are substituted by the pharmacy. In cases when the resident 
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refuses the substituted brand the medications are wasted since the DAA goes back to the 
pharmacy and discarded before repackaging is done. The brand substitution may 
especially be an issue for carers in cases when the pharmacy does not let the nursing 
staff know about the brand substitution. A comment from a carer is given to illustrate 
this: “…sometimes they pack a different brand of medication and they don’t let us know. 
We run back annoying the RN saying this is a white tablet but still has the description of 
the original tablet on the pack and not the new description. There is no note to let you 





5.4.2       Prescription and dispensing related difficulties 
 
Focus group participants indicated a number of prescription and dispensing related 
difficulties when supplying medications to RACF residents. A summary of these ranked 
difficulties is presented below: 
 
 
a) Authority prescriptions  
 
A major difficulty for focus group participants was dealing with medications that require 
authority approval by the PBS in order for them to be supplied to the residents. A nurse 
pointed out how pharmacists cannot supply these medications as owed prescriptions and 
as a result they discontinue supply without notice. This is illustrated by a nurse who 
said: “…you have got a resident with behavioural issues and they stop the drug because 
they haven’t got an authority script and the behaviour problems escalate. Sometimes the 
drug can only be written by specialists so it is not a good system †”. 
 
Pharmacists emphasized the difficulties they encounter with obtaining authority 
prescriptions and this becomes more complex when doctors write a prescription which 
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does not get approved because the pharmacy then returns the prescription back to the 
doctor so the approval is obtained. This also creates further delays in prescription 
dispensing interval. This is illustrated by a pharmacist comment: “I had a doctor who 
has written an authority prescription which did not get approved but sent it to us 
anyway. We did put it through and a month later we got it back rejected. So we were six 
weeks behind again, and we have made the supply meantime ††” Pharmacists also 
pointed out the lack of authority prescriptions when residents are discharged from 
hospitals. This means the medication cannot be supplied as a PBS item. 
 
Doctors pointed out how pharmacies often supply medication as owing and then ask 
doctors for prescriptions without realising that the resident is not eligible under the PBS 
rules to have that medication subsidised. Lack of timely notification of doctors by the 




b) ‘No script no supply’  
 
For nurses/carers, pharmacists and doctors the issue of non-supply as a result of lack of 
prescriptions for pharmacists emerged to be a significant issue of concern. Nurses and 
carers reported how sometimes there are stickers on DAAs indicating ‘no supply 
because no script’. In these cases, a nurse illustrated how “medication chart indicates 
that it is still there and when the pharmacist is contacted about it he/she will say ‘well 
the doctor hasn’t supplied the script’…† “. This is particularly a problem with authority 
prescriptions and especially for medications used in psychiatric conditions because when 
the medication is stopped residents’ behavioral problems escalate.  
 
Pharmacists suggested they get into a position of (not) supplying medications when new 
residents are admitted to RACFs. A comment from a pharmacist illustrates this: “If a 
new resident comes in the facility, they can give you a bunch of prescriptions they expect 
you to dispense and pack with no proper directions on the script and you can’t expect us 
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to really do that †”. A pharmacist indicated how sometimes the process of getting all the 
required information can take almost all day. Difficult decision making situations of 
medication supply were also reported when doctors do not supply prescriptions for 
medications which have been repeatedly supplied more than once based on the owing 
system. 
 
Doctors confirmed the issue of non-supply as a result of lack of prescriptions. According 
to a doctor, sometimes this is not a particularly friendly situation since prescriptions 
requested are well in excess of what they really should be. A doctor suggested that 
sometimes the medication is discontinued because doctors cannot prescribe due to the 
PBS authorization restrictions. This issue of therapy discontinuation is illustrated by a 
doctor: “Occasionally, the issue is pushed that if we (do not) sign and provide those 
prescriptions your patients will not get their medications so we are held to ransom to do 
the scripts that are demanded of us. But I cannot do more Galantamine than the 
Government will authorise and so they stop the supply of that medication if they haven’t 
got the prescription right when it is due ††”. As mentioned above, discarding 
medications when changes are made to residents’ therapy plays a big role in these 
situations where the interval of their prescribing is subject to authorization by the PBS. 
 
 
c) Owing prescriptions  
 
Pharmacists and doctors highlighted the issue of supplying medications to RACFs based 
on an owing system. For pharmacists it seemed that a good part of their medication 
supply is based on an owing system which leaves pharmacists waiting to receive the 
prescriptions for medications already supplied. The system of supplying medications to 
RACFs based on an owing system may also be financially affecting pharmacists since 
they supply the medication without being reimbursed for it until the prescription is 
received. A comment from a pharmacist illustrates this: “You provide all these drugs 




Doctors also recognised the fact that supplying medications based on the owing system 
is a problem for pharmacists because pharmacists are worried about missing out on 
finance if they do not get the scripts from doctors. Doctors raised the issue of 
pharmacists requesting more prescriptions than they expect their residents to consume 
during that period of time. However, it should be noted that not repacking (i.e. 
discarding) DAAs after changes are made to residents’ therapy plays a big role in this 
problem for which some doctors did not seem to have a clear understanding. Doctors 
also raised the issue of pharmacists supplying based on an owing system medications 
which residents are not eligible to have under the PBS. This is a comment by a doctor 
which illustrates this particular problem generated by supply of medications based on an 
owing system: “Medications like Gabapentin and Lactulose, pharmacists are tricky. Not 
all of residents are actually eligible to have them under the PBS. They just supply and 
ask you to do a script. So when you are doing owing prescriptions it is quite difficult to 




d) Backdating prescriptions  
 
The issue of backdating prescriptions were raised by both doctors and nursing staff. For 
nursing staff the backdating of prescriptions seemed to be particularly an issue when 
accounts with prescriptions dispensed are explained to the patient or their family.  
Backdating of prescriptions becomes an issue when they are received after the 
medication has already been supplied as owing and as a result nursing staff get worried 
about the correct charging of residents. Furthermore, nurses may be wasting valuable 
time in matching when the medication was supplied and when the prescription dispensed 
for claiming purposes by the pharmacy since often they need to explain the account 
discrepancies to their residents. A comment from a nurse illustrates this: “…I have to 
calculate how many tablets she would have had then. When was the last time they had it, 
and then I have to ring up the pharmacy, find out when was the last time they were 
charged because they don’t look at all that. They are not going to count it all out. How 
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many medications are in a box of so and so and it can take me ages to sort it out for 
them. I don’t think the pharmacies are ripping them off. I don’t believe that is the case, it 
is just a process that they don’t understand †”. 
 
A doctor expressed concerns with pharmacies asking for backdated prescriptions for 
medications already supplied since this is against prescribing rules. A comment by a 
doctor illustrated how prescriptions are sometimes requested for medications already 
supplied for patients who already passed away: “A patient died six or nine months ago.  
Pharmacy kept sending a script from last year to a patient who died six months ago. It 
happened quite often…†”. It should be noted that this problem directly arises from 
pharmacies supplying medications based on an owing system and delays until those 
prescriptions are received from doctors. In cases when patients pass away and 
medications are already supplied, the only way for the pharmacy to get reimbursed is to 
get prescriptions dated on the day the actual medication was supplied. There appeared to 
be a lack of understanding by some doctors about this particular issue. 
 
 
e) Paperwork  with writing prescriptions  
 
Doctors expressed concerns with the amount of paperwork they have to go through 
when managing their patients at RACFs. These paperwork concerns were mainly related 
to writing prescriptions. This suggested that a significant amount of doctors’ time which 
could be spent on reviewing patients was actually spent in writing prescriptions for the 
pharmacy. A doctor even suggested: “I cannot possibly get through the paperwork 









f) Missing prescriptions  
 
Doctors raised the issue of missing scripts in RACFs. This seemed to happen especially 
when prescriptions are written at the facility and doctors end up writing the prescription 
again. A comment to illustrate this was made by a doctor:  “I might write down the 
antibiotic or eye drop and quickly scribble a script and give it to them. That script 




g) Difficulties with Doctors in obtaining prescriptions  
 
Pharmacists identified difficulties they encounter with doctors during their supply of 
medications to RACFs. These difficulties mainly pertain to delays obtaining 
prescriptions for medications supplied. Currently most pharmacies send reminders for 
the doctors when residents’ repeats are about to run out and then doctors supply a new 
prescription with repeats. This is illustrated by a pharmacist who said: “Every five 
months we require prescriptions, this leaves us one month (before prescription runs out) 
to get other repeats. I go through all patients to check what they need. One doctor did 
that in one week, the other one we are still waiting…†”.  
 
 
h) Labelling and instructions of medications dispensed  
 
Nurses/carers identified problems with labelling and instructions on medications 
dispensed by pharmacies. Identification between short-term, antibiotic and PRN 
medications was a difficulty that nurses and carers highlighted. Additionally this 
generated other problems because antibiotics needed to be recorded in the infection 
control surveillance sheet and when they do their end of month reports the data entered 
does not match. Nurses and carers also pointed out the lack of instructions on PRN 
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medications supplied by pharmacy. This is illustrated by a nurse who said: “With the 
PRN packs, there is not enough information on the pack, when and why we should be 
giving them e.g. when the patient is vomiting ††”. In cases where topical products are 
labelled as ‘apply to affected area’ nursing staff is not aware which area is that and often 
residents, especially those with conditions such as dementia, cannot tell the nursing staff 
where the affected area is. 
 
 
i) Overprescribing  
  
The issue of prescriptions issued in excess of residents needs’ was stressed by doctors.  
This was illustrated by a doctor comment: “Why is it that I have been asked to supply 25-
50% more prescriptions for that period of time that you would normally expect ††”. As 
in the case of the difficulty with ‘no script no supply’, wastage of medication in RACFs 
as a result of current rules allowing no re-packing of DAAs may be a major contributing 




j) Low care facilities  
 
Doctors identified issues with dispensing of medications in low-care facilities where 
carers dispense medications occasionally. According to a doctor, this is a problem that is 
prone to errors and creates situations where residents may receive someone else’s 
medication. This doctor also mentioned another issue in low care facilities where 
nursing staff were not allowed to dispense Schedule Eight drugs on a PRN basis so when 
they have terminal patients or need a PRN Scheduled Eight drug to cope with significant 






k)       Lack of government audit  
 
Lack of audit by the PBS on dispensed medications was brought up by a pharmacist. 
According to this pharmacist “current PBS supply arrangements are not good because 





5.4.3 Potential improved models of medication supply to RACFs 
 
Focus group participants were asked to comment on potential improved models of 
medication supply to RACFs. These models included: a) use of Medical Director 
computer program at the facility to write prescriptions b) use of a centralized medication 
chart, c) extending the number of repeats and d) non-medical prescribing (i.e. expanded 




5.4.3.1 Medical Director  
 
In discussing the use of a Medical Director as a way of improving medication supply to 
RACFs, some potential advantages and limitations were identified. A nurse suggested 
that in the RACF she works, one of the doctors uses the Medical Director program when 
visiting the RACFs and the experience with this is that you know immediately what is 
written and the pharmacy gets the prescription straight away. However, a problem that 
other nurses and carers highlighted with this system was that usually doctors have other 
priorities when visiting RACFs and do not have time to sit down and write prescriptions. 
This is illustrated by a nurse who said that:  “Doctors don’t have time when they visit. 




Pharmacists who had experience with doctors using the Medical Director program noted 
that prescriptions for medications initiated during the time the doctor visits  RACFs are 
received much sooner. However, this system does not address other regular prescriptions 
when repeats run out. This is illustrated by a pharmacist who said: “You have the same 
problem, you have someone on medication every day and the script runs out. You need 
something like a medical chart that satisfies the prescription for example for six months 
††”. 
 
Doctors did not appear to be very keen in using the Medical Director when visiting 
residents at RACFs. A doctor suggested the issue of writing prescriptions in different 
places was difficult while another doctor suggested that when she tried writing 
prescriptions at RACFs she ended up writing them again as they get lost in paperwork. 
However, it seems that the main issue with this system is the fact that doctors generally 
have limited time and other priorities when visiting RACFs. This is illustrated by a 
comment from a doctor: “It is generally a time issue that during the day when you do the 
consulting, you want to see as many patients as you can and spend other time to do the 
scripts. I do my scripts on the computer at the surgery for the requirement that is 
generated by a fax or mail from the respective pharmacies ††”. 
 
 
5.4.4.2 Medication chart  
 
The use of a medication chart/profile as a legal document for supplying medications was 
generally supported. Pharmacists preferred this being done electronically. There were a 
few sub-themes that emerged under the medication chart model. These sub-themes were 
not ranked since it was the focus group facilitator who prompted participants to give 
their comments on the relevant subject. These themes pertained to: a) support for its use, 
b) reviewing the medication chart and c) difficulties with current medication charts and 




a) Support for using a medication chart  
 
Focus group participants were supportive of using a centralized medication chart as a 
legal document which enabled prescribing and dispensing of medications to RACFs 
residents without prescriptions. A nurse considered that medication charts clarify what is 
given to the resident by instantly knowing that is the medication the doctor has 
authorized to give. In some RACFs, medication charts are already the official documents 
by which the nursing staff is guided when giving medications to residents. A comment 
to illustrate this was given by a nurse: “Most of the time we use the medication chart as 
an official document. The only time we have a script is if one of our residents has an 
outside GP, then they come back with the script, we photocopy it and fax it through to 
the pharmacy and they pick up the script when they deliver the medication †”.  
 
Pharmacists were also supportive of medication chart use. In addition to the advantage 
of not having to deal with prescriptions, a pharmacist also specified that there would be 
no variance in repeats’ frequency when medication charts are used as central legal 
documents directing the medication supply for RACF residents. Most pharmacists in 
focus group meetings favoured the use of electronic medication charts (i.e. profile) 
instead of the hardcopy ones. Some of the advantages of using electronic medication 
charts included: enabling doctors to change residents’ therapy electronically and 
pharmacists responding in real time, accuracy by which the pharmacy could see what 
stock would be required to dispense ahead in time. A pharmacist illustrated how an 
electronic medication chart enabled the pharmacist to log in online and dispense the 
medication whilst the PBS could easily see what had been dispensed and therefore 
claimed for each month of supply. This was a comment that illustrated pharmacists’ 
support for using electronic medication charts: “With an electronic medication profile, 
the doctors change the medical profile in real time and you responds in real time if he 
doesn’t change you don’t respond, no change you don’t have to worry about it.  The 
nursing home or hostel becomes central to everything. They retain control of the whole 




Doctors were generally supportive of using medication charts and not spending their 
time writing prescriptions. Centralization of medication supply and clarification of 
medication deliveries were reasons for this support. Doctors also emphasized retaining 
control over what medications their patients had also was an advantage of using 
medication charts. This is a comment that illustrates doctors’ support for using 
medication charts: “We already have medication profiles in most of the facilities and 
they work well. They are easy to read and understand and I think it is reasonable to 
understand that if the profile says that the medications are to be delivered we should be 




b) Reviewing the medication chart  
 
Focus group participants highlighted the need for a regular review of medication charts. 
In nurses and carers’ focus groups, reviewing medication charts emerged as a necessity 
from the experience with the current use of medication charts.  A comment from a nurse 
illustrates this: “Sometimes I don’t think they even review the medication profile because 
if someone is started on Panadol as a regular dose, you would still find it as PRN on the 
bottom so you could find they have had a double dose of Panadol in a day †”. A 
pharmacist went even further to actually put an expiry date on medication charts so that 
it makes it necessary for doctors to review i.e. “they should be valid for six months as it 
forces the doctor to review the patient monthly †”. 
 
The need for medication charts to be reviewed regularly to make sure it was up to date 
was also highlighted by doctors. A doctor also proposed a review interval on medication 
charts. This is illustrated by his comment: “I foresee that it could work provided we 
were required to review it on a quarterly basis. I don’t know that I would want have to 






c) Current problems with medication profiles and potential disadvantages of 
using medication chart system  
 
Nurses and carers as well as pharmacists identified difficulties they currently 
encountered when working with medication charts. All three groups of health 
professional identified some potential difficulties with using a centralized medication 
chart as a legal document without prescriptions.  
 
Nurses and carers identified difficulties such as changes of residents’ therapy during the 
weekend. An example is with cases where medication charts do not correspond with 
what the nursing staff actually administers as the doctor might have not written it in the 
chart and the pharmacy does not supply a new medication profile until Monday. Another 
current difficulty is occasional lack of residents’ photos on their medication profiles. 
Residents’ photo in their medication profile is part of the checking process when 
medications are administered by the nursing staff. Another interesting potential problem 
for nurses and carers with using medication charts as central documents was the fact that 
it may not solve the problem of medications prescribed for short-term or PRN use. This 
was illustrated by a comment from a nurse: “Medication chart model will not entirely 
solve our problem. Although the medication chart is your legal document you still need 
medications prescribed for different conditions at different times like urine infection, 
vomiting and diarrhoea, constipation so you still need someone to add those medications 
onto that document †”.  
 
Pharmacists raised the issue of legible writing with paper-based medication charts, 
especially when working with duplicates, as a potential problem. Another pharmacist 
queried the claiming procedures with using paper-based medication charts as it may 
create confusion as to whether that was the original medication chart that had not been 
submitted for claiming. When using electronic medication charts one pharmacist 
questioned potential technical problems with computers affecting the process. Another 
pharmacist suggested that older doctors may not be comfortable with using the 
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electronic version of medications charts. 
 
For doctors, the main difficulty that needed to be addressed when using the medication 
chart model was the potential lack of control of medications that are dispensed by the 
pharmacy. This is illustrated by a comment from a doctor: “I would be in favour of using 
medication charts but that would require somebody to monitor the pharmacies 
delivering medications. How many prescriptions they dispense in our name because we 
will then no longer be responsible for the number of scripts going out in our name ††”. 
 
 
5.4.4.3 Repeat extension 
 
Extending the current number of repeats was discussed in focus group meetings as an 
option which could improve current medication supply system to RACFs.                
 
Nurses/carers attitudes on extension of repeats varied in different focus group meetings.  
Some suggested that extending the number of repeats would make no difference to their 
practice. However, the nurses that supported the extension of repeats highlighted 
medications for which currently the PBS does not allow any repeats such as Temazepam 
and combination of Paracetamol with codeine products. This was illustrated by a nurse 
who said: “Absolutely (i.e. a good idea), especially in aged care. If someone is on 
Temazepam, are they ever going to go off Temaze? Very rarely. The same with 
Panadeine Forte. In young people, sure they can do lots of stuff with it but for severe 
pain management in the elderly where they need to have one Panadeine Forte and one 
Panadol and you know that that is going to carry on QID until the year dot for their 
pain management †”. A carer suggested that extending the number of repeats would not 
pose an overdosing risk to the residents since the administration is restricted to what is 
on the prescription and the nursing staff has to follow that.  
 
Pharmacists generally did not show support for extension of number of repeats as for 
them problems remained the same since the repeats would eventually run out and they 
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would again have to ask doctors for their prescriptions. Additionally, short-term 
medications would not be addressed by this model. A pharmacist even suggested that 
doctors are not using the recent extension of repeats for certain medications on the PBS.  
A pharmacist illustrated the extension of repeats model by saying: “…for the first six 
months it would be great, it stretches out but it catches the tail eventually ††”. 
 
Doctors who did not support an extension of repeats model highlighted issues such as 
the model requiring a care plan to be in place for the resident and lack of time for 
doctors to implement that. A doctor considered this model to be a fine tuning to start 
with and pointed out how using the medication chart model would enable getting away 
from having to write prescriptions in the first place. Another doctor was concerned with 
the model potentially generating difficulties when for example the dose of the same 
medication was increased and hence having to re-write the prescription with an extended 
number of repeats. A doctor did say that he was not using the current extension of 
number of repeats (which allows up to eleven repeats for certain medications) because 
the patient has to be reviewed at least twice in six months. 
 
A doctor stated that while he still preferred the medication chart model, the extension of 
repeats model would allow him to have control over the medication that was dispensed 
on his name and he would accept it since it was a one step closer to writing fewer 
prescriptions. A doctors’ comment illustrated the attitude of doctors that partially 
support the extended repeats model: “I still have to write the scripts. I think theoretically 
at the most it would halve our time we spent in writing scripts but that is a theoretical 
level. It might improve by 30% at the most. For some specific things such as 








5.4.4.4 Non-medical prescribing 
 
Expanding the prescribing role for pharmacists and nurses was discussed in focus group 
meetings as an option which could improve current medication supply system to 
RACFs. This section was divided into a) support for non-medical prescribing and b) 
attitudes against non-medical prescribing 
 
 
a) Comments in favour of non-medical prescribing 
 
Nurses and carers that were in favour of non-medical prescribing considered that it 
would be convenient in certain situations to have an RN with prescribing authority. 
These situations pertained to acute short-term conditions such as nausea and vomiting. A 
nurse suggested that in many occasions doctors ask her about what to prescribe 
suggesting it is just a matter of not having the power to prescribe. 
A nurse who supported nurse prescribing indicated that there should be a list of what 
medication can be prescribed. This was her comment: “I think there should be a list of 
what can be initiated when prescribing because then you got that confirmed…you know 
they have been vomiting for all day so it would be great if I could just give them the 
medication for it and relieve their symptoms rather than wait for the doctor to come up 
so I could give the medication †”. 
A nurse that supported expanded pharmacist prescribing believed that pharmacists have 
the knowledge to prescribe and that even now when they have cases of residents 
experiencing adverse effects to medications, pharmacists are capable to advise what 
medication they can take. 
 
Pharmacists who were in favour of extended pharmacist prescribing considered that this 
model is a better model than the current one however ‘you need a system that just 
flows’. Another pharmacist who supported this model commented: “I think pharmacist 
prescribing would help. Something has got to change because doctors don’t have time to 
write scripts †”. 
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Doctors who were not against non-medical prescribing indicated they would not oppose 
such as model as long as they were not responsible for the medication prescribed. In this 
context, doctors were happy to make the diagnosis but not be responsible for someone 
else writing prescriptions and continue the supply of that medication. As with the 
medication chart model, the doctors raised the issue of not having control over the 
amount of medication that comes from the pharmacy. A doctor that supported non-
medical prescribing suggested that: “Time spent in re-writing scripts would have to be 
re-deployed from script-writing time to really go through those medication profiles a lot 
more diligently and we would certainly benefit from doing that †”. A doctor suggested 
that pharmacist prescribers should come from the government since there would be no 
conflict of interest between pharmacists prescribing and dispensing that medication. 
Another advantage for the idea of the government pharmacist prescriber was that it is 
‘governments’ medication and they would make sure the authority scripts were correct, 
restrictions were correct and the amounts were correct †’. 
 
 
b) Comments against non-medical prescribing 
 
Nurses and carers who were against expanded pharmacist prescribing suggested that 
such a model would not change the situation as their problems were not attached to 
prescription writing. It was suggested that pharmacists not being located in the pharmacy 
means the problems would be the same as with doctors. This was illustrated by a 
comment: “Who will give the prescribing pharmacist information about the resident, the 
carer? They would have to come to the facility same as the doctors so I cannot see the 
difference ††”. The nurses and carers who rejected pharmacist prescribing because of 
this reason suggested that a non-medical prescriber would need to be located in the 
facility. 
 
In terms of nurse prescribing specifically, it was indicated that it could solve pharmacy 
problems only. A nurse suggested how some years ago they would write prescriptions 
and doctors would sign on them. This nurse was concerned with the lack of knowledge 
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that nurses have on PBS rules and pharmacology. 
 
Pharmacists who were against non-medical prescribing questioned the need for 
prescriptions in the first place i.e. the medication chart model would solve the 
prescription problem. It was indicated that non-medical prescribing could only be 
‘shifting deckchairs’ rather than solving the current difficulties. In terms of pharmacist 
prescribing specifically, pharmacists raised the issue of increased cost with hiring a 
prescribing pharmacist and indemnity. In terms of dependent prescribing, a pharmacist 
indicated that he would not take the responsibility of continuing to write prescriptions 
when doctors initially diagnose and prescribe highlighting the legal liability to be an 
issue. 
 
Pharmacists who were not in favour of non-medical prescribing, considered that nurse 
prescribing would not make any positive difference for them. A comment illustrates this: 
“I don’t think a nurse practitioner writing scripts would make any difference. Just like 
the doctor, the nurse would say: I do not have time or I am too busy administering a 
medication, change a dressing ††”. A pharmacist considered that the only way 
pharmacist prescribing in RACFs would work is if this pharmacist was from the 
government since a prescribing pharmacist from the same pharmacy that supplies the 
medications constituted a conflict of interest. 
 
Doctors that were not in favour of non-medical prescribing considered that medication 
chart model would make the concept of someone else prescribing unnecessary. This is 
illustrated by a comment from a doctor: “I think the biggest problem we have with the 
current system that I see from a personal time point of view, is having to sit down and 
write scripts. If we can get rid of that and I think we should, as long as checks and 
balances are in place, you don’t have to worry about this concept of someone else 
writing scripts ††”. Confusion between prescribers with generated prescriptions and 
potential duplication of tasks when seeking authority approvals also emerged as reasons 
for rejecting such a model. A doctor described how re-writing prescriptions helps with 
‘mentally checking’ if that resident still needed that medication, so this would be lost. A 
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5.4.4.5 Training for expanded non-medical prescribing 
 
Focus group participants were asked to comment if additional training would be needed 
if nurses or pharmacists would assume further prescribing roles. A nurse considered that 
if the diagnosis was done by a doctor, there would be no need for training nurses on 
prescribing repeat prescriptions. A nurse also considered that the current knowledge that 
pharmacists have would be enough for them to assume further prescribing roles. This is 
illustrated by a nurse comment: “My understanding is they know what they are making 
up and they know what that medication is for.  Nine times out of ten I have gone in for a 
personal prescription, the chemist will turn around and say “have you got so and so?” 
They know what the medication is for so they understand †”.  
 
Pharmacists were generally of the opinion that more training, guidance and accreditation 
would be needed if they would assume further prescribing responsibilities. 
 
A few doctors considered that nurses would need so much training with focus on PBS 
rules up to the point that it questions whether they need to go through that process. In 
comparison, doctors considered that pharmacists already had the knowledge to continue 
prescribing repeat prescriptions for conditions they diagnose. This is illustrated by a 
doctor comment: “I don’t see a point in training a nurse. There are too many drugs and 
too many rules. A pharmacist knows that. I don’t see a point in training a nurse to do a 






5.4.4.6 Other proposed solutions to improving medication supply and management 
in RACFs 
 
Focus group participants made a few other suggestions which in their opinion could 
improve medication supply and management in RACFs. A summary of these proposed 
suggestions is given below:  
 
 
a) Sharing PRN medications/Imprest system  
 
A nurse suggested that when you had medications such as paracetamol to share amongst 
the residents for PRN use there was not so much wastage. 
The issue of PRN and short-term medications was also raised by a doctor who 
considered that there were cases where there may availability of these medications at the 
facility but they cannot be used due to current legalities. His comments illustrates this: 
“If I wanted to give a PRN medication, such as Mylanta or GTN, there may be 
availability of that medication at that facility but under the current system the facility 
won’t use any medication that has not got a patients’ label on it, so it has to come up 
from the pharmacy. A full bottle of Mylanta or GTN and the patient might only have just 
one dose of it. Another example would be terminal patients who just need morphine at 
the end of life and they might only get one dose e.g. 2mL out of 200mL bottle Ordine and 
that is just discarded after and then when you do need it, it would be useful to be just be 
there at the facility. I am in favour of any imprest of medications at the facility that 
could be used…I’m not in favour of all medications need to be packed †”. 
 
Use of the imprest system was also supported by another doctor who suggested that this 
avoids delays in getting medications to the resident and that it is very useful for 
situations like when antibiotics are needed. Her experience with a RACF that uses this 
system was positive. This doctor suggested that if you are going to a nursing home and 
you need an antibiotic at that time there is no other way to get that medication at that 
time for that patient. A doctor who was not in favour of using this system highlighted 
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concerns such as high burden on nurses, their lack of dispensing knowledge and he was 




b)  Pharmacist on site  
 
A nurse explained how the system was very good when RACFs had a dispensary and a 
pharmacist on site i.e.: “we would go into the pharmacy and there was a book and we 
would write down if you take something. We never had any problems it was a very good 
system †”.  
 
 
c) Using the local Pharmacy  
 
Using the local pharmacy emerged as a theme in a nurse/carer focus group and a focus 
group consisting of doctors. A nurse indicated how when the pharmacy was smaller the 
relationship between the nursing staff and pharmacy was better because they used to get 
a more personalized response. Furthermore, she indicated in the current system there is a 
high changeover rate of pharmacists to deal with. This is illustrated by her comment: 
“these days you wonder which pharmacist is on duty and then when you ring back to 
find out what has happened, you get a different pharmacist. A bit like the agency nurses 
in a hospital, you don’t get the response to your questions until three days later †”.  
 
Doctors in a focus group also considered that it was easier to deal with smaller local 
pharmacies. This was illustrated by a comment: “local small Pharmacy would be easier 






d) The Government taking over the supply of medications to RACFs  
 
A doctor proposed the idea of the government take over medical supply to Aged Care 
facilities. The main reason for this, according to this doctor was since the government 
subsidised a significant amount of these medications and therefore their takeover of 
medication supply would address the issue of medication wastage. This could make the 
system more efficient and could generate positive changes in both pharmacies and 
RACFs. This is a part of his comment: “…it is in their interest to be in control of it and 
look at the wastage that is going on. They could do it a lot more efficiently and I think 
when they see how the system is working at the moment, I think changes will happen 
because anyone who was actually paying for this medication and not just using the 
Government funding to supply it would not tolerate the amount of wastage. There would 
be changes at the pharmacy end and the facility end †”.  
 
 
e) Pharmacy printing scripts for doctors to sign  
 
A pharmacist mentioned the system of using an electronic software that generated 
prescriptions in printed form for doctors to sign. This could ease the burden associated 
with large amounts of prescriptions that doctors have to write. Her experience with this 
system was positive.  
 
5.4.4.7  “The best model” 
 
Focus group participants were asked about which out of all models of medication supply 
to RACFs discussed would be the best in their opinion. Using the centralized medication 
chart as a legal document was the most preferred model. As a supplementation of the 
medication chart model, nurses and carers proposed the idea of an RN working in the 
facility that is trained for prescribing short-term medications. Pharmacists proposed the 
electronic version of medication chart model while the doctors proposed contracting the 
local pharmacy to the current system. 
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5.4.4 A summary of medication supply models and their relationship with 
difficulties identified 
 
The following illustrates the potential of the main models of medication supply to 
RACFs discussed in this study to address the difficulties identified by focus group 
participants with current medication supply systems to RACFs.  
 
It should be emphasized that the level to which these models address a particular 
difficulty is not explored and there are certainly instances whereas a model may address 
one aspect of a particular difficulty but not others. For example, the medication chart 
model may address the difficulty of ‘after hours/weekends’ by making the system easier 
to manage during pharmacists’ changeover or with reduction of paperwork related 
discrepancies with medication changes during weekend. However, the difficulty with 
availability of pharmacy to deal with medication changes and initiations during 
weekends and after hours when that pharmacy is unavailable remains unaddressed.  
 
Boxes in red represent difficulties classified as highly relevant (i.e.  difficulties). 
Yellow boxes represent difficulties of medium relevance (i.e.  difficulties) while 
white boxes represent difficulties of low relevance (i.e.  difficulties). These are given 
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Figure 5.2 Medical Director based model and its potential for addressing 
current medication supply difficulties identified 
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Figure 5.3 Repeat extension based model and its potential for addressing 
current medication supply difficulties identified 
 
 













































A           NA 
A           NA 
A          NA 


























δAddressing difficulties, †Not addressing difficulties, ≠ unicolour columns represent one category of 
ranked difficulties 
                             Difficulty of high relevance (***) 
Difficulty of medium relevance (**) 
Difficulty of low relevance (*) 
 
Figure 5.4 Non-medical prescribing based model and its potential for 
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Figure 5.5 A summary of main models of medication supply to RACFs discussed 












































































































This study has explored the data collected from three main health professional groups 
involved in therapeutic management of residents currently living in RACFs. Carers 
working in RACFs did also participate. As a result, this study has identified some key 
difficulties that are present in the current systems of medication supply to RACFs. 
Additionally, potential models which could improve the current systems of medication 
supply to RACFs have been proposed.  
 
The main strength of this study is the representation of doctors, pharmacists as well as 
nurses and carers in focus group meetings. These health professionals were all 
experienced in dealing with medication supply to RACFs and they were currently 
working in at least one RACF.  
 
The main weakness of this study is the fact that it was conducted only in WA and did 
not include participants from other Australian States and Territories. Therefore 
participants’ representativeness may be limited. However, the limitation to WA may be 
considered to be of minimal effect to the overall study results given the achievement of a 
saturation point in terms of new ideas and comments made by focus group participants 
as well as the similarity of medication supply systems to RACFs across the Australian 
States and Territories. This study used homogenous groups of participants (i.e. same 
professionals) in focus group meetings. The aim was to capitalize on common 
experiences of participants.13 Segmentation of focus group participants also facilitates a 
comparative data analysis.14 However, it should be emphasized that an exploration of 
different perspectives with diverse focus groups of health professionals dealing with 
RACFs is a potential advantage which may have been missed with the use of 
homogenous focus groups.13 As suggested by Kitzinger, the professional hierarchy of 
focus group participants (in this study consisting of nurses and carers) may have also 





a) Difficulties identified  
Difficulties with medication supply systems to RACFs identified by focus group 
participants were grouped into two main themes: a) difficulties with medication supply 
to RACFs and b) prescription and dispensing related difficulties. The most highly ranked 
medication supply difficulties (i.e.  difficulties) identified were: medication 
wastage, after hours and weekends works, communication, medication charges to the 
residents, delivery of medication, medication changes, residents’ discharge from 
hospitals and PRN/short-term medications. Residents’ discharge from hospitals was also 
identified by the HMAs to be an issue of concern. 9 In addition to HMAs concerns with 
transfer of residents from hospitals to RACFs, this study has also found issues such as: 
lack of trained staff at RACFs to handle medications supplied to residents by the 
hospital, inaccurate or lack of discharge summaries and the difficulty for doctors in 
continuing to prescribe medications which were initially prescribed as non-PBS items 
and ‘off label’ in the hospital.  
 
Medication wastage has been reported by the HMAs as a result of changes to residents’ 
therapy and discarded DAAs.9 In this study medication wastage was one of the most 
significant concerns that focus group participants had with the current system. In 
addition to the HMAs reasons this study has identified that the current system of 
supplying short term and PRN medications induced significant wastage as well.  
 
Difficulties with current medication supply systems to RACFs ranked as ‘highly 
relevant’ were followed by difficulties of ‘medium relevance’ (i.e.  difficulties). 
These were: faxed orders, medication brands and inaccurate packaging and 
discrepancies. Carruthers et al. have also highlighted the issue of inaccurate packaging 
of DAAs.15 This needs to be interpreted in the context of the fact that supplying 
medicines from a bulk stock resulted in a rate of administration errors of as high as 15-
20% in comparison to individualized supplies (i.e. DAAs) which reduces this error to 5-
8%. 15,16 Focus group participants also identified issues with the sachet system of 
packaging. However, as previously stated with the sachet packaging, not all comments 
compared this system with the blister system of packaging implying that these 
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difficulties are not necessarily excluded from the blister method of packaging. 
Therefore, more research is needed to explore and compare this method of packaging 
with the blister packaging.  
 
Most highly ranked prescription and dispensing related difficulties identified were 
difficulties with authority prescriptions and the issue of no supply without a prescription. 
Difficulties with the doctors obtaining authority prescriptions were also identified by the 
HMAs who suggested that the time consumed in obtaining authority prescriptions may 
be an unnecessary use of doctors’ time and skills.9 Prescription and dispensing related 
difficulties ranked as ‘highly relevant’ were followed by difficulties of ‘medium 
relevance’. These were: backdating prescriptions, labelling and instructions of 
medications dispensed, overprescribing and the amount of paperwork with prescription 
writing. Difficulties with prescription writing were also reported in the literature. 2,3 
Bessel et al. identified how in some cases doctors decide to discontinue the therapy 
hence leaving pharmacists without a prescription.8 Difficulties for pharmacists in 
obtaining prescriptions from doctors was one of the difficulties of ‘medium relevance’ 
identified by this study as well. This process may be an unnecessary use of pharmacists’ 
time and skills. 
 
Difficulties with owing prescriptions, ranked with ‘medium relevance’ in this study, 
were also reported by the HMAs who stated that pharmacies often supplied PBS 
medicines without a prescription, which should then be received from doctor within 
seven days.9 However, sometimes doctors do not send their prescriptions within seven 
days hence pharmacists have to remind doctors about their outstanding prescriptions.9   
 
Findings from this study are also in line with the HMAs who suggested that due to 
‘owing prescriptions’ pharmacists performed additional tasks in requesting prescriptions 
from doctors and that doctors were concerned with duplicating tasks. Additionally, 
HMAs have suggested that pharmacists have delays submitting claims to the PBS which 
results in their cash-flow being affected.9 This is illustrated by a comment from a focus 
group pharmacist in this study who stated: “You provide all these drugs and you haven’t 
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been reimbursed for them and you have to bear this cost”. Furthermore, the system of 
‘owing prescriptions’ may be also negatively affecting the relationship between 
pharmacists and doctors with doctors sometimes being concerned with pharmacies 
requesting prescriptions in excess of what they think their patients could use.  
 
The current system generated significant amounts of wastage through DAAs not being 
repacked. This induced wastage of medication which affects the interval of prescriptions 
dispensed by the pharmacy. Accreditation requirements prevent pharmacies from re-
packaging medications. These accreditation requirements are in place to protect patients 
since the quality of medications to be re-packaged is no longer certain and potentially 
dangerous given that they are not fully labelled. Medications in DAAs are removed from 
original packages and not stored under initial packaged requirements. 
  
 
b) Main models of medication supply discussed 
Out of all potential models discussed, the medication chart model was the most preferred 
one amongst focus group participants. There were indications that in some RACFs the 
medication chart was already the central document that superseded prescriptions. This 
emerged in pharmacists’ focus group meetings with pharmacists saying: a) “Facility 
calls to say the script written is different to the medication profile. So we go based on 
the medication profile not the script”, b) “My experience is that the medication profile 
always wins over the script. This problem would not be there if the only focus was the 
medication profile.” 
 
The medication chart model was also proposed by the Australian government under the 
Fifth Community Pharmacy Agreement. According to this model, there would be no 
need for prescriptions and a medication chart would be the central legal document by 
which medication supply to RACFs would take place. In this study, pharmacists 
favoured this be done electronically. The medication chart model, especially when done 
electronically, appeared to address more difficulties identified by focus group 
participants than other models. Focus group respondents stressed the need for a regular 
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review of medication charts and cautioned about legible writing and claiming procedures 
which could be eliminated by an electronic medication chart system. A pharmacist also 
suggested that “with electronic medication profile and no prescriptions you can very 
accurately see what will be required a month ahead of time to dispense.” This could 
have positive effects in stock management for pharmacies. Furthermore, theoretically, an 
electronic medication chart system accessible to hospitals could also improve current 
difficulties when residents are discharged from hospitals.  
 
The medication chart model has the potential to partially or fully address most of the 
difficulties identified by focus group participants. However, some ‘highly relevant’ 
difficulties such as medication wastage, PRN medications, delivery of medication and 
difficulties with packaging using the sachet system still may remain unaddressed with 
this model. This model does not overcome having to re-package medications when 
changes to residents’ therapy occur. It also does not address the issue of pharmacists’ 
reimbursement when wastage occurs since cost recovery for medication wastage when 
re-packaging is required cannot occur by writing a new prescription. 
 
The use of a Medical Director program by doctors appears to address only two ‘highly 
relevant’ difficulties identified by focus group participants. Doctors using the Medical 
Director program at RACFs may be in a position to provide prescriptions in a timelier 
manner to the pharmacy and hence alleviate the difficulty with pharmacy charging 
residents when late owing prescriptions are received, which creates confusion for 
residents and their families. However, this does not address the problem of charging the 
residents when their medication is wasted. Using the Medical Director may also improve 
issues with ‘no script no supply’, again through doctors providing prescriptions in a 
timelier manner. However, this may be very limited given that focus group participants 
mentioned medications requiring special authority for prescribing to be the core issue of 
this difficulty. This model appears to address none of the difficulties ranked with ‘low 
relevance’ in this study. Additionally, there appeared to be concerns with doctors not 
having time to use the Medical Director when visiting RACFs since their focus during 
this time was on other priorities. 
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The repeat extension model may address some prescription and dispensing related 
difficulties of ‘medium relevance’ as well as ‘highly relevant’ difficulties with authority 
prescriptions and the issue of pharmacies not supplying as a result of a lack of 
prescription. However, this model appears to temporarily address these difficulties and 
hence postpone rather than provide a solution to them. This model does not address any 
of the difficulties of ‘low relevance’. Additionally, it may have the potential for causing 
a greater confusion when medications are changed. Nevertheless, repeat extension 
model may reduce the amount paperwork for doctors in prescription writing.  
 
In general, the non-medical prescribing model was perceived with mixed support by all 
three groups of professionals. This model, which included expanded pharmacist 
prescribing and RN prescribing, may have a greater potential for addressing more 
‘highly relevant’ difficulties, in comparison to the repeat extension and Medical Director 
model. It could alleviate the issue of medication charges to the residents by provision of 
prescriptions to the pharmacy in a timelier manner and therefore less confusion for 
residents and family with their accounts when owed prescriptions are received late and 
dispensed to replace a previous supply. However, the problem of charging the residents 
as a result of medication wastage still remains unaddressed.  
 
The ‘after hours/weekends’ and ‘PRN/short-term medications’ difficulties may be 
addressed through the availability of an extra non-medical prescriber which could avoid 
the delay in doctors getting located to the facility. However, this may not apply to 
pharmacists who are usually not at the facility. This was also illustrated by one of the 
nurses who said “Pharmacists have to come to the facility, so the same problems like the 
doctor have. It is best to have someone within the facility”. On the other hand, 
pharmacists were also sceptical of nurse prescribing with one pharmacist emphasizing: 
“I don’t think nurse practitioner writing scripts would make any difference. Just like the 
doctor, the nurse would say: I do not have time or I am too busy administering a 
medication, change a dressing”. In terms of pharmacist prescribing specifically, 
pharmacists emphasized a few limitations such as: cost of pharmacist prescribers, 
professional indemnity and legal liability. They also questioned the need for such a 
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direction since the medication chart model in their opinion was a better model. Doctors 
also questioned the availability of RNs and did not seem to see the need for expanded 
prescribing given that a medication chart model would be a better solution. This was 
illustrated by one of the doctors saying: “I think if we go with that (i.e. expanded 
prescribing) you would introduce another person in the system that does not have to be 
there to start with if we would use the medication profile as your legal document. I feel 
like answering the question that does not have to be there”. 
 
Possibly due to lack of trust on pharmacies supplying medications without doctors’ 
control and potential conflict of interest, prescribing by a government pharmacist 
emerged as an option in a doctors focus group meeting if an expanded pharmacist 
prescribing model was adopted. This same idea also came out in a pharmacist focus 
group in which the conflict of interest in pharmacists prescribing and supplying the 
medication prompted one pharmacist to suggest a government pharmacist as a suitable 
pharmacist for such a role. 
 
In relation to pharmacist and nurse prescribing, it should be noted that there may be a 
difference in terms of workforce availability for these two groups of health 
professionals. The Hogan Review has highlighted a current shortage of trained nurses in 
RACFs as well as ageing of nurses, compared to other areas. 17 On the other hand, the 
workforce availability may be different for pharmacists with pharmacy degrees almost 
tripling over the last decade.18,19 Furthermore, in January 2010, Human Capital Alliance 
(HCA) projected an oversupply of pharmacists by 2025. 20 These circumstances may 
place pharmacists in a better position than nurses when it comes to assuming new 
professional roles such as expanded prescribing, even in RACFs.  
 
Although it was clear that the medication chart model emerged as the model of choice in 
focus group meetings, there could be some room for this model to be supplemented by 
an expanded prescribing role for pharmacists and RNs. As stated by a participant from 
nurses/carers focus group meeting: “Medication chart model will not entirely solve our 
problem. Although the medication chart is your legal document you still need 
278 
 
medications prescribed for different conditions at different times like urine infection, 
vomiting and diarrhoea, constipation so you still need someone to add those medications 
onto that document”. An expanded role in prescribing for suitably trained pharmacists 
and RNs, in addition to the medication chart model, could address the abovementioned 
difficulty. 
  
In this study, focus group participants came up with other potential ways which could 
improve medication supply to RACFs. They suggested: sharing PRN medications and a 
wider availability of an imprest system, the availability of a pharmacist on site, use of 
local pharmacies, an RN at the facility in charge of monitoring prescriptions written at 
RACFs, the Government taking over the supply of medications to RACFs and pharmacy 
printing scripts for doctors to sign. More research is needed to ascertain the benefits and 
feasibility of each of these options proposed by focus group participants. Sharing PRN 
medications has the potential to reduce wastage. However, this needs to be weighed 
against the risks involved when doing this.  
 
It should be noted that none of the main models of medication supply to RACFs 
discussed in this study appear to address the issue of medication wastage which mainly 
occurs during changes to residents’ therapy, discarded DAAs and discarded or unused 
PRN and short-term medications. The medication wastage has largely arisen from a lack 
of suitably trained staff to administer medications in RACFs. This cost has been passed 
to the pharmacy and the PBS. More research is needed to explore ways of reducing 
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3.1 General discussion  
 
 
This study has considered the likely acceptance of expanding pharmacist prescribing in 
Australia by the pharmacy profession and pharmacy clients. This is one way that should 
enable pharmacists to expand their professional role and better utilize their education 
and training.  
Prescribing of medicines was considered as within the medical domain. This has its 
roots in the apothecary who prescribed and dispensed. Separation of these roles occurred 
with the establishment of pharmacists who dispensed and prescribed “over-the-counter” 
medications. Prescribing in Australia has been expanded to include dentists, 
optometrists, physiotherapists, podiatrists and nurses. The former prescribe within 
restrictions of their practice, whereas nurse practitioners prescribe within a range of 
defined specialty areas. Pharmacists have well established expertise in drug usage and 
their professional role is within the context of the quality use of medicines. 
 
This project has evaluated Australian pharmacists’ and community pharmacy clients’ 
views on expanding pharmacists’ prescribing role. An emphasis was put on defining 
their preferred models and therapeutic areas of prescribing. The Agency Theory was 
used to explore the relationships between the main stakeholders involved in the domain 
of expanded pharmacist prescribing. In employing the Agency Theory, emphasis was 
given to explaining a possible disruption of this relationship by an introduction of 
expanded prescribing role for pharmacists. This project has also explored potential 
improved medication supply models, including expanded pharmacist prescribing, which 










6.1.1 Pharmacists’ attitudes on expanded prescribing 
 
 
Results from a large sample of Australian pharmacists suggested that pharmacists in 
Australia support an expanded prescribing role.  
 
In this study, it was hypothesised that pharmacists’ professional practice area would not 
affect their support for an expanded prescribing role i.e. H1:  There is no significant 
difference between pharmacists’ support for expanded prescribing and their 
professional practice area. This hypothesis was accepted since chi-square testing 
resulted in no significant difference (p=0.139) between pharmacists’ professional 
practice setting in relation to their support for expanded pharmacist prescribing. It was 
further hypothesised that pharmacists would prefer both supplementary and independent 
prescribing models i.e. H2: There is no significant difference between pharmacists’ 
preference for supplementary or independent prescribing models. This hypothesis was 
rejected since a vast majority of pharmacists supported the supplementary model of 
prescribing. Of the respondents, 896 agreed that pharmacists should prescribe in a 
supplementary, independent or both models. Data cross-tabulation revealed that of these, 
69.1% (n=620) preferred pharmacists prescribing in a supplementary fashion only as 
opposed to 3.3% (n=30) who supported independent prescribing only. Both supplementary 
and independent prescribing were positive predictors of expanding pharmaceutical 
services through prescribing (p<0.0001), however, pharmacists who were in favour of 
supplementary prescribing showed a stronger association towards this expansion (β 
=0.52 vs. β =0.18). These findings suggest that expanded pharmacist prescribing in 
Australia would be strongly supported if introduced in a supplementary model. This role 
for Australian pharmacists should take into consideration potential limitations of the 
supplementary prescribing model reported in the UK. 1,2,3,4,5 It is worth mentioning that 
support for supplementary prescribing was also reported by Hobson and Sewell who 
suggested that despite concerns, pharmacists had a positive attitude towards this model.6  
The main drivers for Australian pharmacists supporting an expanded role in prescribing 
were: better use of pharmacists’ skills, easing the burden from overloaded general 
practitioners and pharmacists’ drug knowledge. In several ‘Crown Reports’, a greater 
285 
 
use of pharmacist skills was identified as one of the main drivers for expanding 
pharmacist prescribing in the UK.7,8 All potential drivers of pharmacist prescribing 
identified in this study were positive predictors of an expansion of pharmaceutical 
services through pharmacist prescribing (β=0.747, p<0.0001). Additionally, 
pharmacists’ opinion based upon their perceptions of their clients’ and pharmacy 
ownership were also shown to be important positive predictors of expanding 
pharmaceutical services through prescribing (β=0.127, p=0.005 and β=0.01, p=0.004). 
Inadequate training in patient assessment, diagnosis and monitoring were perceived as 
the greatest barriers towards pharmacists assuming an expanded prescribing role. These 
potential barriers were also the strongest negative predictors of expanding pharmacists’ 
role in prescribing (β=-0.098), p<0.0001), while increased cost and deterioration of 
patients’ care were the weakest negative predictors for expanding pharmacist prescribing 
role (β=-0.075, p=0.004). 
 
The vast majority of respondents considered further training was needed for pharmacists 
to assume additional prescribing roles. In this regard, strongest preferences for further 
training were shown for areas of pathophysiology of conditions, principles of diagnosis 
and patient monitoring. Respondents showed lower levels of support for training in 
pharmacodynamics and pharmacokinetics, adverse drug reactions and drug interactions 
and communication skills. Further training in clinical pharmacology as well as 
pharmacodynamics and pharmacokinetics was supported more by pharmacists who were 
registered for longer than 20 years (p<0.0001). These findings should be interpreted in 
conjunction with evidence from the UK where Dawoud et al. that observed how 
pharmacists undertaking supplementary prescribing considered they were 
knowledgeable in areas such as pharmacology and pharmacokinetics but they needed 
more training in patient assessment and counseling. 9   
 
In Australia, the potential benefits of a supplementary prescribing model need to be 
weighed against current forms of dependent prescribing available to Australian 
pharmacists, particularly the repeat system of prescribing. In a supplementary 
prescribing model, special emphasis should be put on defining pharmacists’ 
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remuneration, access to patient records and intervals of patient visits and reviews by 
prescribing pharmacists. Furthermore, the extent to which pharmacists should be able to 
stabilize or modify patients’ therapy needs to be clarified. In the current repeat system of 
prescribing, pharmacists are not able to modify doctors’ prescriptions whereas 
pharmacists’ remuneration (of dispensing only) and prescription refill interval are 
regulated by the PBS.   
 
The potential benefits reported with supplementary pharmacist prescribing in the UK 
which included improved patient management, job satisfaction for pharmacists and 
greater patient satisfaction should be taken into account when establishing an expanded 
prescribing role for pharmacists in Australia.10  This also needs to be weighed against the 
fact that the health system in Australia is under stress from factors such as the ageing 
population, increased morbidity, increased chronic diseases and insufficient doctors to 
keep pace with population growth.11 Insufficient numbers of health professionals is 
driving task transfer.12 Furthermore, there are indications that fewer medical graduates 
are choosing general practice as a career, hence adding to the existing general 
practitioner shortage.13 Joyce et al. projected a continued shortage of general 
practitioners in Australia, hence suggesting that innovative primary medical care policies 
were necessary.14 Therefore, better utilization of pharmacists’ skills in expanded 
pharmacist prescribing, highly supported by respondents in this study, should be 












6.1.2 Community pharmacy clients’ attitudes on expanded prescribing 
 
 
Most respondents trusted pharmacists adopting an expanded role in prescribing and like 
pharmacist respondents from the first part of this project, considered that pharmacists 
needed further training to assume further prescribing roles. The support shown by 
pharmacy clients in this study was in line with results reported by Stewart et al. who 
indicated that expanded pharmacist prescribing was generally supported by patients.15 
This was despite the fact that their respondents were drawn from a pool of the general 
public and hence were not pharmacy clients only used in this study. Hobson et al. also 
indicated patients’ support for expanded pharmacist prescribing.16 
 
A majority of pharmacy clients in this study supported expanded pharmacist prescribing 
only after a diagnosis had been made by a doctor. These findings further strengthen the 
idea of a dependent (i.e. supplementary) rather than independent model of prescribing 
for initial introduced in Australia. Pharmacy clients who supported an independent 
prescribing role for pharmacists preferred this be done for therapeutic areas of pain 
management and antibiotics for limited number of infections. Interestingly, pharmacists 
who supported independent prescribing showed strongest preference for independent 
prescribing in areas of pain management and antibiotics for limited number of 
infections. These findings are a good indication for narrowing down therapeutic areas 
for independent pharmacist prescribing, if this role is assumed by Australian pharmacists 
in the future.  
 
This study hypothesized that pharmacy clients would prefer both supplementary and 
independent prescribing models i.e. H3: There is no significant difference in pharmacy 
clients’ support for supplementary or independent prescribing models. This hypothesis 
was rejected since 77% (n=400) of pharmacy clients supported an expanded prescribing 
role for pharmacist only when the condition was first diagnosed by their doctor (i.e. 
supplementary model) with 33% (n=400) of respondents accepting pharmacists 




This study hypothesized that doctors continuing to diagnose the condition does not 
significantly contribute to pharmacy clients’ perception of trust in pharmacists assuming 
an expanded prescribing role i.e. H4: There is no significant difference in pharmacy 
clients’ perception of trust in pharmacists assuming an expanded prescribing role 
dependent on doctors continuing to diagnose the condition. This hypothesis was rejected 
since a continuing role of doctors in patient diagnosis positively contributed to pharmacy 
clients’ perception of trust in expanded prescribing role for pharmacists (β=0.129, 
p=0.01).  
 
This study also hypothesized that medication access would not significantly influence 
pharmacy clients’ perception of trust in expanded pharmacist prescribing i.e. H5: There 
is no significant difference in pharmacy clients’ perception of trust in pharmacists 
assuming an expanded prescribing role dependent on this role’s potential to improve 
access to prescription medicines. This hypothesis was rejected since improved access to 
prescription medicines (β =0.368, p=<0.0001) contributed positively to pharmacy 
clients’ perception of trust in expanded pharmacist prescribing. In fact, improved access 
to prescription medicines was shown to be the strongest single positive predictor. 
 
These findings should be interpreted having in mind that Bessell et al. developed four 
practice models where pharmacists could initiate, modify and monitor use of 
prescription medicines with the aim of improving patients’ access to medications.17 
Additionally, improved medication access was one of the main aims identified by 












6.1.3 Potential improved models of medication supply to RACFs 
 
 
A comment made by a doctor in a focus group meeting illustrated one of the most 
fundamental differences in medication access between residents living in RACFs and 
those in community i.e.: “The patients in nursing home are far worse than those living in 
a community. Those living in a community when they get a prescription walk to the 
pharmacy and receive the medication immediately, but patients in RACFs can’t do that”. 
 
This study has identified a range of difficulties related to current systems of medication 
supply to RACFs. These included: medication wastage, after hours and weekends, 
communication between health professionals, medication charges to the residents, 
delivery of medication, medication changes, residents’ discharge from tertiary hospitals 
and PRN/short-term medications. The main prescription and dispensing related 
difficulties identified were with authority prescriptions and the issue of no medication 
supply without a prescription. Medication supply based on an ‘owing’ system was 
identified as an important difficulty as well. Many of these difficulties have also been 
reported by Bessell et al.17 and the HMA review.19  
 
Out of all potential improved models discussed, a centralized medication chart model 
was the most preferred amongst focus group participants. Furthermore, there were 
indications that in some RACFs the medication chart was already the central document 
that supersedes prescriptions. In comparison to other models discussed in focus group 
meetings, a centralized medication chart model appeared to have the potential to address 
most of difficulties identified by focus group participants. This was particularly likely 
with an electronic version of a centralized medication chart model. It should be noted 
that these charts currently do not meet all legal requirements for prescriptions in 
Australia. The medication chart model was also proposed by the Australian government 
under the Fifth Community Pharmacy Agreement and was overwhelmingly supported 
by stakeholders in the HMA review.19 It should be emphasized that the HMA review 
suggested that a paper-based medication chart should be only a transition to an 
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electronic version and this version was strongly supported by stakeholders in this 
review.19 
 
It should be noted that some ‘highly relevant’ difficulties such as medication wastage, 
PRN medications, delivery of medication and difficulties with packaging still remain 
largely unaddressed even with a medication chart model. A significant amount of 
medication wastage arises from medications not being re-packaged by pharmacies. This 
was also found in the HMA review. Pharmacies should not re-package medications due 
to accreditation requirements which protect patients since the quality of medications to 
be re-packaged is no longer certain. They have been removed from original packages, 
been stored in contact with other drugs and stored under conditions of temperature and 
light exposure that is unknown. It appeared that doctors especially, may lack an 
understanding of these limitations which in turn may be adversely affecting their 
relationship with pharmacists. For instance, doctors identified the need to write too 
many prescriptions, compared to the drug regimen. They consider pharmacists maybe 
over- servicing and did not appear to appreciate issues of medication wastage which as a 
result increases medication dispensing frequency. This was particularly evident with 
cases involving medications that require prior PBS authority approval for prescribing as 
their dispensing frequency is affected. In worse case scenarios this ultimately results in 
dangerous cases of medication discontinuation as a consequence of doctors being unable 
to obtain PBS authority approvals and pharmacists not supplying the medication as a 
result of lack of prescription. This emphasized the need for a modification of current 
PBS authority arrangements, as also highlighted in the HMA review.19 
 
Medication chart model does not overcome the issue of medication wastage and could 
exacerbate the need for pharmacist payment when wastage occurs. Inevitably with 
DAA’s, medication wastage occurs and pharmacists need remuneration for medications 
dispensed. However, the HMA review concluded that no fundamental change in the 
remuneration system would be required with the adoption of the medication chart 
system. An electronic version of the medication chart model could address remuneration 
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concerns but more research is needed to identify ways of dealing with difficulties not 
addressed by a medication chart model.  
 
Focus group participants generally did not see a need in expanding non-medical 
prescribing (i.e. pharmacist and nurse prescribing) role given the potential introduction 
of a centralized medication chart model which makes the prescription writing process 
unnecessary. A significant barrier to expanding pharmacists’ prescribing role was the 
fact that pharmacists were not located within RACFs hence offering no significant 
advantage over doctors. Additionally, cost of pharmacist prescribers, their professional 
indemnity, conflict of interest with supplying and prescribing medications as well as the 
legal liability appeared to be potential barriers to expanding pharmacists prescribing role 
in RACFs. The availability (i.e. shortage) and current PBS-rules level of knowledge by 
nurses appeared to be limitations for nurse prescribing. Shortage of nurse practitioners 
was a reason that a collaborative nurse practitioner prescribing model was suggested by 
stakeholders in the HMA review to be considered in future when nurse practitioner 
numbers increase. Nevertheless, non-medical prescribing appeared to have a greater 
potential for addressing more ‘highly relevant’ difficulties identified by this study, in 
comparison to repeat extension and Medical Director model. Furthermore, non-medical 
prescribing could supplement the already preferred medication chart model in a limited 
supply of PRN and short-term medications.  
 
In discussing pharmacist and nurse prescribing, it should be emphasized that this study 
did not consider the specifics of comparing the two professional groups. However, it is 
obvious that there may be a difference in terms of workforce availability for pharmacists 
and nurses. The Hogan Review has highlighted the current shortage of trained nurses in 
RACFs as well as ageing of nurses, compared to other areas. 20 The availability of 
pharmacists is set to change given that pharmacy degrees have almost tripled over the 
last decade and a projected oversupply of pharmacists by 2025. 21,22,23 These 
circumstances may place pharmacists in a better position than nurses when it comes to 
assuming new professional roles such as expanded prescribing, even in RACFs. 
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However, it should be noted that nurses are already prescribing in Australia and this role 
is expanding.  
 
 
6.1.4 Agency Theory 
 
This study has found that the Agency Theory can be applied to explore the relationship 
between the main stakeholders of expanded pharmacist prescribing. Pharmacy clients’ 
preference for doctors to retain their role in diagnosis illustrates a strong agency 
relationship that already exists between doctors and patients. Furthermore, pharmacy 
clients’ preference for doctors retaining disease diagnosis was a positive predictor to 
their perception of trust and therefore acceptance of pharmacist prescribing. However, 
this study has suggested that from an Agency Theory perspective, expanded pharmacist 
prescribing may disrupt the relationship that currently exists between doctors and 
patients. This may be done through an introduction of a decision making authority of a 
second agent (i.e. pharmacist) into an already established relationship between patients 
and doctors. This may be particularly evident with the supplementary model which 
involves an agreement between a doctor, pharmacist and patient. It is worth emphasizing 
that a qualitative study on supplementary prescribing in the UK revealed that this model 
was perceived as a potential threat to independent prescribing and infringement of 
professional boundaries by pharmacists and doctors who participated in this study.2  
 
The theory highlights the greater complexity of introducing supplementary prescribing 
as compared to independent prescribing. Supplementary prescribing requires the current 
principal-agent relationship to be disrupted by the introduction of a third agent and the 
already established agent to develop care plans and monitor the patient periodically. 
Independent prescribing establishes a new agency relationship and is not encumbered 
with the previous disruptions.  However, this model was not preferred by pharmacists or 
pharmacy clients and compared to a supplementary prescribing model it was found to be 
a weaker predictor of expanding pharmacists’ prescribing roles, in evaluating both 
pharmacists’ and pharmacy clients’ views. This suggests that pharmacist expanded 
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prescribing should be introduced in a form that it does not negatively affect the existing 
principal-agent relationship between doctors and patients. Such a change should be 
facilitated by addressing issues with patients that highlight access to medicines, easing 
the current high workload of doctors and better utilizing pharmacists’ skills.  This study 




6.2 Study limitations    
 
 
Although a response rate of 40.4% was achieved from postal surveying of pharmacists, 
it still leaves a possibility of some non-respondents not sharing the same views as 
respondents. Additionally, the method of using a postal questionnaire to collect the data 
may have limited a more in-depth expression of pharmacists’ views hence potentially 
affecting the exploration of the issue of pharmacist prescribing in Australia. A lower 
response rate (34.7%) was achieved in telephone interviewing of pharmacy clients. The 
fact that respondents were only those that had not experienced expanded pharmacist 
prescribing may also be a limitation in terms of a broader exploration of clients’ 
perspectives. However, an expanded role in prescribing for pharmacists in Australia is 
not yet established. It should also be emphasized that the interview questionnaire was 
previously validated by a small pharmacist focus group and the company administering 
it which were members of the lay public, which were experienced in this form of 
surveying. However, the face validity and questionnaire piloting was not done with 
target respondents and key study findings relied on pharmacy clients’ interpretation of 
terms such as ‘trust in pharmacist prescribing’. The question arrangement in the 
interview questionnaire may have influenced respondents’ responses. However, due to 
the interview being conducted over the phone and time limitations involved the 
questions needed to be as clear as possible for respondents and focus their thinking.  
 
In terms of data analysis, different factors might have been derived if factor analysis had 
been performed on the entire set of statements measuring attitudes using a Likert scale. 
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However, throughout the data analyses the intention was to reduce the number of 
variables within specific sections of the questionnaire since different sections related to 
various aspects of pharmacist prescribing. It should also be recognized that in both 
questionnaires used other dependent and independent variables could have been chosen 




The main limitation in exploring potential improved models of medications supply to 
RACFs was the fact that it was only conducted in WA and did not include participants 
from other Australian states and territories. Therefore participants’ representativeness 
may have been limited. However, the limitation to WA may be considered to be of 
minimal effect to the overall study results given the achievement of a saturation point in 
terms of new ideas and comments made by focus group participants as well as the 
similarity of medication supply systems to RACFs across the Australian states and 
territories. The abovementioned limitations should be taken into consideration by future 
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This project has explored the issue of expanded pharmacist prescribing from 
pharmacists’ and pharmacy clients’ perspective. Additionally, this study has considered 
the potential value of an expanded prescribing role for pharmacists and improved 
medication supply systems in Australian RACFs.  
 
Pharmacists strongly supported an expanded pharmacist prescribing role, despite 
perceived barriers. Pharmacists’ preference was for a supplementary rather than 
independent prescribing model, with support of this model being a strong predictor for 
expansion of pharmaceutical services provision through prescribing.  
 
In addition to known pharmacist prescribing drivers such as better utilization of 
pharmacists’ skills and easing the burden from overloaded GP’s,  pharmacists’ opinion 
based on their current perceptions of their clients acceptance of this role was also a 
significant predictor to expanding pharmaceutical services through prescribing. 
Important identified barriers were pharmacists’ inadequate training in patient 
assessment, diagnosis and monitoring for assuming additional prescribing roles. Study 
findings indicated pharmacists’ perceived need for training in these areas implied that 
pharmacists’ current level of training in these areas should be expanded as a pre-
requisite to assuming further prescribing roles.  
 
Pharmacists diagnosing the condition appeared to be a perceived barrier for pharmacy 
clients as well given that their views indicated support for pharmacist expanded 
prescribing where doctors had made the primary diagnosis. Pharmacists’ diagnosing and 
prescribing, doctors making the diagnosis, and improved access to medicines positively 
contributed to an increased patients’ perception of trust in pharmacists performing an 
expanded role in prescribing. In comparison to doctors diagnosing the disease (i.e. a 
supplementary model of prescribing), pharmacists diagnosing and prescribing (i.e. an 
independent model of prescribing) was a weaker contributor to an increased patients’ 
perception of trust in pharmacist expanded prescribing. This is consistent with 
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pharmacists’ views which indicated that independent prescribing was a weaker predictor 
than a supplementary prescribing model for an expansion of pharmaceutical services 
through prescribing.  
 
This project has shown that the Agency Theory can be employed as a model to explore 
the impact of expanded pharmacist prescribing. Application of this theory in this project 
indicated that pharmacist prescribing should be introduced in a way that it facilitates 
rather than disrupts the already established relationships between doctors and patients. 
This is because in introducing expanded pharmacist prescribing, particularly the 
supplementary model which involves a patient management through agreement between 
a doctor, pharmacist and patient, Agency Theory predicts a possibility for disruption of 
the agency relationship that already existed between doctors and patients. This 
disruption involves the introduction of a decision making authority of a second agent 
(i.e. pharmacist) into an already established relationship between patients and doctors. 
 
A range of problems were identified in current systems of medication supply to RACFs. 
Compared to other potential improved models of medication supply to RACFs, a 
medication chart based model may partially or fully address a majority of difficulties 
identified. This was more likely with an electronic version. However, some highly 
ranked difficulties such as medication wastage, medication delivery and difficulties with 
PRN and short-term medications remain unaddressed by this model. These findings 
indicate that further research should explore ways of addressing these difficulties. The 
support for an expanded role in prescribing for pharmacists in RACFs appeared diluted 
by the support for medication chart model. However, there may be a limited role for 
expanded pharmacist prescribing supplementing the medication chart model with PRN 











Findings of this study have suggested a wide support for expanded pharmacist 
prescribing by pharmacists and community pharmacy clients. Therefore, the first 
recommendation of this project is: 
R1: “Australian regulatory bodies should note the wide support of pharmacists and 
pharmacy clients in future pharmacist prescribing”  
 
Pharmacists’ preference for supplementary prescribing as well as pharmacy clients’ 
support for expanded pharmacist prescribing provided doctors retain their role in 
diagnosis, suggest that a dependent (i.e. supplementary) rather than independent model 
of prescribing should be initially introduced in Australia. This was further supported by 
findings that views of both pharmacists and pharmacy clients indicated that independent 
prescribing in comparison to a supplementary prescribing model is a weaker predictor to 
expanding pharmacists’ prescribing role.  
The second recommendation stemming from this project is: 
R2: “In expanding pharmacists’ role, Australian regulatory bodies should initially 
consider a supplementary prescribing model”. 
 
There was an interesting point of agreement in attitudes of pharmacy clients and 
pharmacists in their support for an independent prescribing role for pharmacists. Both 
pharmacists and pharmacy clients showed strongest support for independent pharmacist 
prescribing in therapeutic areas of pain management and limited range of infections. 
Additionally, findings from exploration of potential improved medication supply models 
to RACFs suggested that there may be some efficiency by introducing a limited 
expanded prescribing model to supplement the medication chart model for short-term 
and PRN medications, which mainly consist of antibiotics and analgesics. Therefore, the 
third recommendation of this project is: 
R3: “The feasibility of a limited independent prescribing role for pharmacists in 





Findings from this project have indicated that both pharmacists and pharmacy clients 
considered that additional training is needed for pharmacists assuming further 
prescribing roles. Pharmacists identified therapeutic areas which are currently not taught 
in much detail in current Australian pharmacy courses as areas they needed most 
training. Training areas supported the most were: disease pathophysiology, disease 
diagnosis and patient monitoring. Therefore, the fourth recommendation of this project 
is: 
R4: “Australian pharmacists need additional training in order to assume expanded 
prescribing roles. This training should be focused around clinical areas specific to 
prescribing such as disease pathophysiology, disease diagnosis and patient 
monitoring”. 
 
Pharmacy clients’ preference for retaining their doctors’ role in diagnosis despite 
supporting an expanded prescribing role illustrated an established doctor-patient 
relationship. The Agency Theory predicts a potential disruption of this relationship by an 
introduction of a decision making third agent (i.e. pharmacist) into an already 
established relationship. Therefore, the fifth recommendation of this study is: 
R5: “Expanded pharmacist prescribing should take into consideration the existing 
agency relationship between doctors and their patients and should be introduced in a 
way that it maintains rather than disrupts this relationship”. 
 
Out of all potential improved medication supply models discussed in this project, a 
centralized medication chart model was the most preferred by doctors, pharmacists, 
nurses and carers working in RACFs. This model, particularly the electronic version of 
it, has the potential to address many difficulties identified and would make the use of 
prescriptions to supply medications to RACFs unnecessary. Therefore, the sixth 
recommendation of this project is: 
R6: “A medication chart system, preferably electronic, should replace the current 
prescription-based medication supply system to RACFs. Additionally, future research 
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should focus in exploring ways of dealing with difficulties not addressed by this 
model, especially medication wastage”. 
 
Findings from focus group meetings have indicated that there may be limited room for 
non-medical (nurse and pharmacist) prescribing in supplementing a future medication 
chart model in dealing with PRN and short-term medications. Pharmacists may be in a 
better position than nurses to assume this role, in terms of their workforce availability as 
well as their PBS and drug knowledge. However, nurses may be in a better position than 
pharmacists in terms of their location at RACFs. Therefore, the seventh recommendation 
of this project is: 
R7: “Non-medical prescribing as means of supplementing a future medication 
chart based model with PRN and short-term medications should be considered. 
Further research is needed to establish the benefits and practicalities of non-medical 
prescribing in RACFs”. 
 
This project, apart from the section of it exploring improved medication supply systems 
to RACFs, has quantitatively assessed the views of Australian pharmacists and 
pharmacy clients on expanded pharmacist prescribing. Additionally, this study has not 
explored any clinical and economical benefits of expanded pharmacist prescribing. 
Therefore, the eighth recommendation from this project is: 
R8:  “Future research in the domain of pharmacist prescribing in Australia should 
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The aim of this project is to assess pharmacists’ perceptions on the role of pharmacists in prescribing. In 
particular, we are interested in investigating areas pharmacists feel they could contribute in prescribing and what 
additional training they feel that they would require in order to assume future prescribing responsibilities.    
 
This questionnaire consists of statements and questions which enable you to give your opinion 
on the issue of pharmacist prescribing.  It is estimated it will take you approximately 10-15 
minutes to complete this questionnaire. Your information will be treated with strictest 
confidence.   
 
To answer this questionnaire please CLICK ON THE BOX NEXT TO THE 
NUMBER that reflects your opinion regarding the statement i.e.:  1 = Strongly 
agree; 2 = Agree; 3 = Neutral; 4 = Disagree; 5 = Strongly disagree. (Some questions 
require typing the response in a yellow shaded area) 
 
 
        1)   
 In relation to the way you see the future of the Pharmacy profession, please answer the 
following:  
 
I would like the Pharmacy profession to expanded its 
scope of professional services 
1    2       3       4       5       
I would like the Pharmacy profession to expand its scope of 
services, by expanding the prescribing role 
1       2        3       4       5       
I see myself in future as having more expanded 
prescribing responsibilities 
1       2       3        4       5       
I am happy with the current pharmacist’s prescribing role 
limited to S3’s 
1       2       3       4        5       
1= strongly agree; 2= agree; 3= neutral; 4= disagree; 5= strongly disagree 
 
        2) 
Based on your experience with customers in the Pharmacy, please answer the following 
considering how they would react to expanded Pharmacist prescribing: 
 
Customers would accept pharmacists with an expanded 
prescribing role 
1       2       3       4       5       
Customers would trust pharmacists as prescribers 1       2      3       4       5       
Customers would have better access to their medications 
if pharmacists were prescribers 
1       2       3       4       5       
Customers would have a safer access to their 
medications if pharmacists were prescribers 
1       2       3       4       5       
Customers find accessing  their GP’s too difficult and may prefer 
Pharmacists having an expanded prescribing role  
1       2       3       4       5       
Customers appreciate pharmacist ‘s professional advice and may 
prefer pharmacists as prescribers 
1       2       3      4       5       
1= strongly agree; 2= agree; 3= neutral; 4= disagree; 5= strongly disagree 
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         3) 
In relation to reasons for pharmacist prescribing, please answer the following: 
 
I believe customers would have better access to their 
medications if pharmacists were prescribers 
1       2      3       4       5       
Pharmacists prescribing would ease the burden from 
overloaded GP’s and hence improve the functioning 
of our health system 
1        2       3       4       5       
Expanded prescribing responsibilities is a direction 
that the Pharmacy profession should be headed in 
order to secure a more important role in health care 
1      2       3       4       5       
Pharmacists are highly regarded by the community and 
therefore they should assume more prescribing responsibilities 
1       2      3       4       5       
Pharmacists have the necessary drug knowledge to 
assume more prescribing responsibilities 
1       2       3       4       5       
Pharmacists have the necessary patient assessment 
skills to assume more prescribing responsibilities 
1       2       3       4       5       
Pharmacist prescribing enables better use of 
pharmacist’s professional skills 
1       2       3       4       5       
Expanded prescribing will contribute to increased 
Pharmacy profits 
1       2       3       4       5       







           For which of the following reasons do you believe pharmacists should not have 
expanded prescribing rights? 
 
Inadequate training in diagnosis of disease (if this 
were the pharmacist’s responsibility)  
1        2       3       4       5       
Inadequate training in patient assessment and patient 
monitoring 
1       2       3       4       5       
Potential for a reduction in the quality of patient care 1       2       3        4       5       
Potential for increased patient costs 1       2       3       4       5       
Potential for increased hospital admissions 1       2       3       4       5       
Potential for increased government costs 1       2       3       4       5        
Conflict of interest with pharmacists acting both as 
prescribers and dispenses  
1       2       3       4       5       
Pharmacists’ lack of time 1       2      3       4       5       
Increased confusion amongst the public as to the role 
of GP’s and pharmacists 
1       2        3       4       5       
Potential decrease in quality of current services 
offered by pharmacists 
1       2      3       4       5       
Inadequate facilities within pharmacies to allow 
pharmacist prescribing 
1       2       3       4       5       
None of the above 1       2       3       4       5       
1= strongly agree; 2= agree; 3= neutral; 4= disagree; 5= strongly disagree 
 







         Do you think pharmacists should have expanded prescribing rights?    
 Yes       No      
 
If YES please answer question A, if NO go straight to question B:  
 
A) I feel that pharmacists should have expanded prescribing rights in  following areas: 
 
Antibiotics (limited number of infections) 1     2       3       4       5       
Diabetes  1       2       3       4       5       
Hypertension  1      2       3       4       5       
Heart failure 1       2       3       4       5       
Asthma and other respiratory conditions 1        2       3       4       5       
Anticoagulant therapies 1       2       3       4       5       
Pain management 1       2      3       4       5       
Newly S4 scheduled Pseudoephedrine products 1       2       3       4      5       
None i.e. maintain current prescribing responsibilities 
only (i.e. S3 products) 
1       2       3       4       5       
1= strongly agree; 2= agree; 3= neutral; 4= disagree; 5= strongly disagree 
 
 
B)  Do you believe pharmacists have the knowledge, skills and training to diagnose 
conditions such as: 
 
i) Common ailments                   ii) Medical conditions 
 
Hypertension 1
   
2
      
3
      
4
      
5
      
Heart Failure 1
   
2
      
3
      
4
      
5
       
Diabetes 1
   
2
      
3
      
4
      
5
       
Asthma 1
   
2
      
3
      
4
      
5
      
COPD 1
   
2
      
3
      
4
      
5
      
Peptic Ulcer 1
   
2
      
3
      
4
      
5
       
Angina 1
   
2
      
3
      
4
      
5
       














Hayfever 1    2       3       4       5       
Eczema 1     2       3       4       5       
Psoriasis 1    2        3       4       5       
Conjunctivitis 1    2       3       4       5       
Allergic Rhinitis 1    2       3       4       5       
Indigestion 1    2        3       4       5       






          In relation to the way you believe pharmacists should assume expanded prescribing 
responsibilities, please answer the following: 
 
Pharmacists should be able to prescribe 
independent of medical practitioners, this includes 
assuming the responsibility of clinical assessment of 
the patient, establishing diagnosis and clinical 
management 
1       2       3       4       5       
Pharmacists should be able to prescribe in a 
supplementary fashion through a partnership with 
an independent prescriber (a doctor or dentist) 
implementing an agreed patient-specific 
management plan 
1       2       3       4       5       
I believe expanded prescribing should be done by 
Hospital Pharmacists only 
1       2       3       4       5      
Pharmacists should be able to prescribe from a 
limited drug formulary 
1       2       3       4       5       
I believe pharmacist prescribing and dispensing 
should be done separately 
1        2       3       4       5       
Pharmacists should be able to prescribe for 
Pharmacist Only (S3) products only 
1       2       3       4      5       
Pharmacists should be able to prescribe for 30 day 
emergency supply, rather than current 3 day limit 
1       2       3       4       5       
Pharmacists should be able to prescribe for limited 
repeats under GP supervision 
1       2       3       4       5       
1= strongly agree; 2= agree; 3= neutral; 4= disagree; 5= strongly disagree 
 
 7)      
                      If I was about to assume additional prescribing responsibilities, I would need further 
training:        Yes  No   
 
If NO please go straight to question 8.  
 
A)    In order to assume expanded prescribing responsibilities I would need further training in 
following therapeutic areas: 
 
Clinical pharmacology 1       2       3       4       5       
Pharmacodynamics and pharmacokinetics 1       2       3       4       5       
Adverse drug reactions and drug interactions 1       2       3       4       5       
Pathophysiology of conditions that you would prescribe 
for 
1        2       3       4       5       
Selection of drug regimen 1       2       3       4       5       
Physiological changes and drug response in 
different age groups 
1       2       3       4       5       













B)   In order to assume expanded prescribing responsibilities I would need further training in 
following areas: 
 
Patient consultation and decision making 1       2       3       4       5       
Communication skills 1       2       3       4       5       
Principles of diagnosis 1       2       3       4        5       
Evidence based practice  1       2       3       4       5       
Legal and ethical aspects of prescribing 1       2        3       4       5       
Psychology of prescribing  1       2      3       4       5       
Principles and methods of patient monitoring 
(physical examination, laboratory results, patient 
compliance)  
1       2       3       4       5      
Public health issues 1       2       3       4      5       
1= strongly agree; 2= agree; 3= neutral; 4= disagree; 5= strongly disagree 
 
 
C)   In order to assume extended prescribing responsibilities pharmacist prescribers would 
need: 
 
A period of supervision by a Medical 
Practitioner 
1       2       3       4      5       
Demonstration of relevant Continuing 
Education that ensures their prescribing 
skills are kept to date 
1        2       3       4       5       
Other , (please specify):      1       2       3       4       5       
1= strongly agree; 2= agree; 3= neutral; 4= disagree; 5= strongly disagree 
          
 
              
            8) 
           In relation to reimbursement of pharmacists for their expanded prescribing role, I believe 
that pharmacists: 
 
Should charge the patients for their prescribing 
service in addition to charging for their medications 
1        2       3       4       5       
Should be reimbursed by the Government for 
their prescribing services 
1     2       3       4       5       
Prescribing should  be carried out free of charge as a 
part of free quality services offered by  pharmacists to 
community 
1       2       3       4       5       
Should be reimbursed by the Government  for 
prescribing facilities needed  (i.e. IT upgrades, 
consulting area) 
1      2       3       4       5       
Other  sources, (please specify):      1       2       3       4       5       













             9)  
          In relation to the implications of pharmacist prescribing on pharmacy infrastructure: 
 
I believe additional IT resources in the 
Pharmacy would be needed to support 
pharmacist prescribing 
1      2       3       4       5       
I believe I have access to sufficient patient 
information  in order  to make prescribing 
decisions for them 
1       2       3       4        5       
I believe prescribing and dispensing should 
be carried out in separate areas in the 
Pharmacy  
1       2       3       4       5       
I believe a separate quiet consulting area for 
pharmacist prescribing should be created in the 
Pharmacy 
1       2       3       4       5       
I believe current  staff arrangements in the 
Pharmacy  can  support  expanded  pharmacist  
prescribing 
1       2       3       4       5       
1= strongly agree; 2= agree; 3= neutral; 4= disagree; 5= strongly disagree 
 
        
 
 
      10)    Please provide us with some further demographics information 
 
• Gender: M         F              Age:_ years 
• How many years have you been registered as a Pharmacist: _ years 
• Do you own a Pharmacy:  YES                                  NO    
• Where did you complete your undergraduate Pharmacy training 
- Western Australia  
- Other Australian State/territory (Please specify:     ) 
- Overseas         (Please specify the country:     ) 
 
• Where do you work?   Community           Hospital          Medication Reviews             
Other   
• Telephone contact:     (optional) 
 
Please feel free to contribute to this project by adding your personal comments on important factors for 
consideration related to pharmacist prescribing, which have not been addressed in this 
questionnaire:      
 
THANK YOU VERY MUCH FOR YOUR TIME IN PARTICIPATING IN THIS SURVEY 
  
Please ensure no answers have been left out as due to the nature of statistical data analysis applied, 
















The aim of this project is to assess Australian pharmacists’ perceptions on the issue of extended pharmacist 
prescribing. In particular, we are interested in investigating their views on advantages and limitations of such a 
role as well as areas pharmacists feel they should have extended prescribing responsibilities, if any. Pharmacists’ 
views are being sought on what additional training they would require in order to assume future prescribing 
responsibilities.    
 
This questionnaire consists of statements and questions which enable you to give your opinion 
on the issue of pharmacist prescribing.  It is estimated it will take you approximately 10-15 
minutes to complete this questionnaire. Your information will be treated with strictest 
confidence.  Please reply by 26th of November 2007. 
 
To answer this questionnaire please TICK THE BOX NEXT TO THE NUMBER 
that reflects your opinion regarding the statement i.e.:  1 = Strongly disagree; 2 = 
Disagree; 3 = Neutral; 4 = Agree; 5 = Strongly agree. (Some questions require 




        1)   




1= strongly disagree; 2= disagree; 3= neutral; 4= agree; 5= strongly agree 
 
 
        2) 
Based on your experience with customers in the Pharmacy, please answer the following 
considering how they would react to expanded Pharmacist prescribing:    
1= strongly disagree; 2= disagree; 3= neutral; 4= agree; 5= strongly agree 
I would like the Pharmacy profession to expand its scope of 
professional services 
1       2       3       4       5       
I would like the Pharmacy profession to expand its scope of services, by 
expanding the prescribing role 
1       2       3       4       5       
I see myself in future as having more expanded prescribing 
responsibilities 
1       2       3       4       5       
I am happy with the current pharmacist’s prescribing role limited to 
S3’s 
1       2       3       4       5       
Customers would accept pharmacists with an expanded prescribing 
role 
1       2       3       4       5       
Customers would trust pharmacists as prescribers 1       2       3       4       5       
Customers would have safer access to their medications if 
pharmacists were prescribers 
1       2       3       4       5       
Customers find accessing  their GP’s too difficult and may prefer Pharmacists 
having an expanded prescribing role  
1       2       3       4       5       
Customers appreciate pharmacist ‘s professional advice and may prefer 
pharmacists as prescribers 
1       2       3       4       5       
314 
 
       
 
  3) 
In relation to reasons for pharmacist prescribing, please answer the following: 





          In relation to the way you believe pharmacists should assume expanded prescribing 
responsibilities, please answer the following: 
 
Pharmacists should be able to prescribe independent of medical 
practitioners, this includes assuming the responsibility of clinical 
assessment of the patient, establishing diagnosis and clinical 
management for a range of conditions within professional and 
clinical competence. 
1       2       3       4       5       
Pharmacists should be able to prescribe in a supplementary fashion 
through a partnership with an independent prescriber (a doctor or 
dentist) implementing an agreed patient-specific management plan. 
In this model the doctor diagnoses and initiates therapy while the 
pharmacist continues prescribing as long as patient’s condition is 
within agreed management plan parameters. 
1       2       3       4       5       
Pharmacists should be able to prescribe from a limited drug 
formulary which would include current S2’s, S3’s and additional 
drugs depending on pharmacists field of specialization  
1       2       3       4       5       
Pharmacists should be able to prescribe for 30 day emergency 
supply, rather than current 3 day limit 
1       2       3       4       5       
I believe any possible future expanded prescribing should be done 
by Hospital Pharmacists only 
1       2       3       4       5       







I believe customers would have better access to their medications if 
pharmacists were prescribers 
1       2       3       4       5       
Expanded pharmacist prescribing would ease the burden from 
overloaded GP’s and hence improve the functioning of our health 
system 
1       2       3       4       5       
Expanded prescribing responsibilities is a direction that the Pharmacy 
profession should be headed in order to secure a more important role 
in health care 
1       2       3       4       5       
Pharmacists are highly regarded by the community and therefore they should 
assume more prescribing responsibilities 
1       2       3       4       5       
Pharmacists have the necessary drug knowledge to assume more 
prescribing responsibilities 
1       2       3       4       5       
Pharmacists have the necessary patient assessment skills to assume 
more prescribing responsibilities 
1       2       3       4       5       
Pharmacist prescribing enables better use of pharmacist’s 
professional skills 
1       2       3       4       5       






           For which of the following reasons do you believe pharmacists SHOULD NOT have 
expanded prescribing rights? 
 
Inadequate training in diagnosis of disease (if this were the 
pharmacist’s responsibility)  
1       2       3       4       5       
Inadequate training in patient assessment and patient 
monitoring 
1       2       3       4       5       
Potential for a reduction in the quality of patient care 1       2       3       4       5       
Potential for increased patient costs 1       2       3       4       5       
Potential for increased hospital admissions 1       2       3       4       5       
Potential for increased government costs 1       2       3       4       5       
Conflict of interest with pharmacists acting both as prescribers 
and dispensers  
1       2       3       4       5       
Pharmacists’ lack of time 1       2       3       4       5       
Increased confusion amongst the public as to the role of GP’s 
and pharmacists 
1       2       3       4       5       
Potential decrease in quality of current services offered by 
pharmacists 
1       2       3       4       5       
Pharmacists having commercial interest in prescribing 1       2       3       4       5       
Inadequate facilities within pharmacies to allow pharmacist 
prescribing 
1       2       3       4       5       
Increased likelihood of litigation 1       2       3       4       5       
None of the above 1       2       3       4       5       
1= strongly disagree; 2= disagree; 3= neutral; 4= agree; 5= strongly agree 
                       
       a)   Do you think pharmacists should have expanded prescribing rights?              Yes  
      No      
If answered NO please go to QUESTION 7 
 
       b)   Would you wish to take on an expanded role in prescribing?                             Yes    
      No      
 
6) 
A) Please answer the question below if you consider that pharmacists should only have an 
expanded prescribing role in partnership with an independent prescriber (e.g. doctor) for 
any of the following chronic conditions.  
 
Antibiotics (limited number of infections) 1       2       3       4       5       
Diabetes  1       2       3       4       5       
Hypertension  1       2       3       4       5       
Heart failure 1       2       3       4       5       
Asthma and other respiratory conditions 1       2       3       4       5       
Anticoagulant therapies 1       2       3       4       5       
Pain management 1       2       3       4       5       
All of the above 1       2       3       4       5       






B) Please answer the question below if you consider that pharmacists should have an 
independent prescribing role for any of the following chronic conditions.    
 
Antibiotics (limited number of infections) 1       2       3       4       5       
Diabetes  1       2       3       4       5       
Hypertension  1       2       3       4       5       
Heart failure 1       2       3       4       5       
Asthma and other respiratory conditions 1       2       3       4       5       
Anticoagulant therapies 1       2       3       4       5       
Pain management 1       2       3       4       5       
All of the above 1       2       3       4       5       
1= strongly disagree; 2= disagree; 3= neutral; 4= agree; 5= strongly agree 
 
7)      
                      If I was about to assume additional prescribing responsibilities, I would need further 
training:        Yes  No   
 
If NO please go straight to question 8.  
 
A)    In order to assume expanded prescribing responsibilities I would need further training in 
the following therapeutic areas: 
 
Clinical pharmacology 1       2       3       4       5       
Pharmacodynamics and pharmacokinetics 1       2       3       4       5       
Adverse drug reactions and drug interactions 1       2       3       4       5       
Pathophysiology of conditions that you would 
prescribe for 
1       2       3       4       5       
Selection of drug regimen 1       2       3       4       5       
Physiological changes and drug response in 
different age groups 
1       2       3       4       5       
1= strongly disagree; 2= disagree; 3= neutral; 4= agree; 5= strongly agree 
 
B)   In order to assume expanded prescribing responsibilities I would need further training in 
the following areas: 
 
Patient consultation and decision making 1       2       3       4       5       
Communication skills 1       2       3       4       5       
Principles of diagnosis 1       2       3       4       5       
Evidence based practice  1       2       3       4       5       
Legal and ethical aspects of prescribing 1       2       3       4       5       
Psychology of prescribing  1       2       3       4       5       
Principles and methods of patient monitoring (physical 
examination, laboratory results, patient compliance)  
1       2       3       4       5       
Public health issues 1       2       3       4       5       











C)   In order to assume expanded prescribing responsibilities pharmacist prescribers would 
need: 
 
A period of supervision by a Medical Practitioner 1       2       3       4       5       
Demonstration of relevant Continuing Education that 
ensures their prescribing skills are kept to date 
1       2       3       4       5       
Specializing in clinical areas that conform with additional 
prescribing rights assumed (eg. Diabetes, Cardiology, 
Asthma, Anticoagulation, Pain management, Infections) 
1       2       3       4       5       
Specialist registration as presribers with the registering body 1       2       3       4       5       
Other , (please specify):______ 1       2       3       4       5       
1= strongly disagree; 2= disagree; 3= neutral; 4= agree; 5= strongly agree 
               
 
 
8)          In relation to the implications of pharmacist prescribing on pharmacy infrastructure: 
 
I believe additional IT resources in the Pharmacy would 
be needed to support pharmacist prescribing 
1       2       3       4       5       
I believe I have access to sufficient patient information  in order  to 
make prescribing decisions for them 
1       2       3       4       5       
I believe prescribing and dispensing should be carried out 
in separate areas in the Pharmacy  
1       2       3       4       5       
I believe a separate quiet consulting area for pharmacist 
prescribing should be created in the Pharmacy 
1       2       3       4       5       
I believe current  staff arrangements in the Pharmacy  can  
support  expanded  pharmacist  prescribing 
1       2       3       4       5       
I believe independent prescribing  by a pharmacist should NOT 
occur in a  community pharmacy (excluding S3’s)  
1       2       3       4       5       
1= strongly disagree; 2= disagree; 3= neutral; 4= agree; 5= strongly agree 
 
 
9)          In relation to the extension of pharmacists’current roles in the management of minor 
ailments: 
 
      a) 
I believe a more defined consultation system should be 
set up for provision of Pharmacist Only Medicines (i.e. 
S3’s)  
1       2       3       4       5       
I believe such a defined consultation system would 
require a separate consultation room and possibility for 
customers to make appointments with the pharmacist in 
regards to minor ailments 
1       2       3       4       5       
I believe that any extension of current role in  the management  of  
minor ailments would require remuneration 
1       2       3       4       5       
I believe medicines prescribed from an expanded role and 
consultations should be claimable from Medicare  
1       2       3       4       5       
I believe current  staff arrangements in the Pharmacy  can  
support  an expanded  pharmacist’ s role in the management  of  
minor ailments 
1       2       3       4       5       
1= strongly disagree; 2= disagree; 3= neutral; 4= agree; 5= strongly agree 
 
b) I believe that the time required for such a consultation would have to be: 3 minutes , 5 




c) I believe that Pharmacist remuneration (excluding medication cost) for such a service 
would have to be: $_____ per consultation (please specify amount)    
 
 
       10)    Please provide us with some further demographics information 
 
• A)Gender: M         F              Age:____years 
• B)How many years have you been registered as a Pharmacist:____years 
• C)Do you own a Pharmacy:  YES                                  NO    
• D)Where do you practice: 
- Western Australia ; NSW  ; VIC ; QLD ; SA ;TAS ; ACT ; NT
. 
- Overseas         (Please specify the country:_________________) 
 
• E) Where do you work?   Community           Hospital          Medication Reviews             
Other   
• F) Please provide Pharmacy or work location postcode ________ 
• G) If you work in community Pharmacy please indicate its size of operation: small  
(turnover < $2m); large  (turnover >$2 m) 
• H)Telephone contact:______________(OPTIONAL) 
 
Please feel free to contribute to this project by adding your personal comments on important factors for 








THANK YOU VERY MUCH FOR YOUR TIME IN PARTICIPATING IN THIS SURVEY 
 Please ensure no answers have been left out as due to the nature of statistical data analysis applied, 






























We are writing to seeking you input into the above research project being conducted at 
the School of Pharmacy, Curtin University of Technology.  
The aim of this project is to assess Australian pharmacists’ perceptions on the role of 
pharmacists in prescribing. In particular, we are interested in investigating areas 
pharmacists feel they could contribute in prescribing and what additional training they 
feel that they would require in order to assume future prescribing responsibilities.    
 
Usefulness of this project 
 
Extended pharmacist prescribing rights has been an issue of interest in many countries. 
Currently, pharmacists in Australia are restricted to prescribing over-the-counter 
medications only. In the UK pharmacists can act as supplementary prescribers or as 
independent prescribers depending on their level of advanced training. In most US 
states, pharmacists are involved in collaborative drug therapy management where they 
establish agreements with prescribers that allow them to initiate, modify, or discontinue 
medication therapy. Major developments in pharmacist prescribing are taking place in 
Canada as well with Alberta starting a two category prescribing model. One of which 
allows pharmacists to ‘adopt a prescription’ in consultation with a physician and the 
second model which allows them to initiate and manage drug therapy.  
This project is likely to give as insight to the attitudes and perceptions of Australian 
pharmacists on the issue of extended pharmacist prescribing. There is no study to date 
that has assessed this issue in Australia and therefore results  of this project would be 
valuable in constructing future recommendations on the issue of pharmacist prescribing 




Your responses will be treated with strict confidentiality. For the purpose of analysis all 
data is to be group, and no reference will be made to any individual.  
 
How to participate in this project 
 
Please find enclosed a copy of the questionnaire. For completion of the questionnaire 
please follow instructions outlined in the introduction of the questionnaire. After 
completing the questionnaire please post it using the self-addressed envelope provided.  
 
If you have any questions about this project please contact me at 
pharmacy.survey@curtin.edu.au 
 
Thank you for your time in contributing to this project. 
              
 
 











Approximately three weeks ago, we sent a questionnaire to you seeking your 
perceptions on the issue of pharmacist prescribing. We are writing to you again to thank 
if you have for your participation or if you have not already done so to complete and 
return our questionnaire. A self-addressed return envelope was provided with the 
questionnaire; if you have misplaced it please send the questionnaire to the address 
below: 
 
Mr K Hoti 
School of Pharmacy 
Curtin University of Technology 
GPO Box U1987 
Perth, WA, 6845 
 
We see pharmacist prescribing as a very important issue, and a potential future role for 
pharmacists. Because of the importance of this issue for our profession we are seeking 
to obtain as large as possible cross section of opinions on the subject. The results from 
this project will be useful in designing future recommendations on the issue of 
pharmacist prescribing in Australia. 
  
 
If you have misplaced our questionnaire please contact us:  
pharmacy.survey@curtin.edu.au , so we organise another questionnaire be sent to you. 
 
If you have any questions about this project please contact us at 
pharmacy.survey@curtin.edu.au or Kreshnick Hoti on 0410823928. 




































Mrs Daphne D’Souza 









24 November 2008 






Thank you for your “Form C Application for Approval of Research with Low Risk 
(Ethical Requirements)” for the project titled "PHARMACIST PRESCRIBING IN 
AUSTRALIA".  On behalf of the Human Research Ethics Committee I am 
authorised to inform you that the project is approved. 
 
Approval of this project is for a period of twelve months from 21 November 2008 to 
20 November 2009.   
 
If at any time during the twelve months changes/amendments occur, or if a serious or 
unexpected adverse event occurs, please advise me immediately.  The approval number 







Mrs Daphne D’Souza 
A/Committee Secretary  








Please Note:  The following standard statement must be included in the information 
sheet to participants: 
 
This study has been approved by the Curtin University Human Research Ethics Committee.  If 
needed, verification of approval can be obtained either by writing to the Curtin University Human 
Research Ethics Committee, c/- Office of Research and Development, Curtin University of 
Technology, GPO Box U1987, Perth, 6845 or by telephoning 9266 2784. 
 
Division of Health Sciences 
School of Pharmacy 
 
GPO Box U1987 Perth    
Western Australia   6845 
 
Telephone +61 8 9266 7528 










QUESTIONNAIRE FOR CUSTOMERS VIEW ON PHARMACIST 
PRESCRIBING IN AUSTRALIA 
 
 
Hello, my name is XY. I am calling on behalf of Curtin University School of Pharmacy. Can 
I please speak to an adult in the house? 
 
 
(Hello, my name is XY. I am calling from Curtin University School of Pharmacy) 
 
I am calling to seek input into a research project being conducted at the School of 
Pharmacy, Curtin University of Technology. The aim of this project is to assess 
customers’ views on the issue of extended pharmacist prescribing. This includes your 
pharmacist prescribing some of the medications that you currently get only through seeing 
your Doctor. This interview will take approximately 10 minutes of your time and your 
information will be treated with strictest confidence.  
 
You were selected randomly from the public phone directory.  
 
To be eligible to participate you need to have had at least ONE prescription filled in a 
Pharmacy regularly and be over the age of 18 years.  
 
Eligible YES (continue); NO: Is there anybody in the household I could speak to who has 
at least one prescription medicine dispensed at a pharmacy regularly and is over the age of 




• Would you participate?  YES (Remind the participant that he/she can choose NOT to 
proceed at any time during this interview. Double check eligibility and go to question 
1), NO (please go to question A) 
 
 
A) Would you prefer us calling you at another time when you have some time? (if yes 
please specify_________ Log to ‘convenient time calling register’) 
 
B) If the person appears to need assistance, ask if they need to discuss their 
participation with someone who is able to support them in making their decision  
(if yes and nobody there to assist, ask when would be convenient to call and log to 






















-Prefer not to disclose   
 
S4 Household income (in $1000s): 
                          <20 
  20-50 
  50-100 
  >100  
                   Prefer not to disclose 
 
S5 Employment status 
  -Full-time 
  -Part-time 
  -Casual 
  -Retired 
-Not currently employed 
                          -Prefer not to disclose 
   
S6 How many prescriptions do you approximately fill in your Pharmacy? 
  1 a month 
  2-5 a month 
                          >5 a month 
  Other ___________(please specify) 
 
S7 Do you also get over the counter medicines (eg. Pain relievers-Panadol, 
vitamins, herbal products) from your Pharmacy, in addition to filling your 
prescription(s)? 
   




S8 Do you usually get your prescriptions dispensed at the SAME Pharmacy? 
 





For the following questions please indicate your level of agreement to the 
given statement by answering: 
 
Strongly Disagree; Disagree; Neutral; Agree; Strongly agree 
 
 









S10     I am satisfied with my pharmacists’ level of drug knowledge? 
 




S11 I am satisfied with the level of assistance my pharmacist provides when I 
purchase medicines from the Pharmacy 
 
Strongly disagree       ; Disagree ; Neutral ; Agree  ; Strongly agree 
 
 
S12 I am satisfied with how my pharmacist diagnoses minor ailments such as 
cold & flu, indigestion, hayfever, headache, conjunctivitis. 
 
Strongly disagree       ; Disagree ; Neutral ; Agree  ; Strongly agree 
 
 
S13    I find it difficult to access my Doctor, therefore I would prefer my 
pharmacist writing prescriptions for medicines for which I currently need repeat 
prescriptions from my Doctor. 
 




S14 I would trust my pharmacist to write prescriptions for medicines that I 
currently need repeat prescriptions from my Doctor. 
 







S15 I would prefer my pharmacist write prescriptions for ALL medicines that 
I currently need a prescription from my Doctor. 
 
Strongly disagree       ; Disagree ; Neutral ; Agree  ; Strongly agree 
 
 
If neutral, disagree or strongly disagree go to question 16. If agree or strongly 





S16 Are there medicines that you would prefer your pharmacist write 
prescriptions for? such as: 
    
Antibiotics  Strongly disagree 
      




      




      
Disagree       Neutral       Agree       Strongly agree       
Heart medicines Strongly disagree 
      




      





      
Disagree       Neutral       Agree       Strongly agree       
Other Please specify: 









I ONLY HAVE A FEW MORE QUESTIONS BEFORE THIS 




S17 I would find it easier to access my medicines without delay if 
prescriptions were also written by my Pharmacist. 
 




S18 I would only feel comfortable to have my pharmacist write prescriptions 
for my medicines, if my condition is first diagnosed by my Doctor. 
 






S19 I would accept my pharmacist diagnosing a condition (e.g. asthma) and 
writing prescriptions for the same condition diagnosed. 
 
Strongly disagree       ; Disagree ; Neutral ; Agree  ; Strongly agree 
 
If agree or strongly agree go to question 20. If neutral, disagree or strongly 





S20 Which condition(s) would you accept your pharmacist diagnosing and 
writing prescriptions for? 
 
 
Infections Strongly disagree 
      
Disagree       Neutral       Agree       Strongly agree       
Diabetes  Strongly disagree 
      




      




      
Disagree       Neutral       Agree       Strongly agree       
Asthma  Strongly disagree 
      
Disagree       Neutral       Agree       Strongly agree       
Pain Strongly disagree 
      
Disagree       Neutral       Agree       Strongly agree       
Other Please specify: 
 
 
S21 I would be willing to pay a fee for my pharmacist to write prescriptions 
for medicines for which I currently need prescriptions from my Doctor. 
 
Strongly disagree       ; Disagree ; Neutral ; Agree  ; Strongly agree 
 
 
S22 I think that if pharmacists were to assume the expanded role of writing 
prescriptions, they would need further training 
 
Strongly disagree       ; Disagree ; Neutral ; Agree  ; Strongly agree 
 
 
S23 Where do you think the pharmacist who writes the prescription should be 
located: 
 
a) in community pharmacy 
b) at the GP surgery 
c) in their own office 
 
 
S24 I am happy with current arrangements where only my Doctor writes 
prescriptions and my Pharmacist dispenses my medications and no changes 
are needed.  
 





THIS IS THE END OF THE INTERVIEW. THANK YOU FOR YOUR 
TIME. YOUR RESPONSES ARE MUCH APPRECIATED AND 













I am writing to seek your participation in a research project conducted by Curtin 
University of Technology School of Pharmacy. This involves seeking your views in a 
focus group discussion with other doctors currently offering services to aged care 
facilities. 
 
The focus group will be conducted at LOCATION conference room starting DATE and TIME. 
The focus group discussion will last for ONE hour. You will be reimbursed $X for your time spent in 
this focus group.  
 
The aims of this project are: 
 
1) To assess if current prescribing arrangements in residential aged care facilities 
present doctors, facility staff or pharmaceutical service providers with any difficulties.   
 
2)  To examine current medication supply systems in order to determine whether 
there are models that can be developed to improve the current system in aged care 
facilities. 
 
Exploring the abovementioned issues may help us improve current medication supply 





Focus group participants will be asked to respect other participants’ views and privacy. 
For the purpose of statistical analysis all data is to be grouped, and no reference will be 
made to any individual.  
 
 
How to participate in this project 
 
To participate in this focus group please complete the attached consent form and return 
it back to us using the self-addressed envelope provided or fax the consent form to:        
9266 2769 
 
If you have any questions about this project please contact Kreshnik at 




















Thank you for taking time to participate in this focus group. I know you all have a very 
busy schedule and therefore your participation is really appreciated. My name is 
_____________, from__________________. (The focus group facilitator will then 
make introductions). This meeting will last for 60 minutes. 
 
The aim of this project is to examine current medication supply arrangements in 
residential care facilities with a focus on difficulties that health care providers are being 
faced with and potential new models that could improve medication supply and 
management.. 
 
As stated in your invitation letter, for the purposes of data analysis we will audio-record 
this meeting. I would like to ask for your permission to audio-record. No data that 
identifies any individual will be published and the tapes will be stored and disposed of 
according to NH&MRC ethical requirements. 
 
The views of all of you are very important and you are urged to actively participate in 
discussions. There are no correct or incorrect answers to my questions. Negative 










Q1 What do you each think about the current medication supply 






More specific questions/transition questions – anyone can answer, however the facilitator 
must cycle and make sure active participation is achieved. 
 
Q2. What are the main difficulties, if any, which you are facing with the 
current medication supply arrangements 
 
- Difficulties for the Doctor (Doctors to answer only) 
- Difficulties for the Pharmacist (Pharmacists to answer only) 
- Difficulties for the carer (Carers to answer only) 
- Difficulties for the patient (All to answer) 
 
  
Q3 How could current medication supply arrangements be improved in this 
residential aged care facility? 
 
 
Q4 What do you think of the proposition that pharmacists be allowed under 
the PBS to continue supply medications to residential age care facility patients 
by extending the current repeat system beyond the current time allowed? 
 
- Period of repeat extension? 
- Advantages/benefits of this model? 
- Disadvantages/concerns of this model? 




Q5 In a residential age care facility setting, what do you think of the 
proposition that pharmacists are allowed to supply medications based on 
medications listed in a patient’s medication chart for an unlimited period of time 
until the Doctor makes changes to the medication chart? 
 
- Advantages/benefits of this model? 








Q6 What do you think about the idea of having a medical directory facility 
available in residential aged care facilities? 
 
- Advantages/benefits of this model? 





Q7 What do you think about the idea of other health professionals (i.e. 
pharmacists and/or nurses) writing some prescriptions for residential aged care 
facility patients? 
 
- Advantages/benefits of this model? 









Q8 Which one of these models discussed would you prefer?  
 
 
Q9 Do you believe pharmacists would need any additional training in order 
to implement either of these models? 
 
 
Q10       Concluding question 
 


































MEDICATION SUPPLY IN RESIDENTIAL AGED CARE FACILITIES  
 CONSENT TO PARTICIPATE IN A FOCUS GROUP 
 
 
I agree to participate in a focus group meeting organised by Curtin University of 
Technology, School of Pharmacy. I understand that the discussion will focus on 
difficulties that health care providers are facing with current medication supply 
arrangements in residential care facilities and potential new models to overcome them. 
 
By agreeing to participate in this focus group meeting, I accept to be interviewed by the 
focus group facilitator. I also understand that, for the purposes of data analysis, the 
discussions will be audio-taped and transcribed.  
 
I also understand that: 
• All data obtained in the focus group will be stored in a secure location at Curtin 
University of Technology, School of Pharmacy. 
• There will be no publishing of data that will identify any of the participants of 
the focus group. 
• Focus group participants are required to respect other participants’ views and 
privacy. 
• That Ethics approval has been given by Curtin University of Technology to 
conduct this study 
 
Please note that your participation in this focus group is voluntary and you can 








*In order to indicate your agreement to participate in this focus group, please 
sign this form and send it to us using the self-addressed postage paid envelope 
provided or fax it to: 92662769  
